

# CPC COOPERATIVE PATENT CLASSIFICATION

## C CHEMISTRY; METALLURGY

(NOTES omitted)

### CHEMISTRY

## C12 BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING

(NOTES omitted)

## C12N MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ([microbiological testing media C12Q 1/00](#))

### NOTES

1. Attention is drawn to Notes (1) to (3) following the title of class [C12](#).
2. Biocidal, pest repellent, pest attractant or plant growth regulatory activity of compounds or preparations is further classified in subclass [A01P](#).
3. Therapeutic activity of single-cell proteins or enzymes is further classified in subclass [A61P](#).
4. When classifying in this subclass, classification is also made in group [B01D 15/08](#) insofar as subject matter of general interest relating to chromatography is concerned.
5. In this subclass, it is desirable to add the indexing codes of subclass [C12R](#).
6. {Documents relating to the use of vectors or hosts for the preparation of specific peptides, e.g. enzymes, are classified in subclass [C07K](#) or in group [C12N 9/00](#) according to the peptides, with the appropriate indexing codes.}
7. {In this subclass, combination sets [C-Sets] are used. The detailed information about the C-Sets construction and the associated syntax rules is present in the definitions of [C12N](#).}

### WARNINGS

1. The following IPC groups are not in the CPC scheme. The subject matter for these IPC groups is classified in the following CPC groups:

<a href="#">C12N 1/11</a>	covered by	<a href="#">C12N 15/79</a>
<a href="#">C12N 1/13</a>	covered by	<a href="#">C12N 15/79</a>
<a href="#">C12N 1/15</a>	covered by	<a href="#">C12N 15/80</a>
<a href="#">C12N 1/19</a>	covered by	<a href="#">C12N 15/81</a>
<a href="#">C12N 1/21</a>	covered by	<a href="#">C12N 15/74</a>
<a href="#">C12N 5/02</a>	covered by	<a href="#">C12N 5/0006</a> , <a href="#">C12N 5/04</a> - <a href="#">C12N 5/166</a>
<a href="#">C12N 5/07</a> - <a href="#">C12N 5/095</a>	covered by	<a href="#">C12N 5/06</a>
<a href="#">C12N 5/18</a>	covered by	<a href="#">C12N 5/16</a>
<a href="#">C12N 5/20</a>	covered by	<a href="#">C12N 5/163</a>
<a href="#">C12N 5/22</a>	covered by	<a href="#">C12N 5/16</a>
<a href="#">C12N 5/24</a>	covered by	<a href="#">C12N 5/163</a>
<a href="#">C12N 5/26</a>	covered by	<a href="#">C12N 5/166</a>
<a href="#">C12N 5/28</a>	covered by	<a href="#">C12N 5/166</a>
<a href="#">C12N 15/53</a>	covered by	<a href="#">C12N 9/0004</a>
<a href="#">C12N 7/01</a>	covered by	<a href="#">C12N 7/00</a>
<a href="#">C12N 9/02-C12N 9/08</a>	covered by	<a href="#">C12N 9/0004</a>
<a href="#">C12N 9/26</a>	covered by	<a href="#">C12N 9/2408</a>
<a href="#">C12N 9/28-C12N 9/30</a>	covered by	<a href="#">C12N 9/2414</a> - <a href="#">C12N 9/242</a>
<a href="#">C12N 9/32</a>	covered by	<a href="#">C12N 9/2422</a>
<a href="#">C12N 9/34</a>	covered by	<a href="#">C12N 9/2428</a>
<a href="#">C12N 9/36</a>	covered by	<a href="#">C12N 9/2462</a>
<a href="#">C12N 9/38</a>	covered by	<a href="#">C12N 9/2468</a>
<a href="#">C12N 9/40</a>	covered by	<a href="#">C12N 9/2465</a>
<a href="#">C12N 9/42</a>	covered by	<a href="#">C12N 9/2434</a>
<a href="#">C12N 9/44</a>	covered by	<a href="#">C12N 9/2451</a>
<a href="#">C12N 9/46</a>	covered by	<a href="#">C12N 9/2454</a>
<a href="#">C12N 9/56</a>	covered by	<a href="#">C12N 9/54</a>
<a href="#">C12N 9/66</a>	covered by	<a href="#">C12N 9/6448</a>
<a href="#">C12N 9/68</a>	covered by	<a href="#">C12N 9/6435</a>
<a href="#">C12N 9/70</a>	covered by	<a href="#">C07K 14/3153</a>
<a href="#">C12N 9/72</a>	covered by	<a href="#">C12N 9/6462</a>

## C12N

C12N

(continued)

<a href="#">C12N 9/74</a>	covered by	<a href="#">C12N 9/6429</a>
<a href="#">C12N 9/76</a>	covered by	<a href="#">C12N 9/6427</a>
<a href="#">C12N 15/05</a>	covered by	<a href="#">C12N 5/14</a>
<a href="#">C12N 15/06</a>	covered by	<a href="#">C12N 5/16</a>
<a href="#">C12N 15/07</a>	covered by	<a href="#">C12N 5/16</a>
<a href="#">C12N 15/08</a>	covered by	<a href="#">C12N 5/166</a>
<a href="#">C12N 15/12</a>	covered by	<a href="#">C07K 14/435</a>
<a href="#">C12N 15/13</a>	covered by	<a href="#">C07K 16/00</a>
<a href="#">C12N 15/14</a>	covered by	<a href="#">C07K 14/765</a>
<a href="#">C12N 15/15</a>	covered by	<a href="#">C07K 14/81</a>
<a href="#">C12N 15/16</a>	covered by	<a href="#">C07K 14/575</a>
<a href="#">C12N 15/17</a>	covered by	<a href="#">C07K 14/62</a>
<a href="#">C12N 15/18</a>	covered by	<a href="#">C07K 14/61</a>
<a href="#">C12N 15/19</a>	covered by	<a href="#">C07K 14/52</a>
<a href="#">C12N 15/20</a>	covered by	<a href="#">C07K 14/555</a>
<a href="#">C12N 15/21</a>	covered by	<a href="#">C07K 14/56</a>
<a href="#">C12N 15/22</a>	covered by	<a href="#">C07K 14/565</a>
<a href="#">C12N 15/23</a>	covered by	<a href="#">C07K 14/57</a>
<a href="#">C12N 15/24</a>	covered by	<a href="#">C07K 14/54</a>
<a href="#">C12N 15/25</a>	covered by	<a href="#">C07K 14/545</a>
<a href="#">C12N 15/26</a>	covered by	<a href="#">C07K 14/55</a>
<a href="#">C12N 15/27</a>	covered by	<a href="#">C07K 14/53</a>
<a href="#">C12N 15/28</a>	covered by	<a href="#">C07K 14/525</a>
<a href="#">C12N 15/29</a>	covered by	<a href="#">C07K 14/415</a>
<a href="#">C12N 15/30</a>	covered by	<a href="#">C07K 14/44</a>
<a href="#">C12N 15/31</a>	covered by	<a href="#">C07K 14/195</a> , <a href="#">C07K 14/005</a>
<a href="#">C12N 15/32</a>	covered by	<a href="#">C07K 14/325</a>
<a href="#">C12N 15/33</a>	covered by	<a href="#">C07K 14/005</a>
<a href="#">C12N 15/34</a>	covered by	<a href="#">C07K 14/01</a>
<a href="#">C12N 15/35</a>	covered by	<a href="#">C07K 14/015</a>
<a href="#">C12N 15/36</a>	covered by	<a href="#">C07K 14/02</a>
<a href="#">C12N 15/37</a>	covered by	<a href="#">C07K 14/025</a>
<a href="#">C12N 15/38</a>	covered by	<a href="#">C07K 14/03</a>
<a href="#">C12N 15/39</a>	covered by	<a href="#">C07K 14/065</a>
<a href="#">C12N 15/40</a>	covered by	<a href="#">C07K 14/08</a>
<a href="#">C12N 15/41</a>	covered by	<a href="#">C07K 14/085</a>
<a href="#">C12N 15/42</a>	covered by	<a href="#">C07K 14/09</a>
<a href="#">C12N 15/43</a>	covered by	<a href="#">C07K 14/105</a>
<a href="#">C12N 15/44</a>	covered by	<a href="#">C07K 14/11</a>
<a href="#">C12N 15/45</a>	covered by	<a href="#">C07K 14/115</a>
<a href="#">C12N 15/46</a>	covered by	<a href="#">C07K 14/14</a>
<a href="#">C12N 15/47</a>	covered by	<a href="#">C07K 14/145</a>
<a href="#">C12N 15/48</a>	covered by	<a href="#">C07K 14/15</a>
<a href="#">C12N 15/49</a>	covered by	<a href="#">C07K 14/155</a>
<a href="#">C12N 15/50</a>	covered by	<a href="#">C07K 14/165</a>
<a href="#">C12N 15/51</a>	covered by	<a href="#">C07K 14/02</a> , <a href="#">C07K 14/10</a> , <a href="#">C07K 14/18</a>
<a href="#">C12N 15/53</a>	covered by	<a href="#">C12N 9/0004</a>
<a href="#">C12N 15/54</a>	covered by	<a href="#">C12N 9/10</a>
<a href="#">C12N 15/55</a>	covered by	<a href="#">C12N 9/14</a>
<a href="#">C12N 15/56</a>	covered by	<a href="#">C12N 9/24</a>
<a href="#">C12N 15/57</a>	covered by	<a href="#">C12N 9/48</a>
<a href="#">C12N 15/58</a>	covered by	<a href="#">C12N 9/6456</a>
<a href="#">C12N 15/59</a>	covered by	<a href="#">C12N 9/6483</a>
<a href="#">C12N 15/60</a>	covered by	<a href="#">C12N 9/88</a>
<a href="#">C12N 15/61</a>	covered by	<a href="#">C12N 9/90</a>
<a href="#">C12N 15/83</a>	covered by	<a href="#">C12N 15/82</a>
<a href="#">C12N 15/84</a>	covered by	<a href="#">C12N 15/82</a>

2. In this subclass non-limiting references (in the sense of paragraph 39 of the Guide to the IPC) may still be displayed in the scheme.

**1/00 Microorganisms, e.g. protozoa; Compositions thereof** (medicinal preparations containing material from protozoa, bacteria or viruses [A61K 35/66](#), from algae [A61K 36/02](#), from fungi [A61K 36/06](#); preparing medicinal bacterial antigen or antibody compositions, e.g. bacterial vaccines, [A61K 39/00](#)); **Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor**

- 1/005 . {after treatment of microbial biomass not covered by [C12N 1/02](#) - [C12N 1/08](#)}
- 1/02 . Separating microorganisms from their culture media
- 1/04 . Preserving or maintaining viable microorganisms (immobilised microorganisms [C12N 11/00](#))
- 1/06 . Lysis of microorganisms
- 1/063 . . {of yeast}
- 1/066 . . {by physical methods}
- 1/08 . Reducing the nucleic acid content
- 1/10 . Protozoa; Culture media therefor
- 1/105 . . {Protozoal isolates}
- 1/12 . Unicellular algae; Culture media therefor (as new plants [A01H 13/00](#))
- 1/125 . . {Unicellular algae isolates}
- 1/14 . Fungi (culture of mushrooms [A01G 18/00](#); as new plants [A01H 15/00](#)); Culture media therefor
- 1/145 . . {Fungal isolates}
- 1/16 . . Yeasts; Culture media therefor
- 1/165 . . . {Yeast isolates}
- 1/18 . . . Baker's yeast; Brewer's yeast
- 1/185 . . . . {Saccharomyces isolates}
- 1/20 . Bacteria; Culture media therefor
- 1/205 . . {Bacterial isolates}
- 1/22 . Processes using, or culture media containing, cellulose or hydrolysates thereof
- 1/24 . Processes using, or culture media containing, waste sulfite liquor
- 1/26 . Processes using, or culture media containing, hydrocarbons (refining of hydrocarbon oils by using microorganisms [C10G 32/00](#))
- 1/28 . . aliphatic
- 1/30 . . . having five or less carbon atoms
- 1/32 . Processes using, or culture media containing, lower alkanols, i.e. C<sub>1</sub> to C<sub>6</sub>
- 1/34 . Processes using foam culture
- 1/36 . Adaptation or attenuation of cells
- 1/38 . Chemical stimulation of growth or activity by addition of chemical compounds which are not essential growth factors; Stimulation of growth by removal of a chemical compound ([C12N 1/34](#) takes precedence)

**3/00 Spore forming or isolating processes**

**5/00 Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor;** (plant reproduction by tissue culture techniques [A01H 4/00](#))

#### NOTE

In this group, the following words are used with the meanings indicated:

- a "totipotent" cell can differentiate into all somatic lineages (ectoderm, mesoderm,

endoderm), the germ line and extra-embryonic tissues such as the placenta;

- a "pluripotent" cell is a somatic stem cell which can differentiate into cells of at least two of the three somatic lineages (ectoderm, mesoderm, endoderm);
- a "multipotent" cell is restricted to one lineage;
- "progenitor" and "precursor" cells are further restricted within the lineage. If not explicitly foreseen, totipotent cells are classified with pluripotent cells. Multipotent cells should not be classified with pluripotent cells. Unless provided for otherwise, committed progenitors are classified with their progeny.

- 5/0006 . {Modification of the membrane of cells, e.g. cell decoration}
- 5/0012 . {Cell encapsulation}
- 5/0018 . {Culture media for cell or tissue culture (media for specific animal cell type [C12N 5/06](#))}
- 5/0025 . . {Culture media for plant cell or plant tissue culture}
- 5/0031 . . {Serum-free culture media}

#### WARNING

This group is no longer used for the classification of new documents as from January 1, 2012. The backlog of this group is being continuously reclassified to [C12N 5/0037](#) - [C12N 5/0056](#)

- 5/0037 . . {Serum-free medium, which may still contain naturally-sourced components}
- 5/0043 . . {Medium free of human- or animal-derived components}
- 5/005 . . {Protein-free medium}
- 5/0056 . . {Xeno-free medium}
- 5/0062 . {General methods for three-dimensional culture}
- 5/0068 . {General culture methods using substrates (for specific animal cell type [C12N 5/06](#))}
- 5/0075 . . {using microcarriers}
- 5/0081 . {Purging biological preparations of unwanted cells}
- 5/0087 . . {Purging against subsets of blood cells, e.g. purging alloreactive T cells}
- 5/0093 . . {Purging against cancer cells}
- 5/04 . Plant cells or tissues {(culture media [C12N 5/0025](#))}
- 5/06 . {Animal cells or tissues; Human cells or tissues (preservation of living cells or tissues [A01N 1/02](#))}

#### NOTE

{In this group, the following words are used with the meanings indicated:

- a "totipotent" cell can differentiate into all somatic lineages (ectoderm, mesoderm, endoderm), the germ line and extra-embryonic tissues such as the placenta;
- a "pluripotent" cell is a somatic stem cell which can differentiate into cells of at least two of the three somatic lineages (ectoderm, mesoderm, endoderm);
- a "multipotent" cell is restricted to one lineage. }

"Progenitor" and "precursor" cells are further restricted within the lineage. If not explicitly foreseen, totipotent cells are classified with

## C12N

C12N 5/06  
(continued)

pluripotent cells. Multipotent cells should not be classified with pluripotent cells. The last place priority rule does not apply between the subgroups of this group

- 5/0601 . . {Invertebrate cells or tissues, e.g. insect cells; Culture media therefor}
- 5/0602 . . {Vertebrate cells}

### NOTE

Three-dimensional culture, tissue culture or organ culture are classified with the corresponding cells, if not specially provided for

- 5/0603 . . . {Embryonic cells (production of embryos, nuclear transfer [A01K 67/027](#)); Embryoid bodies}
- 5/0604 . . . . {Whole embryos; Culture medium therefor}
- 5/0605 . . . . {Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly}
- 5/0606 . . . . {Pluripotent embryonic cells, e.g. embryonic stem cells [ES] (embryonic germ cells [C12N 5/0611](#), induced pluripotent stem cells [C12N 5/0696](#))}
- 5/0607 . . . {Non-embryonic pluripotent stem cells, e.g. MASC (induced pluripotent stem cells [C12N 5/0696](#))}
- 5/0608 . . . {Germ cells (production of embryos, nuclear transfer [A01K 67/027](#))}
- 5/0609 . . . . {Oocytes, oögonia (fertilised oocytes [C12N 5/0604](#))}
- 5/061 . . . . {Sperm cells, spermatogonia}
- 5/0611 . . . . {Primordial germ cells, e.g. embryonic germ cells [EG]}
- 5/0612 . . . . {Sorting of gametes, e.g. according to sex or motility}
- 5/0613 . . . {Cells from endocrine organs (pancreas [C12N 5/0676](#), gonads [C12N 5/0681](#))}
- 5/0614 . . . . {Adrenal gland}
- 5/0615 . . . . {Pineal gland}
- 5/0616 . . . . {Pituitary gland}
- 5/0617 . . . . {Thyroid and parathyroid glands}
- 5/0618 . . . {Cells of the nervous system}
- 5/0619 . . . . {Neurons}
- 5/062 . . . . {Sensory transducers, e.g. photoreceptors; Sensory neurons, e.g. for hearing, taste, smell, pH, touch, temperature, pain}
- 5/0621 . . . . {Eye cells, e.g. cornea, iris pigmented cells (photoreceptors [C12N 5/062](#))}
- 5/0622 . . . . {Glial cells, e.g. astrocytes, oligodendrocytes; Schwann cells}
- 5/0623 . . . . {Stem cells}
- 5/0625 . . . {Epidermal cells, skin cells; Cells of the oral mucosa}
- 5/0626 . . . . {Melanocytes}
- 5/0627 . . . . {Hair cells}
- 5/0628 . . . . {Hair stem cells; Hair progenitors (mesenchymal stem cells from hair follicles [C12N 5/0666](#))}
- 5/0629 . . . . {Keratinocytes; Whole skin}
- 5/063 . . . . {Keratinocyte stem cells; Keratinocyte progenitors}
- 5/0631 . . . . {Mammary cells}
- 5/0632 . . . . {Cells of the oral mucosa}

- 5/0633 . . . . {Cells of secretory glands, e.g. parotid gland, salivary glands, sweat glands, lacrimal glands}
- 5/0634 . . . {Cells from the blood or the immune system}

### NOTE

Committed progenitors are classified with their progeny

### WARNING

Group [C12N 5/0634](#) is impacted by reclassification into groups [A61K 39/46](#), [A61K 39/461](#) - [A61K 39/46484](#) and [A61K 2239/00](#) - [A61K 2239/59](#).

All groups listed in this Warning should be considered in order to perform a complete search.

- 5/0635 . . . . {B lymphocytes}

### WARNING

Group [C12N 5/0635](#) is impacted by reclassification into groups [A61K 39/46](#), [A61K 39/461](#) - [A61K 39/46484](#) and [A61K 2239/00](#) - [A61K 2239/59](#).

All groups listed in this Warning should be considered in order to perform a complete search.

- 5/0636 . . . . {T lymphocytes}

### WARNING

Group [C12N 5/0636](#) is impacted by reclassification into groups [A61K 39/46](#), [A61K 39/461](#) - [A61K 39/46484](#) and [A61K 2239/00](#) - [A61K 2239/59](#).

All groups listed in this Warning should be considered in order to perform a complete search.

- 5/0637 . . . . . {Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg}

### WARNING

Group [C12N 5/0637](#) is impacted by reclassification into groups [A61K 39/46](#), [A61K 39/461](#) - [A61K 39/46484](#) and [A61K 2239/00](#) - [A61K 2239/59](#).

All groups listed in this Warning should be considered in order to perform a complete search.

- 5/0638 . . . . . {Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]}

### WARNING

Group [C12N 5/0638](#) is impacted by reclassification into groups [A61K 39/46](#), [A61K 39/461](#) - [A61K 39/46484](#) and [A61K 2239/00](#) - [A61K 2239/59](#).

All groups listed in this Warning should be considered in order to perform a complete search.

5/0639 . . . . {Dendritic cells, e.g. Langerhans cells in the epidermis}

#### **WARNING**

Group [C12N 5/0639](#) is impacted by reclassification into groups [A61K 39/46](#), [A61K 39/461](#) - [A61K 39/46484](#) and [A61K 2239/00](#) - [A61K 2239/59](#).

All groups listed in this Warning should be considered in order to perform a complete search.

5/064 . . . . . {Immunosuppressive dendritic cells}

#### **WARNING**

Group [C12N 5/064](#) is impacted by reclassification into groups [A61K 39/46](#), [A61K 39/461](#) - [A61K 39/46484](#) and [A61K 2239/00](#) - [A61K 2239/59](#).

All groups listed in this Warning should be considered in order to perform a complete search.

5/0641 . . . . {Erythrocytes}

5/0642 . . . . {Granulocytes, e.g. basophils, eosinophils, neutrophils, mast cells}

5/0643 . . . . {Osteoclasts}

5/0644 . . . . {Platelets; Megakaryocytes}

5/0645 . . . . {Macrophages, e.g. Kuepfer cells in the liver; Monocytes}

#### **WARNING**

Group [C12N 5/0645](#) is impacted by reclassification into groups [A61K 39/46](#), [A61K 39/461](#) - [A61K 39/46484](#) and [A61K 2239/00](#) - [A61K 2239/59](#).

All groups listed in this Warning should be considered in order to perform a complete search.

5/0646 . . . . {Natural killers cells [NK], NKT cells}

#### **WARNING**

Group [C12N 5/0646](#) is impacted by reclassification into groups [A61K 39/46](#), [A61K 39/461](#) - [A61K 39/46484](#), [A61K 2239/00](#) - [A61K 2239/59](#).

All groups listed in this Warning should be considered in order to perform a complete search.

5/0647 . . . . {Haematopoietic stem cells; Uncommitted or multipotent progenitors}

5/0648 . . . . {Splenocytes}

5/065 . . . . {Thymocytes}

5/0651 . . . . {Lymph nodes}

5/0652 . . . {Cells of skeletal and connective tissues; Mesenchyme}

5/0653 . . . . {Adipocytes; Adipose tissue}

5/0654 . . . . {Osteocytes, Osteoblasts, Odontocytes; Bones, Teeth}

5/0655 . . . . {Chondrocytes; Cartilage}

5/0656 . . . . {Adult fibroblasts}

5/0657 . . . . {Cardiomyocytes; Heart cells}

5/0658 . . . . {Skeletal muscle cells, e.g. myocytes, myotubes, myoblasts}

5/0659 . . . . . {Satellite cells}

5/066 . . . . {Tenocytes; Tendons, Ligaments}

5/0661 . . . . {Smooth muscle cells}

5/0662 . . . . {Stem cells}

5/0663 . . . . . {Bone marrow mesenchymal stem cells (BM-MSC)}

5/0664 . . . . . {Dental pulp stem cells, Dental follicle stem cells}

5/0665 . . . . . {Blood-borne mesenchymal stem cells, e.g. from umbilical cord blood}

5/0666 . . . . . {Mesenchymal stem cells from hair follicles}

5/0667 . . . . . {Adipose-derived stem cells [ADSC]; Adipose stromal stem cells}

5/0668 . . . . . {Mesenchymal stem cells from other natural sources}

5/0669 . . . . {Bone marrow stromal cells; Whole bone marrow (isolated stem cells from bone marrow [C12N 5/0647](#), [C12N 5/0663](#))}

5/067 . . . {Hepatocytes}

5/0671 . . . . {Three-dimensional culture, tissue culture or organ culture; Encapsulated cells}

5/0672 . . . . {Stem cells; Progenitor cells; Precursor cells; Oval cells}

5/0676 . . . {Pancreatic cells}

5/0677 . . . . {Three-dimensional culture, tissue culture or organ culture; Encapsulated cells}

5/0678 . . . . {Stem cells; Progenitor cells; Precursor cells}

5/0679 . . . {Cells of the gastro-intestinal tract}

5/068 . . . . {Stem cells; Progenitors}

5/0681 . . . {Cells of the genital tract; Non-germinal cells from gonads}

5/0682 . . . . {Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells (oocytes [C12N 5/0609](#))}

5/0683 . . . . {Cells of the male genital tract, e.g. prostate, epididymis; Non-germinal cells from testis, e.g. Leydig cells, Sertoli cells (spermatogonia [C12N 5/061](#))}

5/0684 . . . {Cells of the urinary tract or kidneys}

5/0685 . . . . {Bladder epithelial cells}

5/0686 . . . . {Kidney cells}

5/0687 . . . . {Renal stem cells; Renal progenitors}

5/0688 . . . {Cells from the lungs or the respiratory tract}

5/0689 . . . . {Stem cells; Progenitors}

5/069 . . . {Vascular Endothelial cells}

5/0691 . . . . {Vascular smooth muscle cells; 3D culture thereof, e.g. models of blood vessels}

5/0692 . . . . {Stem cells; Progenitor cells; Precursor cells}

5/0693 . . . {Tumour cells; Cancer cells}

5/0694 . . . . {Cells of blood, e.g. leukemia cells, myeloma cells}

5/0695 . . . . {Stem cells; Progenitor cells; Precursor cells}

5/0696 . . . {Artificially induced pluripotent stem cells, e.g. iPS}

5/0697 . . {Artificial constructs associating cells of different lineages, e.g. tissue equivalents (blood vessels [C12N 5/0691](#))}



5/0698	. . . {Skin equivalents}	9/0026	. . . {acting on CH-NH groups of donors (1.5)}
5/10	. Cells modified by introduction of foreign genetic material	9/0028	. . . . {with NAD or NADP as acceptor (1.5.1)}
5/12	. . Fused cells, e.g. hybridomas	9/003	. . . . . {Dihydrofolate reductase [DHFR] (1.5.1.3)}
5/14	. . . Plant cells	9/0032	. . . . . {with oxygen as acceptor (1.5.3)}
5/16	. . . Animal cells	9/0034	. . . . . {Sarcosine oxidase (1.5.3.1)}
5/163	. . . . {one of the fusion partners being a B or a T lymphocyte}	9/0036	. . . {acting on NADH or NADPH (1.6)}
5/166	. . . . . {resulting from interspecies fusion}	9/0038	. . . . . {with a heme protein as acceptor (1.6.2)}
7/00	<b>Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, <a href="#">A61K 39/00</a>)</b>	9/004	. . . . . {Cytochrome-b5 reductase (1.6.2.2)}
	<b>WARNING</b>	9/0042	. . . . . {NADPH-cytochrome P450 reductase (1.6.2.4)}
	From March 15, 2012 groups <a href="#">C12N 7/02</a> - <a href="#">C12N 7/08</a> and subgroups thereof are no longer used for the classification of new documents. The documents in these (sub)groups are being reclassified to the corresponding codes in the range <a href="#">C12N 2710/00-C12N 2795/00</a> .	9/0044	. . . {acting on other nitrogen compounds as donors (1.7)}
7/02	. Recovery or purification	9/0046	. . . . . {with oxygen as acceptor (1.7.3)}
7/025	. . {Packaging cell lines, e.g. transcomplementing cell lines, for production of virus}	9/0048	. . . . . {Uricase (1.7.3.3)}
7/04	. Inactivation or attenuation; Producing viral sub-units	9/0051	. . {acting on a sulfur group of donors (1.8)}
7/045	. . {Pseudoviral particles; Non infectious pseudovirions, e.g. genetically engineered}	9/0053	. . {acting on a heme group of donors (1.9)}
7/06	. . {Inactivation or attenuation} by chemical treatment	9/0055	. . {acting on diphenols and related substances as donors (1.10)}
7/08	. . {Inactivation or attenuation} by serial passage of virus	9/0057	. . . {with oxygen as acceptor (1.10.3)}
9/00	<b>Enzymes; Proenzymes; Compositions thereof (preparations containing enzymes for cleaning teeth <a href="#">A61K 8/66</a>, <a href="#">A61Q 11/00</a>; medicinal preparations containing enzymes or proenzymes <a href="#">A61K 38/43</a>; enzyme containing detergent compositions <a href="#">C11D</a>; {enzymes with nucleic acid structure, e.g. ribozymes, <a href="#">C12N 15/113</a>}); Processes for preparing, activating, inhibiting, separating or purifying enzymes (preparation of malt <a href="#">C12C 1/00</a>)</b>	9/0059	. . . . . {Catechol oxidase (1.10.3.1), i.e. tyrosinase}
	<b>NOTE</b>	9/0061	. . . . . {Laccase (1.10.3.2)}
	Enzymes are generally categorized below according to the "Nomenclature and Classification of Enzymes" of the International Commission on Enzymes. Where appropriate, this designation appears in the groups below in parenthesis.	9/0063	. . . . . {Ascorbate oxidase (1.10.3.3)}
9/0002	. {Antibodies with enzymatic activity, e.g. abzymes}	9/0065	. . {acting on hydrogen peroxide as acceptor (1.11)}
9/0004	. {Oxidoreductases (1.)}	9/0067	. . {acting on hydrogen as donor (1.12)}
9/0006	. . {acting on CH-OH groups as donors (1.1)}	9/0069	. . {acting on single donors with incorporation of molecular oxygen, i.e. oxygenases (1.13)}
9/0008	. . {acting on the aldehyde or oxo group of donors (1.2)}	9/0071	. . {acting on paired donors with incorporation of molecular oxygen (1.14)}
9/001	. . {acting on the CH-CH group of donors (1.3)}	9/0073	. . . {with NADH or NADPH as one donor, and incorporation of one atom of oxygen 1.14.13}
9/0012	. . {acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)}	9/0075	. . . . . {Nitric-oxide synthase (1.14.13.39)}
9/0014	. . . {acting on the CH-NH <sub>2</sub> group of donors (1.4)}	9/0077	. . . {with a reduced iron-sulfur protein as one donor (1.14.15)}
9/0016	. . . . {with NAD or NADP as acceptor (1.4.1)}	9/0079	. . . . . {Steroid 11 beta monooxygenase (P-450 protein)(1.14.15.4)}
9/0018	. . . . . {Phenylalanine dehydrogenase (1.4.1.20)}	9/0081	. . . . . {Cholesterol monooxygenase (cytochrome P 450scs)(1.14.15.6)}
9/002	. . . . . {with a cytochrome as acceptor (1.4.2)}	9/0083	. . . {Miscellaneous (1.14.99)}
9/0022	. . . . . {with oxygen as acceptor (1.4.3)}	9/0085	. . . . . {Steroid 17 alpha-monooxygenase (1.14.99.9)}
9/0024	. . . . . {D-Amino acid oxidase (1.4.3.3)}	9/0087	. . . . . {Steroid 21-monooxygenase (1.14.99.10)}
		9/0089	. . {acting on superoxide as acceptor (1.15)}
		9/0091	. . {oxidizing metal ions (1.16)}
		9/0093	. . {acting on CH or CH <sub>2</sub> groups (1.17)}
		9/0095	. . {acting on iron-sulfur proteins as donor (1.18)}
		9/0097	. . {acting on reduced flavodoxin as donor (1.19)}
		9/10	. Transferases (2.) ( <a href="#">ribonucleases C12N 9/22</a> )
		9/1003	. . {transferring one-carbon groups (2.1)}
		9/1007	. . . {Methyltransferases (general) (2.1.1.)}
		9/1011	. . . . . {Catechol O-methyltransferase (2.1.1.6)}
		9/1014	. . . {Hydroxymethyl-, formyl-transferases (2.1.2)}
		9/1018	. . . {Carboxy- and carbamoyl transferases (2.1.3)}
		9/1022	. . {transferring aldehyde or ketonic groups (2.2)}
		9/1025	. . {Acyltransferases (2.3)}
		9/1029	. . . {transferring groups other than amino-acyl groups (2.3.1)}
		9/1033	. . . . . {Chloramphenicol O-acetyltransferase (2.3.1.28)}
		9/1037	. . . . . {Naringenin-chalcone synthase (2.3.1.74), i.e. chalcone synthase}
		9/104	. . . {Aminoacyltransferases (2.3.2)}

9/1044	. . . . {Protein-glutamine gamma-glutamyltransferase (2.3.2.13), i.e. transglutaminase or factor XIII}	9/2411	. . . . . {Amylases}
9/1048	. . {Glycosyltransferases (2.4)}	9/2414	. . . . . {Alpha-amylase (3.2.1.1.)}
9/1051	. . . {Hexosyltransferases (2.4.1)}	9/2417	. . . . . {from microbiological source}
9/1055	. . . . {Levansucrase (2.4.1.10)}	9/242	. . . . . {Fungal source}
9/1059	. . . . {Cellulose synthases (2.4.1.12; 2.4.1.29)}	9/2422	. . . . . {from plant source}
9/1062	. . . . {Sucrose synthase (2.4.1.13)}	9/2425	. . . . . {Beta-amylase (3.2.1.2)}
9/1066	. . . . {Sucrose phosphate synthase (2.4.1.14)}	9/2428	. . . . . {Glucan 1,4-alpha-glucosidase (3.2.1.3), i.e. glucoamylase}
9/107	. . . . {1,4-Alpha-glucan branching enzyme (2.4.1.18)}	9/2431	. . . . . {Beta-fructofuranosidase (3.2.1.26), i.e. invertase}
9/1074	. . . . {Cyclomaltodextrin glucanotransferase (2.4.1.19)}	9/2434	. . . . . {acting on beta-1,4-glucosidic bonds}
9/1077	. . . {Pentosyltransferases (2.4.2)}	9/2437	. . . . . {Cellulases (3.2.1.4; 3.2.1.74; 3.2.1.91; 3.2.1.150)}
9/1081	. . . {transferring other glycosyl groups (2.4.99)}	9/244	. . . . . {Endo-1,3(4)-beta-glucanase (3.2.1.6)}
9/1085	. . {transferring alkyl or aryl groups other than methyl groups (2.5)}	9/2442	. . . . . {Chitinase (3.2.1.14)}
9/1088	. . . {Glutathione transferase (2.5.1.18)}	9/2445	. . . . . {Beta-glucosidase (3.2.1.21)}
9/1092	. . . {3-Phosphoshikimate 1-carboxyvinyltransferase (2.5.1.19), i.e. 5-enolpyruvylshikimate-3-phosphate synthase}	9/2448	. . . . . {Licheninase (3.2.1.73)}
9/1096	. . {transferring nitrogenous groups (2.6)}	9/2451	. . . . . {acting on alpha-1,6-glucosidic bonds}
9/12	. . transferring phosphorus containing groups, e.g. kinases (2.7)	9/2454	. . . . . {Dextranase (3.2.1.11)}
9/1205	. . . {Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases}	9/2457	. . . . . {Pullulanase (3.2.1.41)}
9/1211	. . . . {Thymidine kinase (2.7.1.21)}	9/246	. . . . . {Isoamylase (3.2.1.68)}
9/1217	. . . {Phosphotransferases with a carboxyl group as acceptor (2.7.2)}	9/2462	. . . . {Lysozyme (3.2.1.17)}
9/1223	. . . {Phosphotransferases with a nitrogenous group as acceptor (2.7.3)}	9/2465	. . . . {acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase (3.2.1.22)}
9/1229	. . . {Phosphotransferases with a phosphate group as acceptor (2.7.4)}	9/2468	. . . . {acting on beta-galactose-glycoside bonds, e.g. carrageenases (3.2.1.83; 3.2.1.157); beta-agarase (3.2.1.81)}
9/1235	. . . {Diphosphotransferases (2.7.6)}	9/2471	. . . . . {Beta-galactosidase (3.2.1.23), i.e. exo-(1->4)-beta-D-galactanase}
9/1241	. . . {Nucleotidyltransferases (2.7.7)}	9/2474	. . . . {Hyaluronoglucosaminidase (3.2.1.35), i.e. hyaluronidase}
9/1247	. . . . {DNA-directed RNA polymerase (2.7.7.6)}	9/2477	. . . . {Hemicellulases not provided in a preceding group}
9/1252	. . . . {DNA-directed DNA polymerase (2.7.7.7), i.e. DNA replicase}	9/248	. . . . . {Xylanases}
9/1258	. . . . {Polyribonucleotide nucleotidyltransferase (2.7.7.8), i.e. polynucleotide phosphorylase}	9/2482	. . . . . {Endo-1,4-beta-xylanase (3.2.1.8)}
9/1264	. . . . {DNA nucleotidylexotransferase (2.7.7.31), i.e. terminal nucleotidyl transferase}	9/2485	. . . . . {Xylan endo-1,3-beta-xylosidase (3.2.1.32), i.e. endo-1,3-beta-xylanase}
9/127	. . . . {RNA-directed RNA polymerase (2.7.7.48), i.e. RNA replicase}	9/2488	. . . . . {Mannanases}
9/1276	. . . . {RNA-directed DNA polymerase (2.7.7.49), i.e. reverse transcriptase or telomerase}	9/2491	. . . . . {Beta-mannosidase (3.2.1.25), i.e. mannanase}
9/1282	. . . . {RNA uridylyltransferase (2.7.7.52)}	9/2494	. . . . . {Mannan endo-1,4-beta-mannosidase (3.2.1.78), i.e. endo-beta-mannanase}
9/1288	. . . {Transferases for other substituted phosphate groups (2.7.8)}	9/2497	. . . {hydrolysing N- glycosyl compounds (3.2.2)}
9/1294	. . . {Phosphotransferases with paired acceptors (2.7.9)}	9/48	. . acting on peptide bonds (3.4)
9/13	. . {transferring sulfur containing groups (2.8)}	9/485	. . . {Exopeptidases (3.4.11-3.4.19)}
9/14	. Hydrolases (3)	9/50	. . . Proteinases {, e.g. Endopeptidases (3.4.21-3.4.25)}
9/16	. . acting on ester bonds (3.1)	9/503	. . . . {derived from viruses}
9/18	. . . Carboxylic ester hydrolases {(3.1.1)}	9/506	. . . . . {derived from RNA viruses}
9/20	. . . . Triglyceride splitting, e.g. by means of lipase	9/52	. . . . derived from bacteria {or Archaea}
9/22	. . . Ribonucleases {RNAses, DNAses (catalytic nucleic acids C12N 15/113)}	<b>NOTE</b>	
9/24	. . acting on glycosyl compounds (3.2)	{In this group, Archaea, formerly known as Archaeobacteria, are classified with bacteria.}	
9/2402	. . . {hydrolysing O- and S- glycosyl compounds (3.2.1)}	9/54	. . . . . bacteria being Bacillus
9/2405	. . . . {Glucanases}	9/58	. . . . . derived from fungi
9/2408	. . . . . {acting on alpha -1,4-glucosidic bonds}	9/60	. . . . . from yeast
		9/62	. . . . . from Aspergillus
		9/63	. . . . . {derived from plants}
		9/64	. . . . . derived from animal tissue
		9/6402	. . . . . {from non-mammals}

9/6405	. . . . .	{ not being snakes }	9/86	. . .	acting on amide bonds in cyclic amides, e.g. penicillinase {(3.5.2)}
9/6408	. . . . .	{ Serine endopeptidases (3.4.21) }	9/88	. Lyases (4.)	
9/641	. . . . .	{ Cysteine endopeptidases (3.4.22) }	9/90	. Isomerases (5.)	
9/6413	. . . . .	{ Aspartic endopeptidases (3.4.23) }	9/92	. . Glucose isomerase {(5.3.1.5; 5.3.1.9; 5.3.1.18)}	
9/6416	. . . . .	{ Metalloendopeptidases (3.4.24) }	9/93	. {Ligases (6)}	
9/6418	. . . . .	{ from snakes }	9/94	. Pancreatin	
9/6421	. . . . .	{ from mammals }	9/96	. Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates	
9/6424	. . . . .	{ Serine endopeptidases (3.4.21) }	9/98	. Preparation of granular or free-flowing enzyme compositions ( <a href="#">C12N 9/96 takes precedence</a> )	
9/6427	. . . . .	{ Chymotrypsins (3.4.21.1; 3.4.21.2); Trypsin (3.4.21.4) }	9/99	. Enzyme inactivation by chemical treatment	
9/6429	. . . . .	{ Thrombin (3.4.21.5) }	<b>11/00</b>	<b>Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof</b>	
9/6432	. . . . .	{ Coagulation factor Xa (3.4.21.6) }	11/02	. Enzymes or microbial cells immobilised on or in an organic carrier	
9/6435	. . . . .	{ Plasmin (3.4.21.7), i.e. fibrinolysin }	11/04	. . entrapped within the carrier, e.g. gel or hollow fibres	
9/6437	. . . . .	{ Coagulation factor VIIa (3.4.21.21) }	11/06	. . attached to the carrier via a bridging agent	
9/644	. . . . .	{ Coagulation factor IXa (3.4.21.22) }	11/08	. . the carrier being a synthetic polymer	
9/6443	. . . . .	{ Coagulation factor XIa (3.4.21.27) }	11/082	. . . obtained by reactions only involving carbon-to-carbon unsaturated bonds	
9/6445	. . . . .	{ Kallikreins (3.4.21.34; 3.4.21.35) }	11/084	. . . . Polymers containing vinyl alcohol units	
9/6448	. . . . .	{ Elastases, e.g. pancreatic elastase (3.4.21.36); leukocyte elastase (3.4.31.37) }	11/087	. . . . Acrylic polymers	
9/6451	. . . . .	{ Coagulation factor XIIa (3.4.21.38) }	11/089	. . . obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds	
9/6454	. . . . .	{ Dibasic site splicing serine proteases, e.g. kexin (3.4.21.61); furin (3.4.21.75) and other proprotein convertases }	11/091	. . . . Phenol resins; Amino resins	
9/6456	. . . . .	{ Plasminogen activators }	11/093	. . . . Polyurethanes	
9/6459	. . . . .	{ t-plasminogen activator (3.4.21.68), i.e. tPA }	11/096	. . . . Polyesters; Polyamides	
9/6462	. . . . .	{ u-Plasminogen activator (3.4.21.73), i.e. urokinase }	11/098	. . . formed in the presence of the enzymes or microbial cells	
9/6464	. . . . .	{ Protein C (3.4.21.69) }	11/10	. . the carrier being a carbohydrate	
9/6467	. . . . .	{ Granzymes, e.g. granzyme A (3.4.21.78); granzyme B (3.4.21.79) }	11/12	. . . Cellulose or derivatives thereof	
9/647	. . . . .	{ Blood coagulation factors not provided for in a preceding group or according to more than one of the proceeding groups }	11/14	. Enzymes or microbial cells immobilised on or in an inorganic carrier	
9/6472	. . . . .	{ Cysteine endopeptidases (3.4.22) }	11/16	. Enzymes or microbial cells immobilised on or in a biological cell	
9/6475	. . . . .	{ Interleukin 1-beta convertase-like enzymes (3.4.22.10; 3.4.22.36; 3.4.22.63) }	11/18	. Multi-enzyme systems	
9/6478	. . . . .	{ Aspartic endopeptidases (3.4.23) }	<b>13/00</b>	<b>Treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic waves</b>	
9/6481	. . . . .	{ Pepsins (3.4.23.1; 3.4.23.2; 3.4.23.3) }	<b>15/00</b>	<b>Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor (mutants or genetically engineered microorganisms, per se <a href="#">C12N 1/00</a>, <a href="#">C12N 5/00</a>, <a href="#">C12N 7/00</a>; new plants per se <a href="#">A01H 1/00</a>; plant reproduction by tissue culture techniques <a href="#">A01H 4/00</a>; new animals per se <a href="#">A01K 67/00</a>; use of medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases, gene therapy <a href="#">A61K 48/00</a>)</b>	
9/6483	. . . . .	{ Chymosin (3.4.23.4), i.e. rennin }	15/01	. Preparation of mutants without inserting foreign genetic material therein; Screening processes therefor	
9/6486	. . . . .	{ Renin (3.4.23.15) }	15/02	. Preparation of hybrid cells by fusion of two or more cells, e.g. protoplast fusion {(monoclonal antibodies <a href="#">C07K 16/00</a> ; apparatus for cell fusion <a href="#">C12M</a> )}	
9/6489	. . . . .	{ Metalloendopeptidases (3.4.24) }	15/03	. . Bacteria	
9/6491	. . . . .	{ Matrix metalloproteases [MMP's], e.g. interstitial collagenase (3.4.24.7); Stromelysins (3.4.24.17; 3.2.1.22); Matrilysin (3.4.24.23) }	15/04	. . Fungi	
9/6494	. . . . .	{ Neprilysin (3.4.24.11), i.e. enkephalinase or neutral-endopeptidase 24.11 }	15/09	. Recombinant DNA-technology	
9/6497	. . . . .	{ Endothelin-converting enzyme (3.4.24.71) }			
9/78	. .	acting on carbon to nitrogen bonds other than peptide bonds (3.5)			
9/80	. . .	acting on amide bonds in linear amides {(3.5.1)}			
9/82	. . . .	Asparaginase {(3.5.1.1)}			
9/84	. . . .	Penicillin amidase {(3.5.1.11)}			



- 15/10 . . . Processes for the isolation, preparation or purification of DNA or RNA ([chemical preparation of DNA or RNA C07H 21/00](#); [preparation of non-structural polynucleotides from microorganisms or with enzymes C12P 19/34](#))
- NOTE**
- {In groups [C12N 15/10](#) - [C12N 15/1096](#), C-Sets are used for classification. The detailed information about the C-Sets construction and the associated syntax rules are found in the Definitions of [C12N](#)}.
- 15/1003 . . . {Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor}
- 15/1006 . . . . {by means of a solid support carrier, e.g. particles, polymers}
- 15/101 . . . . {by chromatography, e.g. electrophoresis, ion-exchange, reverse phase}
- 15/1013 . . . . {by using magnetic beads}
- 15/1017 . . . . {by filtration, e.g. using filters, frits, membranes}
- 15/102 . . . {Mutagenizing nucleic acids}
- 15/1024 . . . . {*In vivo* mutagenesis using high mutation rate "mutator" host strains by inserting genetic material, e.g. encoding an error prone polymerase, disrupting a gene for mismatch repair}
- 15/1027 . . . . {by DNA shuffling, e.g. RSR, STEP, RPR}
- 15/1031 . . . . {mutagenesis by gene assembly, e.g. assembly by oligonucleotide extension PCR}
- 15/1034 . . . {Isolating an individual clone by screening libraries}
- 15/1037 . . . . {Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display}
- 15/1041 . . . . {Ribosome/Polysome display, e.g. SPERT, ARM}
- 15/1044 . . . . {Preparation or screening of libraries displayed on scaffold proteins}
- 15/1048 . . . . {SELEX}
- 15/1051 . . . . {Gene trapping, e.g. exon-, intron-, IRES-, signal sequence-trap cloning, trap vectors}
- 15/1055 . . . . {Protein x Protein interaction, e.g. two hybrid selection}
- 15/1058 . . . . {Directional evolution of libraries, e.g. evolution of libraries is achieved by mutagenesis and screening or selection of mixed population of organisms}
- 15/1062 . . . . {mRNA-Display, e.g. polypeptide and encoding template are connected covalently}
- 15/1065 . . . . {Preparation or screening of tagged libraries, e.g. tagged microorganisms by STM-mutagenesis, tagged polynucleotides, gene tags}
- 15/1068 . . . . {Template (nucleic acid) mediated chemical library synthesis, e.g. chemical and enzymatical DNA-templated organic molecule synthesis, libraries prepared by non ribosomal polypeptide synthesis [NRPS], DNA/RNA-polymerase mediated polypeptide synthesis}

- 15/1072 . . . . {Differential gene expression library synthesis, e.g. subtracted libraries, differential screening}
- 15/1075 . . . . {by coupling phenotype to genotype, not provided for in other groups of this subclass}
- 15/1079 . . . . {Screening libraries by altering the phenotype or phenotypic trait of the host ([reporter assays C12N 15/1086](#))}
- 15/1082 . . . . {Preparation or screening gene libraries by chromosomal integration of polynucleotide sequences, HR-, site-specific-recombination, transposons, viral vectors}
- 15/1086 . . . . {Preparation or screening of expression libraries, e.g. reporter assays}
- 15/1089 . . . . {Design, preparation, screening or analysis of libraries using computer algorithms}
- 15/1093 . . . . {General methods of preparing gene libraries, not provided for in other subgroups}
- 15/1096 . . . {cDNA Synthesis; Subtracted cDNA library construction, e.g. RT, RT-PCR}
- 15/11 . . . DNA or RNA fragments; Modified forms thereof ([DNA or RNA not used in recombinant technology, C07H 21/00](#)); {Non-coding nucleic acids having a biological activity}

**NOTE**

Documents relating to DNA or its corresponding RNA and their use in recombinant DNA technology or the preparation of specific peptides, e.g. enzymes, are classified in subclass [C07K](#) or in group [C12N 9/00](#) according to the peptides, with the appropriate indexing codes relating to their use in recombinant technology. Groups [C12N 15/11](#) - [C12N 15/117](#) cover also the use of non-coding nucleic acids as active ingredients in medicinal preparations. The [C12N 2303/00](#) ICO scheme has to be applied to these groups. When documents classifiable in one or more subgroups disclose general principles of the technology applicable to the whole field, classification is also made in group [C12N 15/111](#)

- 15/111 . . . {General methods applicable to biologically active non-coding nucleic acids}
- 15/113 . . . Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing ([when used in plants C12N 15/8218](#))}
- 15/1131 . . . . {against viruses}
- 15/1132 . . . . . {against retroviridae, e.g. HIV}
- 15/1133 . . . . . {against herpesviridae, e.g. HSV}
- 15/1135 . . . . {against oncogenes or tumor suppressor genes}
- 15/1136 . . . . {against growth factors, growth regulators, cytokines, lymphokines or hormones}
- 15/1137 . . . . {against enzymes ([viral enzymes C12N 15/1131](#); [receptors C12N 15/1138](#))}
- 15/1138 . . . . {against receptors or cell surface proteins}

- 15/115 . . . Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith {; Nucleic acids binding to non-nucleic acids, e.g. aptamers}

**NOTE**

Aptamers fused to compounds which are already classified in groups [C12N 15/11](#) - [C12N 15/117](#), are classified with the corresponding compound

- 15/117 . . . Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
- 15/52 . . . Genes encoding for enzymes or proenzymes

**NOTE**

In this group genes encoding for proenzymes are classified with the corresponding genes encoding enzymes.

- 15/62 . . . DNA sequences coding for fusion proteins

**NOTE**

In this group, the following term is used with the meaning indicated:

- "fusion" means the fusion of two different proteins.

- 15/625 . . . {containing a sequence coding for a signal sequence}
- 15/63 . . Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- 15/635 . . . {Externally inducible repressor mediated regulation of gene expression, e.g. tetR inducible by tetracycline}
- 15/64 . . . General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host

**NOTE**

{In the group [C12N 15/64](#), C-Sets are used for classification. The detailed information about the C-Sets construction and the associated syntax rules are found in the Definitions of [C12N](#)}

- 15/65 . . . using markers (enzymes used as markers [C12N 15/52](#))

**NOTE**

{In the group [C12N 15/65](#), C-Sets are used for classification. The detailed information about the C-Sets construction and the associated syntax rules are found in the Definitions of [C12N](#)}

- 15/66 . . . General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligation; Use of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease

**NOTES**

1. In this group, the following expression is used with the meaning indicated:
  - "non-functional linkers" means DNA sequences which are used to link DNA

sequences and which have no known function of structural gene or regulating function.

2. {In the group [C12N 15/66](#), C-Sets are used for classification. The detailed information about the C-Sets construction and the associated syntax rules are found in the Definitions of [C12N](#)}

- 15/67 . . . General methods for enhancing the expression
- 15/68 . . . . Stabilisation of the vector
- 15/69 . . . . Increasing the copy number of the vector
- 15/70 . . . Vectors or expression systems specially adapted for E. coli

**NOTES**

1. This group covers the use of E. coli as host.
2. Shuttle vectors also replicating in E. coli are classified according to the other host.

- 15/71 . . . . Expression systems using regulatory sequences derived from the trp-operon
- 15/72 . . . . Expression systems using regulatory sequences derived from the lac-operon
- 15/73 . . . . Expression systems using phage (lambda) regulatory sequences
- 15/74 . . . Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora

**NOTE**

This group covers the use of prokaryotes as hosts.

- 15/743 . . . . {for Agrobacterium; Rhizobium; Bradyrhizobium}
- 15/746 . . . . {for lactic acid bacteria (Streptococcus; Lactococcus; Lactobacillus; Pediococcus; Enterococcus; Leuconostoc; Propionibacterium; Bifidobacterium; Sporolactobacillus)}
- 15/75 . . . . for Bacillus
- 15/76 . . . . for Actinomyces; for Streptomyces
- 15/77 . . . . for Corynebacterium; for Brevibacterium
- 15/78 . . . . for Pseudomonas
- 15/79 . . . Vectors or expression systems specially adapted for eukaryotic hosts

**NOTE**

This group covers the use of eukaryotes as hosts.

- 15/80 . . . . for fungi
- 15/81 . . . . . for yeasts
- 15/815 . . . . . {for yeasts other than Saccharomyces}
- 15/82 . . . . for plant cells {, e.g. plant artificial chromosomes (PACs)}

**WARNING**

Documents are being continuously reclassified into this new classification scheme. See Warning notes below

- 15/8201 . . . . . {Methods for introducing genetic material into plant cells, e.g. DNA, RNA, stable or transient incorporation, tissue culture methods adapted for transformation}

15/8202	. . . . .	{by biological means, e.g. cell mediated or natural vector}	15/8235	. . . . .	{Fruit-specific}
15/8203	. . . . .	{Virus mediated transformation}	15/8237	. . . . .	{Externally regulated expression systems}
15/8205	. . . . .	{Agrobacterium mediated transformation}	15/8238	. . . . .	{chemically inducible, e.g. tetracycline}
15/8206	. . . . .	{by physical or chemical, i.e. non-biological, means, e.g. electroporation, PEG mediated}	15/8239	. . . . .	{pathogen inducible}
15/8207	. . . . .	{by mechanical means, e.g. microinjection, particle bombardment, silicon whiskers}	15/8241	. . . . .	{Phenotypically and genetically modified plants via recombinant DNA technology}
15/8209	. . . . .	{Selection, visualisation of transformants, reporter constructs, e.g. antibiotic resistance markers}	15/8242	. . . . .	{with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits}
		<b>NOTE</b>	15/8243	. . . . .	{involving biosynthetic or metabolic pathways, i.e. metabolic engineering, e.g. nicotine, caffeine}
		Standard selectable markers such as neomycin phosphotransferase (NPT) are not systematically classified in <a href="#">C12N 15/8209</a>	15/8245	. . . . .	{involving modified carbohydrate or sugar alcohol metabolism, e.g. starch biosynthesis}
15/821	. . . . .	{Non-antibiotic resistance markers, e.g. morphogenetic, metabolic markers}	15/8246	. . . . .	{Non-starch polysaccharides, e.g. cellulose, fructans, levans}
15/8212	. . . . .	{Colour markers, e.g. beta-glucuronidase [GUS], green fluorescent protein [GFP], carotenoid}	15/8247	. . . . .	{involving modified lipid metabolism, e.g. seed oil composition}
15/8213	. . . . .	{Targeted insertion of genes into the plant genome by homologous recombination}	15/8249	. . . . .	{involving ethylene biosynthesis, senescence or fruit development, e.g. modified tomato ripening, cut flower shelf-life}
15/8214	. . . . .	{Plastid transformation}	15/825	. . . . .	{involving pigment biosynthesis}
15/8216	. . . . .	{Methods for controlling, regulating or enhancing expression of transgenes in plant cells}			<b>NOTE</b>
15/8217	. . . . .	{Gene switch}			Transgenic plants with altered flower morphology are also classified in this group
15/8218	. . . . .	{Antisense, co-suppression, viral induced gene silencing [VIGS], post-transcriptional induced gene silencing [PTGS]}	15/8251	. . . . .	{Amino acid content, e.g. synthetic storage proteins, altering amino acid biosynthesis}
15/822	. . . . .	{Reducing position variability, e.g. by the use of scaffold attachment region/matrix attachment region (SAR/MAR); Use of SAR/MAR to regulate gene expression}	15/8253	. . . . .	{Methionine or cysteine}
15/8221	. . . . .	{Transit peptides}	15/8254	. . . . .	{Tryptophan or lysine}
15/8222	. . . . .	{Developmentally regulated expression systems, tissue, organ specific, temporal or spatial regulation}	15/8255	. . . . .	{involving lignin biosynthesis}
15/8223	. . . . .	{Vegetative tissue-specific promoters}	15/8257	. . . . .	{for the production of primary gene products, e.g. pharmaceutical products, interferon}
15/8225	. . . . .	{Leaf-specific, e.g. including petioles, stomata}	15/8258	. . . . .	{for the production of oral vaccines (antigens) or immunoglobulins}
15/8226	. . . . .	{Stem-specific, e.g. including tubers, beets}	15/8259	. . . . .	{Phytoremediation}
15/8227	. . . . .	{Root-specific}	15/8261	. . . . .	{with agronomic (input) traits, e.g. crop yield}
15/8229	. . . . .	{Meristem-specific, e.g. nodal, apical}	15/8262	. . . . .	{involving plant development}
15/823	. . . . .	{Reproductive tissue-specific promoters}	15/8263	. . . . .	{Ablation; Apoptosis}
15/8231	. . . . .	{Male-specific, e.g. anther, tapetum, pollen}	15/8265	. . . . .	{Transgene containment, e.g. gene dispersal}
15/8233	. . . . .	{Female-specific, e.g. pistil, ovule}	15/8266	. . . . .	{Abscission; Dehiscence; Senescence}
15/8234	. . . . .	{Seed-specific, e.g. embryo, endosperm}	15/8267	. . . . .	{Seed dormancy, germination or sprouting}
			15/8269	. . . . .	{Photosynthesis}
			15/827	. . . . .	{Flower development or morphology, e.g. flowering promoting factor [FPF]}
			15/8271	. . . . .	{for stress resistance, e.g. heavy metal resistance}
			15/8273	. . . . .	{for drought, cold, salt resistance}
			15/8274	. . . . .	{for herbicide resistance}
			15/8275	. . . . .	{Glyphosate}

15/8277	. . . . .	{Phosphinotricin}	15/8616	. . . . .	{Special methods for targeting systems}
15/8278	. . . . .	{Sulfonylurea}	15/863	. . . . .	Poxviral vectors, {e.g. entomopoxvirus}
15/8279	. . . . .	{for biotic stress resistance, pathogen resistance, disease resistance}	15/8633	. . . . .	{Avian poxviral vectors}
15/8281	. . . . .	{for bacterial resistance}	15/8636	. . . . .	{Vaccina virus vectors}
15/8282	. . . . .	{for fungal resistance}	15/864	. . . . .	Parvoviral vectors {, e.g. parvovirus, densovirus}
15/8283	. . . . .	{for virus resistance}	15/8645	. . . . .	{Adeno-associated virus}
15/8285	. . . . .	{for nematode resistance}	15/866	. . . . .	Baculoviral vectors
15/8286	. . . . .	{for insect resistance}	15/867	. . . . .	Retroviral vectors
15/8287	. . . . .	{for fertility modification, e.g. apomixis}	15/8673	. . . . .	{Special methods for packaging systems}
15/8289	. . . . .	{Male sterility}	15/8676	. . . . .	{Special methods for targeting systems}
15/829	. . . . .	{Female sterility}	15/869	. . . . .	Herpesviral vectors
15/8291	. . . . .	{Hormone-influenced development}	15/8695	. . . . .	{Herpes simplex virus-based vectors}
15/8293	. . . . .	{Abscisic acid [ABA]}	15/87	. .	Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
15/8294	. . . . .	{Auxins}	15/873	. . .	Techniques for producing new embryos, e.g. nuclear transfer, manipulation of totipotent cells or production of chimeric embryos
15/8295	. . . . .	{Cytokinins}	15/877	. . . .	Techniques for producing new mammalian cloned embryos
15/8297	. . . . .	{Gibberellins; GA3}	15/8771	. . . . .	{Bovine embryos}
15/8298	. . . . .	{Brassinosteroids}	15/8772	. . . . .	{Caprine embryos}
15/85	. . . .	for animal cells	15/8773	. . . . .	{Ovine embryos}
15/8509	. . . . .	{for producing genetically modified animals, e.g. transgenic}	15/8775	. . . . .	{Murine embryos}
<b>NOTE</b>			15/8776	. . . . .	{Primate embryos}
Additional aspects of the modified animals are classified in the groups <a href="#">A01K 2207/00</a> - <a href="#">A01K 2267/00</a>			15/8777	. . . . .	{Rabbit embryos}
2015/8518	. . . . .	{expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles}	15/8778	. . . . .	{Swine embryos}
2015/8527	. . . . .	{for producing animal models, e.g. for tests or diseases}	15/88	. . .	using microencapsulation, e.g. using {amphiphile} liposome vesicle
2015/8536	. . . . .	{Animal models for genetic diseases}	15/89	. . .	using microinjection
2015/8545	. . . . .	{for Alzheimer's disease}	15/895	. . . .	{using biolistic methods}
2015/8554	. . . . .	{Invertebrates models for Alzheimer's disease}	15/90	. . .	Stable introduction of foreign DNA into chromosome
2015/8563	. . . . .	{for autoimmune diseases, e.g. Insulin-dependent diabetes mellitus}	15/902	. . . .	{using homologous recombination}
2015/8572	. . . . .	{Animal models for proliferative diseases, e.g. comprising an oncogene}	15/905	. . . . .	{in yeast}
2015/8581	. . . . .	{Animal models for infectious diseases, e.g. AIDS}	15/907	. . . . .	{in mammalian cells}
2015/859	. . . . .	{Animal models comprising reporter system for screening tests}	<b>2303/00 Indexing codes associated with general methodologies in the field of biologically active non-coding nucleic acids</b>		
15/86	. . . . .	Viral vectors	<b>NOTE</b>		
<b>WARNING</b>			Indexing codes of group <a href="#">C12N 2303/00</a> are only used in combination with group <a href="#">C12N 15/111</a>		
From March 15, 2012 groups <a href="#">C12N 15/861</a> - <a href="#">C12N 15/869</a> and subgroups thereof are no longer used for the classification of new documents. The documents in these (sub)groups are being reclassified to the corresponding codes in the range <a href="#">C12N 2710/00</a> - <a href="#">C12N 2795/00</a>			<b>2310/00 Structure or type of the nucleic acid</b>		
15/861	. . . . .	Adenoviral vectors	<b>NOTE</b>		
15/8613	. . . . .	{Chimaeric vector systems comprising heterologous sequences for production of another viral vector}	In groups <a href="#">C12N 2310/00</a> - <a href="#">C12N 2310/533</a> , C-Sets are used for classification. The detailed information about the C-Sets construction and the associated syntax rules are found in the Definitions of <a href="#">C12N</a> .		
			2310/10	. .	Type of nucleic acid
			2310/11	. .	Antisense
			2310/111	. . .	spanning the whole gene, or a large part of it
			2310/113	. . .	targeting other non-coding nucleic acids, e.g. antagomirs
			2310/12	. .	catalytic nucleic acids, e.g. ribozymes



2310/121	. . .	Hammerhead	2310/345	. . .	having at least two different backbone modifications
2310/122	. . .	Hairpin	2310/346	. . .	having a combination of backbone and sugar modifications
2310/123	. . .	Hepatitis delta	2310/35	. .	Nature of the modification
2310/124	. . .	based on group I or II introns	2310/351	. . .	Conjugate
2310/1241	. . . .	Tetrahymena	2310/3511	. . . .	intercalating or cleaving agent
2310/126	. . .	involving RNase P	2310/3513	. . . .	Protein; Peptide
2310/127	. . .	DNAzymes	2310/3515	. . . .	Lipophilic moiety, e.g. cholesterol
2310/128	. . .	processing or releasing ribozyme	2310/3517	. . . .	Marker; Tag
2310/13	. .	Decoys	2310/3519	. . . .	Fusion with another nucleic acid
2310/14	. .	interfering N.A.	2310/352	. . .	linked to the nucleic acid via a carbon atom
2310/141	. . .	MicroRNAs, miRNAs	2310/3521	. . . .	Methyl
2310/15	. .	Nucleic acids forming more than 2 strands, e.g. TFOs	2310/3523	. . . .	Allyl
2310/151	. . .	more than 3 strands, e.g. tetrads, H-DNA	2310/3525	. . . .	MOE, methoxyethoxy
2310/152	. . .	on a single-stranded target, e.g. fold-back TFOs	2310/3527	. . . .	Other alkyl chain
2310/153	. . .	with the aid of a protein, e.g. recombinase	2310/3529	. . . .	Aromatic substituent
2310/16	. .	Aptamers	2310/353	. . .	linked to the nucleic acid via an atom other than carbon
2310/17	. .	Immunomodulatory nucleic acids	2310/3531	. . . .	Hydrogen
2310/18	. .	acting by a non-sequence specific mechanism (other than C12N 2310/16 or C12N 2310/17)	2310/3533	. . . .	Halogen
2310/20	. .	involving clustered regularly interspaced short palindromic repeats [CRISPRs]	2310/3535	. . . .	Nitrogen
2310/30	. .	Chemical structure	2310/50	. .	Physical structure
2310/31	. .	of the backbone	2310/51	. .	in polymeric form, e.g. multimers, concatemers
2310/311	. . .	Phosphotriesters	2310/52	. .	branched
2310/312	. . .	Phosphonates	2310/53	. .	partially self-complementary or closed
2310/3125	. . . .	Methylphosphonates	2310/531	. . .	Stem-loop; Hairpin
2310/313	. . .	Phosphorodithioates	2310/532	. . .	Closed or circular
2310/314	. . .	Phosphoramidates	2310/533	. . .	having a mismatch or nick in at least one of the strands
2310/3145	. . . .	with the nitrogen in 3' or 5'-position	<b>2320/00</b>	<b>Applications; Uses</b>	
2310/315	. . .	Phosphorothioates	2320/10	. .	in screening processes
2310/316	. . .	Phosphonothioates	2320/11	. .	for the determination of target sites, i.e. of active nucleic acids
2310/317	. . .	with an inverted bond, e.g. a cap structure	2320/12	. .	in functional genomics, i.e. for the determination of gene function
2310/318	. . .	where the PO2 is completely replaced, e.g. MMI or formacetal	2320/13	. .	in a process of directed evolution, e.g. SELEX, acquiring a new function
2310/3181	. . . .	Peptide nucleic acid, PNA	2320/30	. .	Special therapeutic applications
2310/3183	. . . .	Diol linkers, e.g. glycols or propanediols	2320/31	. .	Combination therapy
2310/319	. . .	linked by 2'-5' linkages, i.e. having a free 3'-position	2320/32	. .	Special delivery means, e.g. tissue-specific
2310/32	. .	of the sugar	2320/33	. .	Alteration of splicing
2310/321	. . .	2'-O-R Modification	2320/34	. .	Allele or polymorphism specific uses
2310/322	. . .	2'-R Modification	2320/35	. .	based on a specific dosage / administration regimen
2310/323	. . .	modified ring structure	2320/50	. .	Methods for regulating/modulating their activity
2310/3231	. . . .	having an additional ring, e.g. LNA, ENA	2320/51	. .	modulating the chemical stability, e.g. nuclease-resistance
2310/3233	. . . .	Morpholino-type ring	2320/52	. .	modulating the physical stability, e.g. GC-content
2310/3235	. . . .	having the O of the ribose replaced by another atom	2320/53	. .	reducing unwanted side-effects
2310/33	. .	of the base	<b>2330/00</b>	<b>Production</b>	
2310/331	. . .	Universal or degenerate base	2330/10	. .	naturally occurring
2310/332	. . .	Abasic residue	2330/30	. .	chemically synthesised
2310/333	. . .	Modified A	2330/31	. .	Libraries, arrays
2310/334	. . .	Modified C	2330/50	. .	Biochemical production, i.e. in a transformed host cell
2310/3341	. . . .	5-Methylcytosine	2330/51	. .	Specially adapted vectors
2310/335	. . .	Modified T or U	<b>2500/00</b>	<b>Specific components of cell culture medium</b>	
2310/336	. . .	Modified G	2500/02	. .	Atmosphere, e.g. low oxygen conditions
2310/337	. . .	in alpha-anomeric form	2500/05	. .	Inorganic components
2310/34	. .	Spatial arrangement of the modifications			
2310/341	. . .	Gapmers, i.e. of the type ===-----			
2310/342	. . .	Hemimers, i.e. of the type =====			
2310/343	. . .	having patterns, e.g. =====			
2310/344	. . .	Position-specific modifications, e.g. on every purine, at the 3'-end			



- 2500/10 . . Metals; Metal chelators ([cobalamine C12N 2500/38](#))
- 2500/12 . . . Light metals, i.e. alkali, alkaline earth, Be, Al, Mg
- 2500/14 . . . . Calcium; Ca chelators; Calcitonin
- 2500/16 . . . . Magnesium; Mg chelators
- 2500/20 . . . . Transition metals
- 2500/22 . . . . Zinc; Zn chelators ([insulin-zinc complexes C12N 2501/33](#))
- 2500/24 . . . . Iron; Fe chelators; Transferrin
- 2500/25 . . . . . Insulin-transferrin; Insulin-transferrin-selenium
- 2500/30 . Organic components ([metal chelators C12N 2500/10](#); [calcitonin C12N 2500/14](#); [transferrin C12N 2500/24](#))
- 2500/32 . . Amino acids
- 2500/33 . . . other than alpha-amino carboxylic acids, e.g. beta-amino acids, taurine
- 2500/34 . . Sugars
- 2500/35 . . Polyols, e.g. glycerin, inositol
- 2500/36 . . Lipids
- 2500/38 . . Vitamins
- 2500/40 . . Nucleotides, nucleosides, bases ([cyclic nucleotides C12N 2501/01](#), [anti-neoplastic drugs C12N 2501/06](#))
- 2500/42 . . Organic phosphate, e.g. beta glycerophosphate
- 2500/44 . . Thiols, e.g. mercaptoethanol
- 2500/46 . . Amines, e.g. putrescine
- 2500/50 . Soluble polymers, e.g. polyethyleneglycol [PEG]
- 2500/60 . Buffer, e.g. pH regulation, osmotic pressure
- 2500/62 . . DMSO
- 2500/70 . Undefined extracts ([conditioned medium C12N 2502/00](#))
- 2500/72 . . from bacteria
- 2500/74 . . from fungi, e.g. yeasts
- 2500/76 . . from plants
- 2500/78 . . from protozoa
- 2500/80 . . from animals
- 2500/82 . . . from invertebrates
- 2500/84 . . . from mammals
- 2500/90 . Serum-free medium, which may still contain naturally-sourced components
- 2500/92 . . Medium free of human- or animal-derived components
- 2500/95 . . Protein-free medium and culture conditions
- 2500/98 . Xeno-free medium and culture conditions
- 2500/99 . Serum-free medium

**WARNING**

This group is no longer used for the classification of new documents as from January 1, 2012.

The backlog of this group is being continuously reclassified to [C12N 2500/90](#) - [C12N 2500/98](#)

**2501/00 Active agents used in cell culture processes, e.g. differentiation**
**NOTE**

Whenever possible, indexation is done by signalling pathway and not by chemical structure, e.g. the group of a protein covers not only peptide analogs of it and the corresponding nucleic acids, as in [C07K 14/00](#), but also antibodies, anti-idiotypic antibodies, non-peptide ligands of the

receptor, the receptor itself, antibodies against the receptor or inhibitors of the conversion enzyme which processes the protein precursor. Unless otherwise provided for, ligands and substrates take precedence over receptors and enzymes.

- 2501/01 . Modulators of cAMP or cGMP, e.g. non-hydrolysable analogs, phosphodiesterase inhibitors, cholera toxin
- 2501/02 . Compounds of the arachidonic acid pathway, e.g. prostaglandins, leukotrienes
- 2501/03 . Compounds acting on the NO pathway, e.g. nitrososarginine
- 2501/04 . Immunosuppressors, e.g. cyclosporin, tacrolimus
- 2501/05 . Adjuvants
- 2501/051 . . Lipid A (MPA, MPL)
- 2501/052 . . Lipopolysaccharides [LPS]
- 2501/054 . . Muramyle peptides
- 2501/056 . . Immunostimulating oligonucleotides, e.g. CpG
- 2501/06 . Anti-neoplastic drugs, anti-retroviral drugs, e.g. azacytidine, cyclophosphamide
- 2501/065 . Modulators of histone acetylation
- 2501/07 . Heat shock proteins
- 2501/10 . Growth factors
- 2501/105 . . Insulin-like growth factors [IGF]
- 2501/11 . . Epidermal growth factor [EGF]
- 2501/113 . . Acidic fibroblast growth factor (aFGF, FGF-1)
- 2501/115 . . Basic fibroblast growth factor (bFGF, FGF-2)
- 2501/117 . . Keratinocyte growth factors (KGF-1, i.e. FGF-7; KGF-2, i.e. FGF-12)
- 2501/119 . . Other fibroblast growth factors, e.g. FGF-4, FGF-8, FGF-10
- 2501/12 . . Hepatocyte growth factor [HGF]
- 2501/125 . . Stem cell factor [SCF], c-kit ligand [KL]
- 2501/13 . . Nerve growth factor [NGF]; Brain-derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial-derived neurotrophic factor [GDNF]; Neurotrophins [NT]; Neuregulins
- 2501/135 . . Platelet-derived growth factor [PDGF]
- 2501/14 . . Erythropoietin [EPO]
- 2501/145 . . Thrombopoietin [TPO]
- 2501/148 . . Transforming growth factor alpha [TGF- $\alpha$ ]
- 2501/15 . . Transforming growth factor beta (TGF- $\beta$ )
- 2501/155 . . Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
- 2501/16 . . Activin; Inhibin; Mullerian inhibiting substance
- 2501/165 . . Vascular endothelial growth factor [VEGF]
- 2501/17 . . Angiopoietin
- 2501/175 . . Cardiotrophin
- 2501/18 . . Liver cell growth factor (LCGF, Gly-His-Lys)
- 2501/185 . . Osteoprotegerin; Osteoclast differentiation factor (ODF, RANKL)
- 2501/19 . . Growth and differentiation factors [GDF]
- 2501/195 . . Heregulin, neu differentiation factor
- 2501/20 . Cytokines; Chemokines
- 2501/21 . . Chemokines, e.g. MIP-1, MIP-2, RANTES, MCP, PF-4
- 2501/22 . . Colony stimulating factors (G-CSF, GM-CSF)
- 2501/23 . . Interleukins [IL]
- 2501/2301 . . . Interleukin-1 (IL-1)
- 2501/2302 . . . Interleukin-2 (IL-2)
- 2501/2303 . . . Interleukin-3 (IL-3)

2501/2304	. . . Interleukin-4 (IL-4)	2501/385	. . . of the family of the retinoic acid receptor, e.g. RAR, RXR; Peroxisome proliferator-activated receptor [PPAR]
2501/2305	. . . Interleukin-5 (IL-5)	2501/39	. . . Steroid hormones
2501/2306	. . . Interleukin-6 (IL-6)	2501/392	. . . Sexual steroids
2501/2307	. . . Interleukin-7 (IL-7)	2501/395	. . . Thyroid hormones
2501/2308	. . . Interleukin-8 (IL-8)	2501/40	. Regulators of development
2501/2309	. . . Interleukin-9 (IL-9)	2501/405	. . Cell cycle regulated proteins, e.g. cyclins, cyclin-dependant kinases
2501/231	. . . Interleukin-10 (IL-10)	2501/41	. . Hedgehog proteins; Cyclopamine (inhibitor)
2501/2311	. . . Interleukin-11 (IL-11)	2501/415	. . Wnt; Frizzled
2501/2312	. . . Interleukin-12 (IL-12)	2501/42	. . Notch; Delta; Jagged; Serrate
2501/2313	. . . Interleukin-13 (IL-13)	2501/48	. . Regulators of apoptosis
2501/2314	. . . Interleukin-14 (IL-14)	2501/50	. Cell markers; Cell surface determinants
2501/2315	. . . Interleukin-15 (IL-15)	2501/505	. . CD4; CD8
2501/2316	. . . Interleukin-16 (IL-16)	2501/51	. . B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
2501/2317	. . . Interleukin-17 (IL-17)	2501/515	. . CD3, T-cell receptor complex
2501/2318	. . . Interleukin-18 (IL-18)	2501/52	. . CD40, CD40-ligand (CD154)
2501/2319	. . . Interleukin-19 (IL-19)	2501/53	. . CD2
2501/232	. . . Interleukin-20 (IL-20)	2501/58	. . Adhesion molecules, e.g. ICAM, VCAM, CD18 (ligand), CD11 (ligand), CD49 (ligand)
2501/2321	. . . Interleukin-21 (IL-21)	2501/585	. . Integrins
2501/2322	. . . Interleukin-22 (IL-22)	2501/59	. . Lectins
2501/2323	. . . Interleukin-23 (IL-23)	2501/599	. . with CD designations not provided for elsewhere
2501/2324	. . . Interleukin-24 (IL-24)	2501/60	. Transcription factors
2501/2325	. . . Interleukin-25 (IL-25)	2501/602	. . Sox-2
2501/2326	. . . Interleukin-26 (IL-26)	2501/603	. . Oct-3/4
2501/2327	. . . Interleukin-27 (IL-27)	2501/604	. . Klf-4
2501/2328	. . . Interleukin-28 (IL-28)	2501/605	. . Nanog
2501/2329	. . . Interleukin-29 (IL-29)	2501/606	. . c-Myc
2501/233	. . . Interleukin-30 (IL-30)	2501/608	. . Lin28
2501/2331	. . . Interleukin-31 (IL-31)	2501/65	. MicroRNA
2501/2332	. . . Interleukin-32 (IL-32)	2501/70	. Enzymes
2501/2333	. . . Interleukin-33 (IL-33)	2501/71	. . Oxidoreductases (EC 1.)
2501/2334	. . . Interleukin-34 (IL-34)	2501/72	. . Transferases (EC 2.) ( <a href="#">acetylation of histones C12N 2501/065</a> )
2501/2335	. . . Interleukin-35 (IL-35)	2501/724	. . . Glycosyltransferases (EC 2.4.)
2501/235	. . . Leukemia inhibitory factor [LIF]	2501/727	. . . Kinases (EC 2.7.)
2501/237	. . Oncostatin M [OSM]	2501/73	. . Hydrolases (EC 3.)
2501/24	. . Interferons [IFN]	2501/734	. . . Proteases (EC 3.4.)
2501/25	. . Tumour necrosis factors [TNF]	2501/80	. Neurotransmitters; Neurohormones
2501/26	. . Flt-3 ligand (CD135L, flk-2 ligand)	2501/805	. . Acetylcholine
2501/30	. Hormones ( <a href="#">derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin C12N 2501/85</a> )	2501/81	. . Adrenaline
2501/305	. . Growth hormone [GH], aka. somatotropin	2501/815	. . Dopamine
2501/31	. . Pituitary sex hormones, e.g. follicle-stimulating hormone [FSH], luteinising hormone [LH]; Chorionic gonadotropins	2501/82	. . Histamine
2501/315	. . Prolactin	2501/825	. . Serotonine (5-HT); Melatonin
2501/32	. . Angiotensins [AT], angiotensinogen	2501/83	. . Tachykinins, e.g. substance P
2501/33	. . Insulin ( <a href="#">together with transferrin C12N 2500/25; Insulin-like growth factors C12N 2501/105</a> )	2501/835	. . Neuropeptide Y [NPY]; Peptide YY [PYY]
2501/335	. . Glucagon; Glucagon-like peptide [GLP]; Exendin	2501/84	. . Excitatory amino acids
2501/34	. . Calcitonin; Calcitonin-gene related peptide [CGRO]; Amylin	2501/845	. . Gamma amino butyric acid [GABA]
2501/345	. . Gastrin; Cholecystokinins [CCK]	2501/85	. Hormones derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
2501/35	. . Vasoactive intestinal peptide [VIP]; Pituitary adenylate cyclase activating polypeptide [PACAP]	2501/855	. . Corticotropin [ACTH]
2501/355	. . Leptin	2501/86	. . Melanocyte-stimulating hormone [MSH]
2501/36	. . Somatostatin	2501/90	. Polysaccharides
2501/365	. . Endothelin	2501/905	. . Hyaluronic acid
2501/37	. . Parathyroid hormone [PTH]	2501/91	. . Heparin
2501/375	. . Thyroid stimulating hormone [TSH]	2501/998	. Proteins not provided for elsewhere
2501/38	. . with nuclear receptors		

**NOTE**

Classification by pathway does not apply.

2501/999 . Small molecules not provided for elsewhere

#### **NOTE**

Classification by pathway does not apply.

#### **2502/00 Coculture with; Conditioned medium produced by**

2502/02 . embryonic cells

2502/025 . . extra-embryonic cells, e.g. amniotic epithelium, placental cells, Wharton's jelly

2502/03 . non-embryonic pluripotent stem cells

2502/04 . germ cells

2502/07 . endocrine cells

2502/072 . . adrenal cells

2502/074 . . pinealocytes

2502/076 . . pituitary cells

2502/078 . . thyroid, parathyroid cells

2502/08 . cells of the nervous system

2502/081 . . neurons

2502/083 . . sensory transducers

2502/085 . . eye cells

2502/086 . . glial cells

2502/088 . . neural stem cells

2502/09 . epidermal cells, skin cells, oral mucosa cells

2502/091 . . melanocytes

2502/092 . . hair cells

2502/094 . . keratinocytes

2502/095 . . mammary cells

2502/097 . . oral mucosa cells

2502/098 . . cells of secretory glands, e.g. parotid gland, salivary glands, sweat glands, lacrymal glands

2502/11 . blood or immune system cells

2502/1107 . . B cells

2502/1114 . . T cells

2502/1121 . . Dendritic cells

2502/1128 . . Erythrocytes

2502/1135 . . Granulocytes

2502/1142 . . Osteoclasts

2502/115 . . Platelets, megakaryocytes

2502/1157 . . Monocytes, macrophages

2502/1164 . . NK cells

2502/1171 . . Haematopoietic stem cells

2502/1178 . . Spleen cells

2502/1185 . . Thymus cells

2502/1192 . . Lymphatic cells

2502/13 . connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"

2502/1305 . . Adipocytes

2502/1311 . . Osteocytes, osteoblasts, odontoblasts

2502/1317 . . Chondrocytes

2502/1323 . . Adult fibroblasts

2502/1329 . . Cardiomyocytes

2502/1335 . . Skeletal muscle cells, myocytes, myoblasts, myotubes

2502/1341 . . Tenocytes, cells from tendons and ligaments

2502/1347 . . Smooth muscle cells

2502/1352 . . Mesenchymal stem cells

2502/1358 . . . Bone marrow mesenchymal stem cells (BM- MSC)

2502/1364 . . . Dental pulp stem cells, dental follicle stem cells

2502/137 . . . Blood-borne mesenchymal stem cells, e.g. Msc from umbilical cord blood

2502/1376 . . . Mesenchymal stem cells from hair follicles

2502/1382 . . . Adipose-derived stem cells [ADSC], adipose stromal stem cells

2502/1388 . . . Mesenchymal stem cells from other natural sources

2502/1394 . . Bone marrow stromal cells; whole marrow

2502/14 . hepatocytes

2502/22 . pancreatic cells

2502/23 . Gastro-intestinal tract cells

2502/24 . Genital tract cells, non-germinal cells from gonads

2502/243 . . Cells of the female genital tract, non-germinal ovarian cells

2502/246 . . Cells of the male genital tract, non-germinal testis cells

2502/25 . Urinary tract cells, renal cells

2502/253 . . Bladder cells

2502/256 . . Renal cells

2502/27 . Lung cells, respiratory tract cells

2502/28 . Vascular endothelial cells

2502/30 . tumour cells

2502/45 . Artificially induced pluripotent stem cells

2502/50 . invertebrate cells

2502/70 . Non-animal cells

2502/99 . genetically modified cells

#### **NOTE**

Use [C12N 2501/00](#) to index the expressed products.

#### **2503/00 Use of cells in diagnostics**

2503/02 . Drug screening

2503/04 . Screening or testing on artificial tissues

2503/06 . . Screening or testing on artificial skin

#### **2506/00 Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells**

#### **NOTE**

This scheme indexes the starting point of a differentiation process and is used in combination with classification in [C12N 5/06](#) for the end product. Differentiation of a restricted progenitor cell into its expected progeny is not indexed. Differentiation of totipotent cells and dedifferentiation are always indexed.

2506/02 . from embryonic cells

2506/025 . . from extra-embryonic cells, e.g. trophoblast, placenta

2506/03 . from non-embryonic pluripotent stem cells

2506/04 . from germ cells

2506/07 . from endocrine cells

2506/072 . . from adrenal cells

2506/074 . . from pinealocytes

2506/076 . . from pituitary cells

2506/078 . . from thyroid, parathyroid cells

2506/08 . from cells of the nervous system

2506/09 . from epidermal cells, from skin cells, from oral mucosa cells

2506/091 . . from melanocytes

2506/092 . . from hair cells

2506/094 . . from keratinocytes

2506/095 . . from mammary cells

2506/097 . . from oral mucosa cells

2506/098	. . from cells of secretory glands, e.g. parotid gland, salivary glands, sweat glands, lacrymal glands
2506/11	. from blood or immune system cells
2506/115	. . from monocytes, from macrophages
2506/13	. from connective tissue cells, from mesenchymal cells
2506/1307	. . from adult fibroblasts
2506/1315	. . from cardiomyocytes
2506/1323	. . from skeletal muscle cells
2506/133	. . from tenocytes
2506/1338	. . from smooth muscle cells
2506/1346	. . from mesenchymal stem cells
2506/1353	. . . from bone marrow mesenchymal stem cells (BM-MSC)
2506/1361	. . . from dental pulp or dental follicle stem cells
2506/1369	. . . from blood-borne mesenchymal stem cells, e.g. MSC from umbilical blood
2506/1376	. . . from mesenchymal stem cells derived from hair follicles
2506/1384	. . . from adipose-derived stem cells [ADSC], from adipose stromal stem cells
2506/1392	. . . from mesenchymal stem cells from other natural sources
2506/14	. from hepatocytes
2506/22	. from pancreatic cells
2506/23	. from cells of the gastro-intestinal tract
2506/24	. from cells of the genital tract, from non-germinal gonad cells
2506/243	. . from cells of the female genital tract cells, from non-germinal ovarian cells
2506/246	. . from cells of the male genital tract cells, from non-germinal testis cells
2506/25	. from renal cells, from cells of the urinary tract
2506/27	. from lung cells, from cells of the respiratory tract
2506/28	. from vascular endothelial cells
2506/30	. from cancer cells, e.g. reversion of tumour cells

**NOTE**

Unless the tumorigenic phenotype is totally reversed, the end product is still classified under [C12N 5/0693](#).

2506/45	. from artificially induced pluripotent stem cells
---------	--

<b>2509/00</b>	<b>Methods for the dissociation of cells, e.g. specific use of enzymes</b>
----------------	--

2509/10	. Mechanical dissociation
---------	---------------------------

<b>2510/00</b>	<b>Genetically modified cells</b>
----------------	-----------------------------------

2510/02	. Cells for production
2510/04	. Immortalised cells

<b>2511/00</b>	<b>Cells for large scale production</b>
----------------	---

<b>2513/00</b>	<b>3D culture</b>
----------------	-------------------

<b>2517/00</b>	<b>Cells related to new breeds of animals</b>
----------------	---

2517/02	. Cells from transgenic animals
2517/04	. Cells produced using nuclear transfer
2517/10	. Conditioning of cells for <u>in vitro</u> fecundation or nuclear transfer

<b>2521/00</b>	<b>Culture process characterised by the use of hydrostatic pressure, flow or shear forces</b>
----------------	---

2521/10	. Sound, e.g. ultrasounds
---------	---------------------------

<b>2523/00</b>	<b>Culture process characterised by temperature</b>
----------------	---

<b>2525/00</b>	<b>Culture process characterised by gravity, e.g. microgravity</b>
----------------	--

<b>2527/00</b>	<b>Culture process characterised by the use of mechanical forces, e.g. strain, vibration</b>
----------------	--

<b>2529/00</b>	<b>Culture process characterised by the use of electromagnetic stimulation</b>
----------------	--

2529/10	. Stimulation by light
---------	------------------------

<b>2531/00</b>	<b>Microcarriers</b>
----------------	----------------------

<b>2533/00</b>	<b>Supports or coatings for cell culture, characterised by material</b>
----------------	---

2533/10	. Mineral substrates
2533/12	. . Glass
2533/14	. . Ceramic
2533/18	. . Calcium salts, e.g. apatite, Mineral components from bones, teeth, shells
2533/20	. Small organic molecules
2533/30	. Synthetic polymers ( <a href="#">thermoreactive polymers, e.g. PNIPAm, C12N 2539/10</a> )
2533/32	. . Polylysine, polyornithine
2533/40	. . Polyhydroxyacids, e.g. polymers of glycolic or lactic acid (PGA, PLA, PLGA); Bioresorbable polymers
2533/50	. Proteins
2533/52	. . Fibronectin; Laminin
2533/54	. . Collagen; Gelatin
2533/56	. . Fibrin; Thrombin
2533/70	. Polysaccharides
2533/72	. . Chitin, chitosan
2533/74	. . Alginate
2533/76	. . Agarose, agar-agar
2533/78	. . Cellulose
2533/80	. . Hyaluronan
2533/90	. Substrates of biological origin, e.g. extracellular matrix, decellularised tissue
2533/92	. . Amnion; Decellularised dermis or mucosa

<b>2535/00</b>	<b>Supports or coatings for cell culture characterised by topography</b>
----------------	--

2535/10	. Patterned coating
---------	---------------------

<b>2537/00</b>	<b>Supports and/or coatings for cell culture characterised by physical or chemical treatment</b>
----------------	--

2537/10	. Cross-linking
---------	-----------------

<b>2539/00</b>	<b>Supports and/or coatings for cell culture characterised by properties</b>
----------------	--

2539/10	. Coating allowing for selective detachment of cells, e.g. thermoreactive coating
---------	---

**Viruses**

<b>2710/00</b>	<b>dsDNA viruses</b>
----------------	----------------------

2710/00011	. Details
2710/00021	. . Viruses as such, e.g. new isolates, mutants or their genomic sequences
2710/00022	. . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2710/00023	. . Virus like particles [VLP]
2710/00031	. . Uses of virus other than therapeutic or vaccine, e.g. disinfectant

- 2710/00032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2710/00033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2710/00034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2710/00041 . . . Use of virus, viral particle or viral elements as a vector
- 2710/00042 . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2710/00043 . . . . viral genome or elements thereof as genetic vector
- 2710/00044 . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2710/00045 . . . . Special targeting system for viral vectors
- 2710/00051 . . . Methods of production or purification of viral material
- 2710/00052 . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2710/00061 . . . Methods of inactivation or attenuation
- 2710/00062 . . . . by genetic engineering
- 2710/00063 . . . . by chemical treatment
- 2710/00064 . . . . by serial passage
- 2710/00071 . . . Demonstrated in vivo effect
- 2710/00088 . . . for redistribution
- 2710/10011 . . . Adenoviridae
- 2710/10021 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2710/10022 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2710/10023 . . . . Virus like particles [VLP]
- 2710/10031 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2710/10032 . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2710/10033 . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2710/10034 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2710/10041 . . . . Use of virus, viral particle or viral elements as a vector
- 2710/10042 . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2710/10043 . . . . . viral genome or elements thereof as genetic vector
- 2710/10044 . . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2710/10045 . . . . . Special targeting system for viral vectors
- 2710/10051 . . . . Methods of production or purification of viral material
- 2710/10052 . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2710/10061 . . . . Methods of inactivation or attenuation
- 2710/10062 . . . . . by genetic engineering
- 2710/10063 . . . . . by chemical treatment
- 2710/10064 . . . . . by serial passage
- 2710/10071 . . . . Demonstrated in vivo effect
- 2710/10088 . . . . for redistribution
- 2710/10111 . . . . Atadenovirus, e.g. ovine adenovirus D
- 2710/10121 . . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2710/10122 . . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2710/10123 . . . . . Virus like particles [VLP]
- 2710/10131 . . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2710/10132 . . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2710/10133 . . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2710/10134 . . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2710/10141 . . . . . Use of virus, viral particle or viral elements as a vector
- 2710/10142 . . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2710/10143 . . . . . . viral genome or elements thereof as genetic vector
- 2710/10144 . . . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2710/10145 . . . . . . Special targeting system for viral vectors
- 2710/10151 . . . . . Methods of production or purification of viral material
- 2710/10152 . . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2710/10161 . . . . . Methods of inactivation or attenuation
- 2710/10162 . . . . . . by genetic engineering
- 2710/10163 . . . . . . by chemical treatment
- 2710/10164 . . . . . . by serial passage
- 2710/10171 . . . . . Demonstrated in vivo effect
- 2710/10188 . . . . . for redistribution
- 2710/10211 . . . . . Aviadenovirus, e.g. fowl adenovirus A
- 2710/10221 . . . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2710/10222 . . . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2710/10223 . . . . . . Virus like particles [VLP]
- 2710/10231 . . . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2710/10232 . . . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2710/10233 . . . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2710/10234 . . . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2710/10241 . . . . . . Use of virus, viral particle or viral elements as a vector
- 2710/10242 . . . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2710/10243 . . . . . . . viral genome or elements thereof as genetic vector



- 2710/10244 . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2710/10245 . . . . Special targeting system for viral vectors
- 2710/10251 . . . . Methods of production or purification of viral material
- 2710/10252 . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2710/10261 . . . . Methods of inactivation or attenuation
- 2710/10262 . . . . by genetic engineering
- 2710/10263 . . . . by chemical treatment
- 2710/10264 . . . . by serial passage
- 2710/10271 . . . . Demonstrated in vivo effect
- 2710/10288 . . . . for redistribution
- 2710/10311 . . . Mastadenovirus, e.g. human or simian adenoviruses
- 2710/10321 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2710/10322 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2710/10323 . . . . Virus like particles [VLP]
- 2710/10331 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2710/10332 . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2710/10333 . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2710/10334 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2710/10341 . . . . Use of virus, viral particle or viral elements as a vector
- 2710/10342 . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2710/10343 . . . . viral genome or elements thereof as genetic vector
- 2710/10344 . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2710/10345 . . . . Special targeting system for viral vectors
- 2710/10351 . . . . Methods of production or purification of viral material
- 2710/10352 . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2710/10361 . . . . Methods of inactivation or attenuation
- 2710/10362 . . . . by genetic engineering
- 2710/10363 . . . . by chemical treatment
- 2710/10364 . . . . by serial passage
- 2710/10371 . . . . Demonstrated in vivo effect
- 2710/10388 . . . . for redistribution
- 2710/12011 . . . Asfarviridae
- 2710/12021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2710/12022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2710/12023 . . . Virus like particles [VLP]
- 2710/12031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2710/12032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2710/12033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2710/12034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2710/12041 . . . Use of virus, viral particle or viral elements as a vector
- 2710/12042 . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2710/12043 . . . . viral genome or elements thereof as genetic vector
- 2710/12044 . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2710/12045 . . . . Special targeting system for viral vectors
- 2710/12051 . . . Methods of production or purification of viral material
- 2710/12052 . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2710/12061 . . . Methods of inactivation or attenuation
- 2710/12062 . . . . by genetic engineering
- 2710/12063 . . . . by chemical treatment
- 2710/12064 . . . . by serial passage
- 2710/12071 . . . Demonstrated in vivo effect
- 2710/12088 . . . for redistribution
- 2710/14011 . . . Baculoviridae
- 2710/14021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2710/14022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2710/14023 . . . Virus like particles [VLP]
- 2710/14031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2710/14032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2710/14033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2710/14034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2710/14041 . . . Use of virus, viral particle or viral elements as a vector
- 2710/14042 . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2710/14043 . . . . viral genome or elements thereof as genetic vectore
- 2710/14044 . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2710/14045 . . . . Special targeting system for viral vectors
- 2710/14051 . . . Methods of production or purification of viral material
- 2710/14052 . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2710/14061 . . . Methods of inactivation or attenuation
- 2710/14062 . . . . by genetic engineering
- 2710/14063 . . . . by chemical treatment

- 2710/14064 . . . . by serial passage
- 2710/14071 . . . . Demonstrated in vivo effect
- 2710/14088 . . . . for redistribution
- 2710/14111 . . . . Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
- 2710/14121 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2710/14122 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2710/14123 . . . . Virus like particles [VLP]
- 2710/14131 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2710/14132 . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2710/14133 . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2710/14134 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2710/14141 . . . . Use of virus, viral particle or viral elements as a vector
- 2710/14142 . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2710/14143 . . . . . viral genome or elements thereof as genetic vector
- 2710/14144 . . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2710/14145 . . . . . Special targeting system for viral vectors
- 2710/14151 . . . . . Methods of production or purification of viral material
- 2710/14152 . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2710/14161 . . . . . Methods of inactivation or attenuation
- 2710/14162 . . . . . by genetic engineering
- 2710/14163 . . . . . by chemical treatment
- 2710/14164 . . . . . by serial passage
- 2710/14171 . . . . . Demonstrated in vivo effect
- 2710/14188 . . . . . For redistribution
- 2710/16011 . . . . Herpesviridae
- 2710/16021 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2710/16022 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2710/16023 . . . . Virus like particles [VLP]
- 2710/16031 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2710/16032 . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2710/16033 . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2710/16034 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2710/16041 . . . . Use of virus, viral particle or viral elements as a vector
- 2710/16042 . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2710/16043 . . . . . viral genome or elements thereof as genetic vector
- 2710/16044 . . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2710/16045 . . . . . Special targeting system for viral vectors
- 2710/16051 . . . . . Methods of production or purification of viral material
- 2710/16052 . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2710/16061 . . . . . Methods of inactivation or attenuation
- 2710/16062 . . . . . by genetic engineering
- 2710/16063 . . . . . by chemical treatment
- 2710/16064 . . . . . by serial passage
- 2710/16071 . . . . . Demonstrated in vivo effect
- 2710/16088 . . . . . for redistribution
- 2710/16111 . . . . . Cytomegalovirus, e.g. human herpesvirus 5
- 2710/16121 . . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2710/16122 . . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2710/16123 . . . . . Virus like particles [VLP]
- 2710/16131 . . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2710/16132 . . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2710/16133 . . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2710/16134 . . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2710/16141 . . . . . Use of virus, viral particle or viral elements as a vector
- 2710/16142 . . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2710/16143 . . . . . . viral genome or elements thereof as genetic vector
- 2710/16144 . . . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2710/16145 . . . . . . Special targeting system for viral vectors
- 2710/16151 . . . . . . Methods of production or purification of viral material
- 2710/16152 . . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2710/16161 . . . . . . Methods of inactivation or attenuation
- 2710/16162 . . . . . . by genetic engineering
- 2710/16163 . . . . . . by chemical treatment
- 2710/16164 . . . . . . by serial passage
- 2710/16171 . . . . . . Demonstrated in vivo effect
- 2710/16188 . . . . . . for redistribution
- 2710/16211 . . . . . . Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
- 2710/16221 . . . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2710/16222 . . . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2710/16223 . . . . . . Virus like particles [VLP]

2710/16231	. . . .	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	2710/16361	. . . .	Methods of inactivation or attenuation
2710/16232	. . . .	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	2710/16362	. . . . .	by genetic engineering
2710/16233	. . . .	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	2710/16363	. . . . .	by chemical treatment
2710/16234	. . . .	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	2710/16364	. . . . .	by serial passage
2710/16241	. . . .	Use of virus, viral particle or viral elements as a vector	2710/16371	. . . .	Demonstrated <u>in vivo</u> effect
2710/16242	. . . . .	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	2710/16388	. . . .	for redistribution
2710/16243	. . . . .	viral genome or elements thereof as genetic vector	2710/16411	. . . .	Rhadinovirus, e.g. human herpesvirus 8
2710/16244	. . . . .	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	2710/16421	. . . .	Viruses as such, e.g. new isolates, mutants or their genomic sequences
2710/16245	. . . . .	Special targeting system for viral vectors	2710/16422	. . . .	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2710/16251	. . . .	Methods of production or purification of viral material	2710/16423	. . . .	Virus like particles [VLP]
2710/16252	. . . . .	relating to complementing cells and packaging systems for producing virus or viral particles	2710/16431	. . . .	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2710/16261	. . . .	Methods of inactivation or attenuation	2710/16432	. . . .	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2710/16262	. . . . .	by genetic engineering	2710/16433	. . . .	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2710/16263	. . . . .	by chemical treatment	2710/16434	. . . .	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2710/16264	. . . . .	by serial passage	2710/16441	. . . .	Use of virus, viral particle or viral elements as a vector
2710/16271	. . . .	Demonstrated <u>in vivo</u> effect	2710/16442	. . . . .	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2710/16288	. . . .	for redistribution	2710/16443	. . . . .	viral genome or elements thereof as genetic vector
2710/16311	. . . .	Mardivirus, e.g. Gallid herpesvirus 2, Marek-like viruses, turkey HV	2710/16444	. . . . .	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2710/16321	. . . .	Viruses as such, e.g. new isolates, mutants or their genomic sequences	2710/16445	. . . . .	Special targeting system for viral vectors
2710/16322	. . . .	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	2710/16451	. . . .	Methods of production or purification of viral material
2710/16323	. . . .	Virus like particles [VLP]	2710/16452	. . . . .	relating to complementing cells and packaging systems for producing virus or viral particles
2710/16331	. . . .	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	2710/16461	. . . .	Methods of inactivation or attenuation
2710/16332	. . . .	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	2710/16462	. . . . .	by genetic engineering
2710/16333	. . . .	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	2710/16463	. . . . .	by chemical treatment
2710/16334	. . . .	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	2710/16464	. . . . .	by serial passage
2710/16341	. . . .	Use of virus, viral particle or viral elements as a vector	2710/16471	. . . .	Demonstrated <u>in vivo</u> effect
2710/16342	. . . . .	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	2710/16488	. . . .	for redistribution
2710/16343	. . . . .	viral genome or elements thereof as genetic vector	2710/16511	. . . .	Roseolovirus, e.g. human herpesvirus 6, 7
2710/16344	. . . . .	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	2710/16521	. . . .	Viruses as such, e.g. new isolates, mutants or their genomic sequences
2710/16345	. . . . .	Special targeting system for viral vectors	2710/16522	. . . .	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2710/16351	. . . .	Methods of production or purification of viral material	2710/16523	. . . .	Virus like particles [VLP]
2710/16352	. . . . .	relating to complementin g cells and packaging systems for producing virus or viral particles	2710/16531	. . . .	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
			2710/16532	. . . .	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
			2710/16533	. . . .	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
			2710/16534	. . . .	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral
			2710/16541	. . . .	Use of virus, viral particle or viral elements as a vector

2710/16542	. . . .	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	2710/16723	. . . .	Virus like particles [VLP]
2710/16543	. . . .	viral genome or elements thereof as genetic vector	2710/16731	. . . .	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2710/16544	. . . .	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	2710/16732	. . . .	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2710/16545	. . . .	Special targeting system for viral vectors	2710/16733	. . . .	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2710/16551	. . . .	Methods of production or purification of viral material	2710/16734	. . . .	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2710/16552	. . . .	relating to complementing cells and packaging systems for producing virus or viral particles	2710/16741	. . . .	Use of virus, viral particle or viral elements as a vector
2710/16561	. . . .	Methods of inactivation or attenuation	2710/16742	. . . .	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2710/16562	. . . .	by genetic engineering	2710/16743	. . . .	viral genome or elements thereof as genetic vector
2710/16563	. . . .	by chemical treatment	2710/16744	. . . .	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2710/16564	. . . .	by serial passage	2710/16745	. . . .	Special targeting system for viral vectors
2710/16571	. . . .	Demonstrated <u>in vivo</u> effect	2710/16751	. . . .	Methods of production or purification of viral material
2710/16588	. . . .	for redistribution	2710/16752	. . . .	relating to complementing cells and packaging systems for producing virus or viral particles
2710/16611	. . .	Simplexvirus, e.g. human herpesvirus 1, 2	2710/16761	. . . .	Methods of inactivation or attenuation
2710/16621	. . . .	Viruses as such, e.g. new isolates, mutants or their genomic sequences	2710/16762	. . . .	by genetic engineering
2710/16622	. . . .	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	2710/16763	. . . .	by chemical treatment
2710/16623	. . . .	Virus like particles [VLP]	2710/16764	. . . .	by serial passage
2710/16631	. . . .	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	2710/16771	. . . .	Demonstrated <u>in vivo</u> effect
2710/16632	. . . .	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	2710/16788	. . . .	for redistribution
2710/16633	. . . .	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	2710/18011	. .	Nimaviridae
2710/16634	. . . .	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	2710/18021	. . .	Viruses as such, e.g. new isolates, mutants or their genomic sequences
2710/16641	. . . .	Use of virus, viral particle or viral elements as a vector	2710/18022	. . .	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2710/16642	. . . .	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	2710/18023	. . .	Virus like particles [VLP]
2710/16643	. . . .	viral genome or elements thereof as genetic vector	2710/18031	. . .	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2710/16644	. . . .	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	2710/18032	. . .	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2710/16645	. . . .	Special targeting system for viral vectors	2710/18033	. . .	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2710/16651	. . . .	Methods of production or purification of viral material	2710/18034	. . .	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2710/16652	. . . .	relating to complementing cells and packaging systems for producing virus or viral particles	2710/18041	. . .	Use of virus, viral particle or viral elements as a vector
2710/16661	. . . .	Methods of inactivation or attenuation	2710/18042	. . . .	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2710/16662	. . . .	by genetic engineering	2710/18043	. . . .	viral genome or elements thereof as genetic vector
2710/16663	. . . .	by chemical treatment	2710/18044	. . . .	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2710/16664	. . . .	by serial passage	2710/18045	. . . .	Special targeting system for viral vectors
2710/16671	. . . .	Demonstrated <u>in vivo</u> effect	2710/18051	. . .	Methods of production or purification of viral material
2710/16688	. . . .	for redistribution	2710/18052	. . . .	relating to complementing cells and packaging systems for producing virus or viral particles
2710/16711	. . .	Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies			
2710/16721	. . . .	Viruses as such, e.g. new isolates, mutants or their genomic sequences			
2710/16722	. . . .	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes			

- 2710/18061 . . . Methods of inactivation or attenuation
- 2710/18062 . . . . by genetic engineering
- 2710/18063 . . . . by chemical treatment
- 2710/18064 . . . . by serial passage
- 2710/18071 . . . Demonstrated in vivo effect
- 2710/18088 . . . for redistribution
- 2710/20011 . . Papillomaviridae
- 2710/20021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2710/20022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2710/20023 . . . Virus like particles [VLP]
- 2710/20031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2710/20032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2710/20033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2710/20034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2710/20041 . . . Use of virus, viral particle or viral elements as a vector
- 2710/20042 . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2710/20043 . . . . viral genome or elements thereof as genetic vector
- 2710/20044 . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2710/20045 . . . . Special targeting system for viral vectors
- 2710/20051 . . . Methods of production or purification of viral material
- 2710/20052 . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2710/20061 . . . Methods of inactivation or attenuation
- 2710/20062 . . . . by genetic engineering
- 2710/20063 . . . . by chemical treatment
- 2710/20064 . . . . by serial passage
- 2710/20071 . . . Demonstrated in vivo effect
- 2710/20088 . . . for redistribution
- 2710/22011 . . Polyomaviridae, e.g. polyoma, SV40, JC
- 2710/22021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2710/22022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2710/22023 . . . Virus like particles [VLP]
- 2710/22031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2710/22032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2710/22033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2710/22034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2710/22041 . . . Use of virus, viral particle or viral elements as a vector
- 2710/22042 . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2710/22043 . . . . viral genome or elements thereof as genetic vector
- 2710/22044 . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2710/22045 . . . . Special targeting system for viral vectors
- 2710/22051 . . . Methods of production or purification of viral material
- 2710/22052 . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2710/22061 . . . Methods of inactivation or attenuation
- 2710/22062 . . . . by genetic engineering
- 2710/22063 . . . . by chemical treatment
- 2710/22064 . . . . by serial passage
- 2710/22071 . . . Demonstrated in vivo effect
- 2710/22088 . . . for redistribution
- 2710/24011 . . Poxviridae
- 2710/24021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2710/24022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2710/24023 . . . Virus like particles [VLP]
- 2710/24031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2710/24032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2710/24033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2710/24034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2710/24041 . . . Use of virus, viral particle or viral elements as a vector
- 2710/24042 . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2710/24043 . . . . viral genome or elements thereof as genetic vector
- 2710/24044 . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2710/24045 . . . . Special targeting system for viral vectors
- 2710/24051 . . . Methods of production or purification of viral material
- 2710/24052 . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2710/24061 . . . Methods of inactivation or attenuation
- 2710/24062 . . . . by genetic engineering
- 2710/24063 . . . . by chemical treatment
- 2710/24064 . . . . by serial passage
- 2710/24071 . . . Demonstrated in vivo effect
- 2710/24088 . . . for redistribution
- 2710/24111 . . . Orthopoxvirus, e.g. vaccinia virus, variola
- 2710/24121 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2710/24122 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2710/24123 . . . . Virus like particles [VLP]



- 2710/24131 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2710/24132 . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2710/24133 . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2710/24134 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2710/24141 . . . . Use of virus, viral particle or viral elements as a vector
- 2710/24142 . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2710/24143 . . . . . viral genome or elements thereof as genetic vector
- 2710/24144 . . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2710/24145 . . . . . Special targeting system for viral vectors
- 2710/24151 . . . . Methods of production or purification of viral material
- 2710/24152 . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2710/24161 . . . . Methods of inactivation or attenuation
- 2710/24162 . . . . . by genetic engineering
- 2710/24163 . . . . . by chemical treatment
- 2710/24164 . . . . . by serial passage
- 2710/24171 . . . . Demonstrated in vivo effect
- 2710/24188 . . . . for redistribution
- 2710/24211 . . . Parapoxvirus, e.g. Orf virus
- 2710/24221 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2710/24222 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2710/24223 . . . . Virus like particles [VLP]
- 2710/24231 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2710/24232 . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2710/24233 . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2710/24234 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2710/24241 . . . . Use of virus, viral particle or viral elements as a vector
- 2710/24242 . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2710/24243 . . . . . viral genome or elements thereof as genetic vector
- 2710/24244 . . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2710/24245 . . . . . Special targeting system for viral vectors
- 2710/24251 . . . . Methods of production or purification of viral material
- 2710/24252 . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2710/24261 . . . . Methods of inactivation or attenuation
- 2710/24262 . . . . . by genetic engineering
- 2710/24263 . . . . . by chemical treatment
- 2710/24264 . . . . . by serial passage
- 2710/24271 . . . . Demonstrated in vivo effect
- 2710/24288 . . . . for redistribution
- 2720/00** **dsRNA viruses**
- 2720/00011 . Details
- 2720/00021 . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2720/00022 . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2720/00023 . . Virus like particles [VLP]
- 2720/00031 . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2720/00032 . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2720/00033 . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2720/00034 . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2720/00041 . . Use of virus, viral particle or viral elements as a vector
- 2720/00042 . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2720/00043 . . . viral genome or elements thereof as genetic vector
- 2720/00044 . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2720/00045 . . . Special targeting system for viral vectors
- 2720/00051 . . Methods of production or purification of viral material
- 2720/00052 . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2720/00061 . . Methods of inactivation or attenuation
- 2720/00062 . . . by genetic engineering
- 2720/00063 . . . by chemical treatment
- 2720/00064 . . . by serial passage
- 2720/00071 . . Demonstrated in vivo effect
- 2720/00088 . . for redistribution
- 2720/10011 . . Birnaviridae
- 2720/10021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2720/10022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2720/10023 . . . Virus like particles [VLP]
- 2720/10031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2720/10032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2720/10033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2720/10034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2720/10041 . . . Use of virus, viral particle or viral elements as a vector

2720/10042	. . . .	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	2720/12131	. . . .	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2720/10043	. . . .	viral genome or elements thereof as genetic vector	2720/12132	. . . .	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2720/10044	. . . .	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	2720/12133	. . . .	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2720/10045	. . . .	Special targeting system for viral vectors	2720/12134	. . . .	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2720/10051	. . .	Methods of production or purification of viral material	2720/12141	. . . .	Use of virus, viral particle or viral elements as a vector
2720/10052	. . . .	relating to complementing cells and packaging systems for producing virus or viral particles	2720/12142	. . . .	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2720/10061	. . .	Methods of inactivation or attenuation	2720/12143	. . . .	viral genome or elements thereof as genetic vector
2720/10062	. . . .	by genetic engineering	2720/12144	. . . .	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2720/10063	. . . .	by chemical treatment	2720/12145	. . . .	Special targeting system for viral vectors
2720/10064	. . . .	by serial passage	2720/12151	. . . .	Methods of production or purification of viral material
2720/10071	. . .	Demonstrated <u>in vivo</u> effect	2720/12152	. . . .	relating to complementing cells and packaging systems for producing virus or viral particles
2720/10088	. . .	for redistribution	2720/12161	. . . .	Methods of inactivation or attenuation
2720/12011	. .	Reoviridae	2720/12162	. . . .	by genetic engineering
2720/12021	. . .	Viruses as such, e.g. new isolates, mutants or their genomic sequences	2720/12163	. . . .	by chemical treatment
2720/12022	. . .	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	2720/12164	. . . .	by serial passage
2720/12023	. . .	Virus like particles [VLP]	2720/12171	. . . .	Demonstrated <u>in vivo</u> effect
2720/12031	. . .	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	2720/12188	. . . .	for redistribution
2720/12032	. . .	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	2720/12211	. . .	Orthoreovirus, e.g. mammalian orthoreovirus
2720/12033	. . .	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	2720/12221	. . . .	Viruses as such, e.g. new isolates, mutants or their genomic sequences
2720/12034	. . .	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	2720/12222	. . . .	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2720/12041	. . .	Use of virus, viral particle or viral elements as a vector	2720/12223	. . . .	Virus like particles [VLP]
2720/12042	. . . .	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	2720/12231	. . . .	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2720/12043	. . . .	viral genome or elements thereof as genetic vector	2720/12232	. . . .	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2720/12044	. . . .	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	2720/12233	. . . .	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2720/12045	. . . .	Special targeting system for viral vectors	2720/12234	. . . .	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2720/12051	. . .	Methods of production or purification of viral material	2720/12241	. . . .	Use of virus, viral particle or viral elements as a vector
2720/12052	. . . .	relating to complementing cells and packaging systems for producing virus or viral particles	2720/12242	. . . .	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2720/12061	. . .	Methods of inactivation or attenuation	2720/12243	. . . .	viral genome or elements thereof as genetic vector
2720/12062	. . . .	by genetic engineering	2720/12244	. . . .	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2720/12063	. . . .	by chemical treatment	2720/12245	. . . .	Special targeting system for viral vectors
2720/12064	. . . .	by serial passage	2720/12251	. . . .	Methods of production or purification of viral material
2720/12071	. . .	Demonstrated <u>in vivo</u> effect	2720/12252	. . . .	relating to complementing cells and packaging systems for producing virus or viral particles
2720/12088	. . .	for redistribution	2720/12261	. . . .	Methods of inactivation or attenuation
2720/12111	. . .	Orbivirus, e.g. bluetongue virus			
2720/12121	. . . .	Viruses as such, e.g. new isolates, mutants or their genomic sequences			
2720/12122	. . . .	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes			
2720/12123	. . . .	Virus like particles [VLP]			

- 2720/12262 . . . . by genetic engineering
- 2720/12263 . . . . by chemical treatment
- 2720/12264 . . . . by serial passage
- 2720/12271 . . . . Demonstrated in vivo effect
- 2720/12288 . . . . for redistribution
- 2720/12311 . . . Rotavirus, e.g. rotavirus A
- 2720/12321 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2720/12322 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2720/12323 . . . . Virus like particles [VLP]
- 2720/12331 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2720/12332 . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2720/12333 . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2720/12334 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2720/12341 . . . . Use of virus, viral particle or viral elements as a vector
- 2720/12342 . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2720/12343 . . . . viral genome or elements thereof as genetic vector
- 2720/12344 . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2720/12345 . . . . Special targeting system for viral vectors
- 2720/12351 . . . . Methods of production or purification of viral material
- 2720/12352 . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2720/12361 . . . . Methods of inactivation or attenuation
- 2720/12362 . . . . by genetic engineering
- 2720/12363 . . . . by chemical treatment
- 2720/12364 . . . . by serial passage
- 2720/12371 . . . . Demonstrated in vivo effect
- 2720/12388 . . . . for redistribution
- 2730/00** **Reverse transcribing DNA viruses**
- 2730/00011 . Details
- 2730/00021 . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2730/00022 . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2730/00023 . . Virus like particles [VLP]
- 2730/00031 . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2730/00032 . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2730/00033 . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2730/00034 . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2730/00041 . . Use of virus, viral particle or viral elements as a vector
- 2730/00042 . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2730/00043 . . . viral genome or elements thereof as genetic vector
- 2730/00044 . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2730/00045 . . . Special targeting system for viral vectors
- 2730/00051 . . . Methods of production or purification of viral material
- 2730/00052 . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2730/00061 . . . Methods of inactivation or attenuation
- 2730/00062 . . . by genetic engineering
- 2730/00063 . . . by chemical treatment
- 2730/00064 . . . by serial passage
- 2730/00071 . . . Demonstrated in vivo effect
- 2730/00088 . . . for redistribution
- 2730/10011 . . . Hepadnaviridae
- 2730/10021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2730/10022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2730/10023 . . . Virus like particles [VLP]
- 2730/10031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2730/10032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2730/10033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2730/10034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2730/10041 . . . Use of virus, viral particle or viral elements as a vector
- 2730/10042 . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2730/10043 . . . . viral genome or elements thereof as genetic vector
- 2730/10044 . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2730/10045 . . . . Special targeting system for viral vectors
- 2730/10051 . . . Methods of production or purification of viral material
- 2730/10052 . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2730/10061 . . . Methods of inactivation or attenuation
- 2730/10062 . . . by genetic engineering
- 2730/10063 . . . by chemical treatment
- 2730/10064 . . . by serial passage
- 2730/10071 . . . Demonstrated in vivo effect
- 2730/10088 . . . for redistribution
- 2730/10111 . . . Orthohepadnavirus, e.g. hepatitis B virus
- 2730/10121 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2730/10122 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2730/10123 . . . . Virus like particles [VLP]

2730/10131	. . . .	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2730/10132	. . . .	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2730/10133	. . . .	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2730/10134	. . . .	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2730/10141	. . . .	Use of virus, viral particle or viral elements as a vector
2730/10142	. . . . .	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2730/10143	. . . . .	viral genome or elements thereof as genetic vector
2730/10144	. . . . .	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2730/10145	. . . . .	Special targeting system for viral vectors
2730/10151	. . . . .	Methods of production or purification of viral material
2730/10152	. . . . .	relating to complementing cells and packaging systems for producing virus or viral particles
2730/10161	. . . . .	Methods of inactivation or attenuation
2730/10162	. . . . .	by genetic engineering
2730/10163	. . . . .	by chemical treatment
2730/10164	. . . . .	by serial passage
2730/10171	. . . . .	Demonstrated <u>in vivo</u> effect
2730/10188	. . . . .	for redistribution
<b>2740/00</b>		<b>Reverse transcribing RNA viruses</b>
2740/00011	. . . . .	Details
2740/00021	. . . . .	Viruses as such, e.g. new isolates, mutants or their genomic sequences
2740/00022	. . . . .	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2740/00023	. . . . .	Virus like particles [VLP]
2740/00031	. . . . .	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2740/00032	. . . . .	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2740/00033	. . . . .	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2740/00034	. . . . .	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2740/00041	. . . . .	Use of virus, viral particle or viral elements as a vector
2740/00042	. . . . .	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2740/00043	. . . . .	viral genome or elements thereof as genetic vector
2740/00044	. . . . .	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2740/00045	. . . . .	Special targeting system for viral vectors
2740/00051	. . . . .	Methods of production or purification of viral material
2740/00052	. . . . .	relating to complementing cells and packaging systems for producing virus or viral particles
2740/00061	. . . . .	Methods of inactivation or attenuation
2740/00062	. . . . .	by genetic engineering
2740/00063	. . . . .	by chemical treatment
2740/00064	. . . . .	by serial passage
2740/00071	. . . . .	Demonstrated <u>in vivo</u> effect
2740/00088	. . . . .	for redistribution
2740/10011	. . . . .	Retroviridae
2740/10021	. . . . .	Viruses as such, e.g. new isolates, mutants or their genomic sequences
2740/10022	. . . . .	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2740/10023	. . . . .	Virus like particles [VLP]
2740/10031	. . . . .	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2740/10032	. . . . .	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2740/10033	. . . . .	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2740/10034	. . . . .	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2740/10041	. . . . .	Use of virus, viral particle or viral elements as a vector
2740/10042	. . . . .	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2740/10043	. . . . .	viral genome or elements thereof as genetic vector
2740/10044	. . . . .	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2740/10045	. . . . .	Special targeting system for viral vectors
2740/10051	. . . . .	Methods of production or purification of viral material
2740/10052	. . . . .	relating to complementing cells and packaging systems for producing virus or viral particles
2740/10061	. . . . .	Methods of inactivation or attenuation
2740/10062	. . . . .	by genetic engineering
2740/10063	. . . . .	by chemical treatment
2740/10064	. . . . .	by serial passage
2740/10071	. . . . .	Demonstrated <u>in vivo</u> effect
2740/10088	. . . . .	for redistribution
2740/11011	. . . . .	Alpharetrovirus, e.g. avian leucosis virus
2740/11021	. . . . .	Viruses as such, e.g. new isolates, mutants or their genomic sequences
2740/11022	. . . . .	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2740/11023	. . . . .	Virus like particles [VLP]
2740/11031	. . . . .	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2740/11032	. . . . .	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2740/11033	. . . . .	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2740/11034	. . . . .	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2740/11041	. . . . .	Use of virus, viral particle or viral elements as a vector

2740/11042	. . . .	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	2740/13023	. . . .	Virus like particles [VLP]
2740/11043	. . . .	viral genome or elements thereof as genetic vector	2740/13031	. . . .	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2740/11044	. . . .	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	2740/13032	. . . .	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2740/11045	. . . .	Special targeting system for viral vectors	2740/13033	. . . .	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2740/11051	. . . .	Methods of production or purification of viral material	2740/13034	. . . .	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2740/11052	. . . .	relating to complementing cells and packaging systems for producing virus or viral particles	2740/13041	. . . .	Use of virus, viral particle or viral elements as a vector
2740/11061	. . . .	Methods of inactivation or attenuation	2740/13042	. . . .	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2740/11062	. . . .	by genetic engineering	2740/13043	. . . .	viral genome or elements thereof as genetic vector
2740/11063	. . . .	by chemical treatment	2740/13044	. . . .	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2740/11064	. . . .	by serial passage	2740/13045	. . . .	Special targeting system for viral vectors
2740/11071	. . . .	Demonstrated <u>in vivo</u> effect	2740/13051	. . . .	Methods of production or purification of viral material
2740/11088	. . . .	for redistribution	2740/13052	. . . .	relating to complementing cells and packaging systems for producing virus or viral particles
2740/12011	. . .	Betaretrovirus, e.g. mouse mammary tumour virus	2740/13061	. . . .	Methods of inactivation or attenuation
2740/12021	. . . .	Viruses as such, e.g. new isolates, mutants or their genomic sequences	2740/13062	. . . .	by genetic engineering
2740/12022	. . . .	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	2740/13063	. . . .	by chemical treatment
2740/12023	. . . .	Virus like particles [VLP]	2740/13064	. . . .	by serial passage
2740/12031	. . . .	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	2740/13071	. . . .	Demonstrated <u>in vivo</u> effect
2740/12032	. . . .	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	2740/13088	. . . .	for redistribution
2740/12033	. . . .	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	2740/14011	. . .	Deltaretrovirus, e.g. bovine leukaemia virus
2740/12034	. . . .	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	2740/14021	. . . .	Viruses as such, e.g. new isolates, mutants or their genomic sequences
2740/12041	. . . .	Use of virus, viral particle or viral elements as a vector	2740/14022	. . . .	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2740/12042	. . . .	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	2740/14023	. . . .	Virus like particles [VLP]
2740/12043	. . . .	viral genome or elements thereof as genetic vector	2740/14031	. . . .	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2740/12044	. . . .	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	2740/14032	. . . .	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2740/12045	. . . .	Special targeting system for viral vectors	2740/14033	. . . .	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2740/12051	. . . .	Methods of production or purification of viral material	2740/14034	. . . .	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2740/12052	. . . .	relating to complementing cells and packaging systems for producing virus or viral particles	2740/14041	. . . .	Use of virus, viral particle or viral elements as a vector
2740/12061	. . . .	Methods of inactivation or attenuation	2740/14042	. . . .	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2740/12062	. . . .	by genetic engineering	2740/14043	. . . .	viral genome or elements thereof as genetic vector
2740/12063	. . . .	by chemical treatment	2740/14044	. . . .	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2740/12064	. . . .	by serial passage	2740/14045	. . . .	Special targeting system for viral vectors
2740/12071	. . . .	Demonstrated <u>in vivo</u> effect	2740/14051	. . . .	Methods of production or purification of viral material
2740/12088	. . . .	for redistribution	2740/14052	. . . .	relating to complementing cells and packaging systems for producing virus or viral particles
2740/13011	. . .	Gammaretrovirus, e.g. murine leukaemia virus			
2740/13021	. . . .	Viruses as such, e.g. new isolates, mutants or their genomic sequences			
2740/13022	. . . .	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes			



- 2740/14061 . . . . Methods of inactivation or attenuation
- 2740/14062 . . . . . by genetic engineering
- 2740/14063 . . . . . by chemical treatment
- 2740/14064 . . . . . by serial passage
- 2740/14071 . . . . Demonstrated in vivo effect
- 2740/14088 . . . . for redistribution
- 2740/15011 . . . . Lentivirus, not HIV, e.g. FIV, SIV
- 2740/15021 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2740/15022 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2740/15023 . . . . Virus like particles [VLP]
- 2740/15031 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2740/15032 . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2740/15033 . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2740/15034 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2740/15041 . . . . Use of virus, viral particle or viral elements as a vector
- 2740/15042 . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2740/15043 . . . . . viral genome or elements thereof as genetic vector
- 2740/15044 . . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2740/15045 . . . . . Special targeting system for viral vectors
- 2740/15051 . . . . Methods of production or purification of viral material
- 2740/15052 . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2740/15061 . . . . Methods of inactivation or attenuation
- 2740/15062 . . . . . by genetic engineering
- 2740/15063 . . . . . by chemical treatment
- 2740/15064 . . . . . by serial passage
- 2740/15071 . . . . Demonstrated in vivo effect
- 2740/15088 . . . . for redistribution
- 2740/16011 . . . . Human Immunodeficiency Virus, HIV
- 2740/16021 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2740/16022 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2740/16023 . . . . Virus like particles [VLP]
- 2740/16031 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2740/16032 . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2740/16033 . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2740/16034 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2740/16041 . . . . Use of virus, viral particle or viral elements as a vector
- 2740/16042 . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2740/16043 . . . . . viral genome or elements thereof as genetic vector
- 2740/16044 . . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2740/16045 . . . . . Special targeting system for viral vectors
- 2740/16051 . . . . Methods of production or purification of viral material
- 2740/16052 . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2740/16061 . . . . Methods of inactivation or attenuation
- 2740/16062 . . . . . by genetic engineering
- 2740/16063 . . . . . by chemical treatment
- 2740/16064 . . . . . by serial passage
- 2740/16071 . . . . Demonstrated in vivo effect
- 2740/16088 . . . . for redistribution
- 2740/16111 . . . . concerning HIV env
- 2740/16122 . . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2740/16134 . . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2740/16171 . . . . . Demonstrated in vivo effect
- 2740/16188 . . . . . for redistribution
- 2740/16211 . . . . concerning HIV gagpol
- 2740/16222 . . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2740/16234 . . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2740/16271 . . . . . Demonstrated in vivo effect
- 2740/16288 . . . . . for redistribution
- 2740/16311 . . . . concerning HIV regulatory proteins
- 2740/16322 . . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2740/16334 . . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2740/16371 . . . . . Demonstrated in vivo effect
- 2740/16388 . . . . . for redistribution
- 2740/17011 . . . . Spumavirus, e.g. chimpanzee foamy virus
- 2740/17021 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2740/17022 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2740/17023 . . . . Virus like particles [VLP]
- 2740/17031 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2740/17032 . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2740/17033 . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2740/17034 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

- 2740/17041 . . . . Use of virus, viral particle or viral elements as a vector
- 2740/17042 . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2740/17043 . . . . . viral genome or elements thereof as genetic vector
- 2740/17044 . . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2740/17045 . . . . . Special targeting system for viral vectors
- 2740/17051 . . . . Methods of production or purification of viral material
- 2740/17052 . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2740/17061 . . . . Methods of inactivation or attenuation
- 2740/17062 . . . . . by genetic engineering
- 2740/17063 . . . . . by chemical treatment
- 2740/17064 . . . . . by serial passage
- 2740/17071 . . . . Demonstrated in vivo effect
- 2740/17088 . . . . . for redistribution
- 2750/00 ssDNA viruses**
- 2750/00011 . Details
- 2750/00021 . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2750/00022 . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2750/00023 . . Virus like particles [VLP]
- 2750/00031 . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2750/00032 . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2750/00033 . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2750/00034 . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2750/00041 . . Use of virus, viral particle or viral elements as a vector
- 2750/00042 . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2750/00043 . . . viral genome or elements thereof as genetic vector
- 2750/00044 . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2750/00045 . . . Special targeting system for viral vectors
- 2750/00051 . . Methods of production or purification of viral material
- 2750/00052 . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2750/00061 . . Methods of inactivation or attenuation
- 2750/00062 . . . by genetic engineering
- 2750/00063 . . . by chemical treatment
- 2750/00064 . . . by serial passage
- 2750/00071 . . Demonstrated in vivo effect
- 2750/00088 . . for redistribution
- 2750/10011 . . Circoviridae
- 2750/10021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2750/10022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2750/10023 . . . Virus like particles [VLP]
- 2750/10031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2750/10032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2750/10033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2750/10034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2750/10041 . . . Use of virus, viral particle or viral elements as a vector
- 2750/10042 . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2750/10043 . . . . viral genome or elements thereof as genetic vector
- 2750/10044 . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2750/10045 . . . . Special targeting system for viral vectors
- 2750/10051 . . . Methods of production or purification of viral material
- 2750/10052 . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2750/10061 . . . Methods of inactivation or attenuation
- 2750/10062 . . . . by genetic engineering
- 2750/10063 . . . . by chemical treatment
- 2750/10064 . . . . by serial passage
- 2750/10071 . . . Demonstrated in vivo effect
- 2750/10088 . . . for redistribution
- 2750/12011 . . Geminiviridae
- 2750/12021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2750/12022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2750/12023 . . . Virus like particles [VLP]
- 2750/12031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2750/12032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2750/12033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2750/12034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2750/12041 . . . Use of virus, viral particle or viral elements as a vector
- 2750/12042 . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2750/12043 . . . . viral genome or elements thereof as genetic vector
- 2750/12044 . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2750/12045 . . . . Special targeting system for viral vectors
- 2750/12051 . . . Methods of production or purification of viral material

- 2750/12052 . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2750/12061 . . . Methods of inactivation or attenuation
- 2750/12062 . . . by genetic engineering
- 2750/12063 . . . by chemical treatment
- 2750/12064 . . . by serial passage
- 2750/12071 . . . Demonstrated in vivo effect
- 2750/12088 . . . for redistribution
- 2750/14011 . . . Parvoviridae
- 2750/14021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2750/14022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2750/14023 . . . Virus like particles [VLP]
- 2750/14031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2750/14032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2750/14033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2750/14034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2750/14041 . . . Use of virus, viral particle or viral elements as a vector
- 2750/14042 . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2750/14043 . . . viral genome or elements thereof as genetic vector
- 2750/14044 . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2750/14045 . . . Special targeting system for viral vectors
- 2750/14051 . . . Methods of production or purification of viral material
- 2750/14052 . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2750/14061 . . . Methods of inactivation or attenuation
- 2750/14062 . . . by genetic engineering
- 2750/14063 . . . by chemical treatment
- 2750/14064 . . . by serial passage
- 2750/14071 . . . Demonstrated in vivo effect
- 2750/14088 . . . for redistribution
- 2750/14111 . . . Dependovirus, e.g. adenoassociated viruses
- 2750/14121 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2750/14122 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2750/14123 . . . Virus like particles [VLP]
- 2750/14131 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2750/14132 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2750/14133 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2750/14134 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2750/14141 . . . Use of virus, viral particle or viral elements as a vector
- 2750/14142 . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2750/14143 . . . viral genome or elements thereof as genetic vector
- 2750/14144 . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2750/14145 . . . Special targeting system for viral vectors
- 2750/14151 . . . Methods of production or purification of viral material
- 2750/14152 . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2750/14161 . . . Methods of inactivation or attenuation
- 2750/14162 . . . by genetic engineering
- 2750/14163 . . . by chemical treatment
- 2750/14164 . . . by serial passage
- 2750/14171 . . . Demonstrated in vivo effect
- 2750/14188 . . . for redistribution
- 2750/14211 . . . Erythrovirus, e.g. B19 virus
- 2750/14221 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2750/14222 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2750/14223 . . . Virus like particles [VLP]
- 2750/14231 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2750/14232 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2750/14233 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2750/14234 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2750/14241 . . . Use of virus, viral particle or viral elements as a vector
- 2750/14242 . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2750/14243 . . . viral genome or elements thereof as genetic vector
- 2750/14244 . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2750/14245 . . . Special targeting system for viral vectors
- 2750/14251 . . . Methods of production or purification of viral material
- 2750/14252 . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2750/14261 . . . Methods of inactivation or attenuation
- 2750/14262 . . . by genetic engineering
- 2750/14263 . . . by chemical treatment
- 2750/14264 . . . by serial passage
- 2750/14271 . . . Demonstrated in vivo effect
- 2750/14288 . . . for redistribution
- 2750/14311 . . . Parvovirus, e.g. minute virus of mice
- 2750/14321 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences

- 2750/14322 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2750/14323 . . . . Virus like particles [VLP]
- 2750/14331 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2750/14332 . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2750/14333 . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2750/14334 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2750/14341 . . . . Use of virus, viral particle or viral elements as a vector
- 2750/14342 . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2750/14343 . . . . . viral genome or elements thereof as genetic vector
- 2750/14344 . . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2750/14345 . . . . . Special targeting system for viral vectors
- 2750/14351 . . . . Methods of production or purification of viral material
- 2750/14352 . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2750/14361 . . . . Methods of inactivation or attenuation
- 2750/14362 . . . . . by genetic engineering
- 2750/14363 . . . . . by chemical treatment
- 2750/14364 . . . . . by serial passage
- 2750/14371 . . . . Demonstrated *in vivo* effect
- 2750/14388 . . . . for redistribution
- 2760/00** **ssRNA viruses negative-sense**
- 2760/00011 . Details
- 2760/00021 . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/00022 . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/00023 . . Virus like particles [VLP]
- 2760/00031 . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/00032 . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/00033 . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/00034 . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/00041 . . Use of virus, viral particle or viral elements as a vector
- 2760/00042 . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/00043 . . . viral genome or elements thereof as genetic vector
- 2760/00044 . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/00045 . . . Special targeting system for viral vectors
- 2760/00051 . . Methods of production or purification of viral material
- 2760/00052 . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/00061 . . Methods of inactivation or attenuation
- 2760/00062 . . . by genetic engineering
- 2760/00063 . . . by chemical treatment
- 2760/00064 . . . by serial passage
- 2760/00071 . . Demonstrated *in vivo* effect
- 2760/00088 . . for redistribution
- 2760/10011 . . Arenaviridae
- 2760/10021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/10022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/10023 . . . Virus like particles [VLP]
- 2760/10031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/10032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/10033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/10034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/10041 . . . Use of virus, viral particle or viral elements as a vector
- 2760/10042 . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/10043 . . . . viral genome or elements thereof as genetic vector
- 2760/10044 . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/10045 . . . . Special targeting system for viral vectors
- 2760/10051 . . . Methods of production or purification of viral material
- 2760/10052 . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/10061 . . . Methods of inactivation or attenuation
- 2760/10062 . . . . by genetic engineering
- 2760/10063 . . . . by chemical treatment
- 2760/10064 . . . . by serial passage
- 2760/10071 . . . Demonstrated *in vivo* effect
- 2760/10088 . . . for redistribution
- 2760/10111 . . . Deltavirus, e.g. hepatitis delta virus
- 2760/10121 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/10122 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/10123 . . . . Virus like particles [VLP]
- 2760/10131 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/10132 . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/10133 . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

2760/10134	. . . .	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	2760/12121	. . . .	Viruses as such, e.g. new isolates, mutants or their genomic sequences
2760/10141	. . . .	Use of virus, viral particle or viral elements as a vector	2760/12122	. . . .	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2760/10142	. . . .	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	2760/12123	. . . .	Virus like particles [VLP]
2760/10143	. . . .	viral genome or elements thereof as genetic vector	2760/12131	. . . .	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2760/10144	. . . .	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	2760/12132	. . . .	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2760/10145	. . . .	Special targeting system for viral vectors	2760/12133	. . . .	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2760/10151	. . . .	Methods of production or purification of viral material	2760/12134	. . . .	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2760/10152	. . . .	relating to complementing cells and packaging systems for producing virus or viral particles	2760/12141	. . . .	Use of virus, viral particle or viral elements as a vector
2760/10161	. . . .	Methods of inactivation or attenuation	2760/12142	. . . .	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2760/10162	. . . .	by genetic engineering	2760/12143	. . . .	viral genome or elements thereof as genetic vector
2760/10163	. . . .	by chemical treatment	2760/12144	. . . .	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2760/10164	. . . .	by serial passage	2760/12145	. . . .	Special targeting system for viral vectors
2760/10171	. . . .	Demonstrated <u>in vivo</u> effect	2760/12151	. . . .	Methods of production or purification of viral material
2760/10188	. . . .	for redistribution	2760/12152	. . . .	relating to complementing cells and packaging systems for producing virus or viral particles
2760/12011	. .	Bunyaviridae	2760/12161	. . . .	Methods of inactivation or attenuation
2760/12021	. . .	Viruses as such, e.g. new isolates, mutants or their genomic sequences	2760/12162	. . . .	by genetic engineering
2760/12022	. . .	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	2760/12163	. . . .	by chemical treatment
2760/12023	. . .	Virus like particles [VLP]	2760/12164	. . . .	by serial passage
2760/12031	. . .	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	2760/12171	. . . .	Demonstrated <u>in vivo</u> effect
2760/12032	. . .	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	2760/12188	. . . .	for redistribution
2760/12033	. . .	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	2760/12211	. . .	Phlebovirus, e.g. Rift Valley fever virus
2760/12034	. . .	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	2760/12221	. . . .	Viruses as such, e.g. new isolates, mutants or their genomic sequences
2760/12041	. . .	Use of virus, viral particle or viral elements as a vector	2760/12222	. . . .	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2760/12042	. . . .	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	2760/12223	. . . .	Virus like particles [VLP]
2760/12043	. . . .	viral genome or elements thereof as genetic vector	2760/12231	. . . .	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2760/12044	. . . .	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	2760/12232	. . . .	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2760/12045	. . . .	Special targeting system for viral vectors	2760/12233	. . . .	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2760/12051	. . .	Methods of production or purification of viral material	2760/12234	. . . .	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2760/12052	. . . .	relating to complementing cells and packaging systems for producing virus or viral particles	2760/12241	. . . .	Use of virus, viral particle or viral elements as a vector
2760/12061	. . .	Methods of inactivation or attenuation	2760/12242	. . . .	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2760/12062	. . . .	by genetic engineering	2760/12243	. . . .	viral genome or elements thereof as genetic vector
2760/12063	. . . .	by chemical treatment	2760/12244	. . . .	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2760/12064	. . . .	by serial passage	2760/12245	. . . .	Special targeting system for viral vectors
2760/12071	. . .	Demonstrated <u>in vivo</u> effect			
2760/12088	. . .	for redistribution			
2760/12111	. . .	Hantavirus, e.g. Hantaan virus			



- 2760/12251 . . . . Methods of production or purification of viral material
- 2760/12252 . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/12261 . . . . Methods of inactivation or attenuation
- 2760/12262 . . . . by genetic engineering
- 2760/12263 . . . . by chemical treatment
- 2760/12264 . . . . by serial passage
- 2760/12271 . . . . Demonstrated in vivo effect
- 2760/12288 . . . . for redistribution
- 2760/14011 . . Filoviridae
- 2760/14021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/14022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/14023 . . . Virus like particles [VLP]
- 2760/14031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/14032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/14033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/14034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/14041 . . . Use of virus, viral particle or viral elements as a vector
- 2760/14042 . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/14043 . . . . viral genome or elements thereof as genetic vector
- 2760/14044 . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/14045 . . . . Special targeting system for viral vectors
- 2760/14051 . . . Methods of production or purification of viral material
- 2760/14052 . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/14061 . . . Methods of inactivation or attenuation
- 2760/14062 . . . . by genetic engineering
- 2760/14063 . . . . by chemical treatment
- 2760/14064 . . . . by serial passage
- 2760/14071 . . . Demonstrated in vivo effect
- 2760/14088 . . . for redistribution
- 2760/14111 . . . Ebolavirus, e.g. Zaire ebolavirus
- 2760/14121 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/14122 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/14123 . . . . Virus like particles [VLP]
- 2760/14131 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/14132 . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/14133 . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/14134 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/14141 . . . . Use of virus, viral particle or viral elements as a vector
- 2760/14142 . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/14143 . . . . . viral genome or elements thereof as genetic vector
- 2760/14144 . . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/14145 . . . . . Special targeting system for viral vectors
- 2760/14151 . . . . Methods of production or purification of viral material
- 2760/14152 . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/14161 . . . . Methods of inactivation or attenuation
- 2760/14162 . . . . . by genetic engineering
- 2760/14163 . . . . . by chemical treatment
- 2760/14164 . . . . . by serial passage
- 2760/14171 . . . . Demonstrated in vivo effect
- 2760/14188 . . . . for redistribution
- 2760/14211 . . . Marburgvirus, e.g. lake Victoria marburgvirus
- 2760/14221 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/14222 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/14223 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/14231 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/14232 . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/14233 . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/14234 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/14241 . . . . Use of virus, viral particle or viral elements as a vector
- 2760/14242 . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/14243 . . . . . viral genome or elements thereof as genetic vector
- 2760/14244 . . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/14245 . . . . . Special targeting system for viral vectors
- 2760/14251 . . . . Methods of production or purification of viral material
- 2760/14252 . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/14261 . . . . Methods of inactivation or attenuation
- 2760/14262 . . . . . by genetic engineering
- 2760/14263 . . . . . by chemical treatment
- 2760/14264 . . . . . by serial passage
- 2760/14271 . . . . Demonstrated in vivo effect
- 2760/14288 . . . . for redistribution
- 2760/16011 . . Orthomyxoviridae

- 2760/16021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/16022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/16023 . . . Virus like particles [VLP]
- 2760/16031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/16032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/16033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/16034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/16041 . . . Use of virus, viral particle or viral elements as a vector
- 2760/16042 . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/16043 . . . viral genome or elements thereof as genetic vector
- 2760/16044 . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/16045 . . . Special targeting system for viral vectors
- 2760/16051 . . . Methods of production or purification of viral material
- 2760/16052 . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/16061 . . . Methods of inactivation or attenuation
- 2760/16062 . . . by genetic engineering
- 2760/16063 . . . by chemical treatment
- 2760/16064 . . . by serial passage
- 2760/16071 . . . Demonstrated in vivo effect
- 2760/16088 . . . for redistribution
- 2760/16111 . . . Influenzavirus A, i.e. influenza A virus
- 2760/16121 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/16122 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/16123 . . . Virus like particles [VLP]
- 2760/16131 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/16132 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/16133 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/16134 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/16141 . . . Use of virus, viral particle or viral elements as a vector
- 2760/16142 . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/16143 . . . viral genome or elements thereof as genetic vector
- 2760/16144 . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/16145 . . . Special targeting system for viral vectors
- 2760/16151 . . . Methods of production or purification of viral material
- 2760/16152 . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/16161 . . . Methods of inactivation or attenuation
- 2760/16162 . . . by genetic engineering
- 2760/16163 . . . by chemical treatment
- 2760/16164 . . . by serial passage
- 2760/16171 . . . Demonstrated in vivo effect
- 2760/16188 . . . for redistribution
- 2760/16211 . . . Influenzavirus B, i.e. influenza B virus
- 2760/16221 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/16222 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/16223 . . . Virus like particles [VLP]
- 2760/16231 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/16232 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/16233 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/16234 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/16241 . . . Use of virus, viral particle or viral elements as a vector
- 2760/16242 . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/16243 . . . viral genome or elements thereof as genetic vector
- 2760/16244 . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/16245 . . . Special targeting system for viral vectors
- 2760/16251 . . . Methods of production or purification of viral material
- 2760/16252 . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/16261 . . . Methods of inactivation or attenuation
- 2760/16262 . . . by genetic engineering
- 2760/16263 . . . by chemical treatment
- 2760/16264 . . . by serial passage
- 2760/16271 . . . Demonstrated in vivo effect
- 2760/16288 . . . for redistribution
- 2760/16311 . . . Influenzavirus C, i.e. influenza C virus
- 2760/16321 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/16322 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/16323 . . . Virus like particles [VLP]
- 2760/16331 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/16332 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/16333 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

- 2760/16334 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/16341 . . . . Use of virus, viral particle or viral elements as a vector
- 2760/16342 . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/16343 . . . . . viral genome or elements thereof as genetic vector
- 2760/16344 . . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/16345 . . . . . Special targeting system for viral vectors
- 2760/16351 . . . . Methods of production or purification of viral material
- 2760/16352 . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/16361 . . . . Methods of inactivation or attenuation
- 2760/16362 . . . . . by genetic engineering
- 2760/16363 . . . . . by chemical treatment
- 2760/16364 . . . . . by serial passage
- 2760/16371 . . . . Demonstrated in vivo effect
- 2760/16388 . . . . for redistribution
- 2760/18011 . . Paramyxoviridae
- 2760/18021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/18022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/18023 . . . Virus like particles [VLP]
- 2760/18031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/18032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/18033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/18034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/18041 . . . Use of virus, viral particle or viral elements as a vector
- 2760/18042 . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/18043 . . . . viral genome or elements thereof as genetic vector
- 2760/18044 . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/18045 . . . . Special targeting system for viral vectors
- 2760/18051 . . . Methods of production or purification of viral material
- 2760/18052 . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/18061 . . . Methods of inactivation or attenuation
- 2760/18062 . . . . by genetic engineering
- 2760/18063 . . . . by chemical treatment
- 2760/18064 . . . . by serial passage
- 2760/18071 . . . Demonstrated in vivo effect
- 2760/18088 . . . for redistribution
- 2760/18111 . . . Avulavirus, e.g. Newcastle disease virus
- 2760/18121 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/18122 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/18123 . . . . Virus like particles [VLP]
- 2760/18131 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/18132 . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/18133 . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/18134 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/18141 . . . . Use of virus, viral particle or viral elements as a vector
- 2760/18142 . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/18143 . . . . . viral genome or elements thereof as genetic vector
- 2760/18144 . . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/18145 . . . . . Special targeting system for viral vectors
- 2760/18151 . . . . Methods of production or purification of viral material
- 2760/18152 . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/18161 . . . . Methods of inactivation or attenuation
- 2760/18162 . . . . . by genetic engineering
- 2760/18163 . . . . . by chemical treatment
- 2760/18164 . . . . . by serial passage
- 2760/18171 . . . . Demonstrated in vivo effect
- 2760/18188 . . . . for redistribution
- 2760/18211 . . . Henipavirus, e.g. hendra virus
- 2760/18221 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/18222 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/18223 . . . . Virus like particles [VLP]
- 2760/18231 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/18232 . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/18233 . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/18234 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/18241 . . . . Use of virus, viral particle or viral elements as a vector
- 2760/18242 . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/18243 . . . . . viral genome or elements thereof as genetic vector
- 2760/18244 . . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/18245 . . . . . Special targeting system for viral vectors

- 2760/18251 . . . . Methods of production or purification of viral material
- 2760/18252 . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/18261 . . . . Methods of inactivation or attenuation
- 2760/18262 . . . . by genetic engineering
- 2760/18263 . . . . by chemical treatment
- 2760/18264 . . . . by serial passage
- 2760/18271 . . . . Demonstrated in vivo effect
- 2760/18288 . . . . for redistribution
- 2760/18311 . . . Metapneumovirus, e.g. avian pneumovirus
- 2760/18321 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/18322 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/18323 . . . . Virus like particles [VLP]
- 2760/18331 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/18332 . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/18333 . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/18334 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/18341 . . . . Use of virus, viral particle or viral elements as a vector
- 2760/18342 . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/18343 . . . . viral genome or elements thereof as genetic vector
- 2760/18344 . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/18345 . . . . Special targeting system for viral vectors
- 2760/18351 . . . . Methods of production or purification of viral material
- 2760/18352 . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/18361 . . . . Methods of inactivation or attenuation
- 2760/18362 . . . . by genetic engineering
- 2760/18363 . . . . by chemical treatment
- 2760/18364 . . . . by serial passage
- 2760/18371 . . . . Demonstrated in vivo effect
- 2760/18388 . . . . for redistribution
- 2760/18411 . . . Morbillivirus, e.g. Measles virus, canine distemper
- 2760/18421 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/18422 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/18423 . . . . Virus like particles [VLP]
- 2760/18431 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/18432 . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/18433 . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/18434 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/18441 . . . . Use of virus, viral particle or viral elements as a vector
- 2760/18442 . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/18443 . . . . viral genome or elements thereof as genetic vector
- 2760/18444 . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/18445 . . . . Special targeting system for viral vectors
- 2760/18451 . . . . Methods of production or purification of viral material
- 2760/18452 . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/18461 . . . . Methods of inactivation or attenuation
- 2760/18462 . . . . by genetic engineering
- 2760/18463 . . . . by chemical treatment
- 2760/18464 . . . . by serial passage
- 2760/18471 . . . . Demonstrated in vivo effect
- 2760/18488 . . . . For redistribution
- 2760/18511 . . . Pneumovirus, e.g. human respiratory syncytial virus
- 2760/18521 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/18522 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/18523 . . . . Virus like particles [VLP]
- 2760/18531 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/18532 . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/18533 . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/18534 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/18541 . . . . Use of virus, viral particle or viral elements as a vector
- 2760/18542 . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/18543 . . . . viral genome or elements thereof as genetic vector
- 2760/18544 . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/18545 . . . . Special targeting system for viral vectors
- 2760/18551 . . . . Methods of production or purification of viral material
- 2760/18552 . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/18561 . . . . Methods of inactivation or attenuation
- 2760/18562 . . . . by genetic engineering
- 2760/18563 . . . . by chemical treatment
- 2760/18564 . . . . by serial passage
- 2760/18571 . . . . Demonstrated in vivo effect
- 2760/18588 . . . . for redistribution

- 2760/18611 . . . . Respirovirus, e.g. Bovine, human parainfluenza 1,3
- 2760/18621 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/18622 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/18623 . . . . Virus like particles [VLP]
- 2760/18631 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/18632 . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/18633 . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/18634 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/18641 . . . . Use of virus, viral particle or viral elements as a vector
- 2760/18642 . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/18643 . . . . . viral genome or elements thereof as genetic vector
- 2760/18644 . . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/18645 . . . . . Special targeting system for viral vectors
- 2760/18651 . . . . . Methods of production or purification of viral material
- 2760/18652 . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/18661 . . . . . Methods of inactivation or attenuation
- 2760/18662 . . . . . by genetic engineering
- 2760/18663 . . . . . by chemical treatment
- 2760/18664 . . . . . by serial passage
- 2760/18671 . . . . . Demonstrated in vivo effect
- 2760/18688 . . . . . for redistribution
- 2760/18711 . . . . Rubulavirus, e.g. mumps virus, parainfluenza 2,4
- 2760/18721 . . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/18722 . . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/18723 . . . . . Virus like particles [VLP]
- 2760/18731 . . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/18732 . . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/18733 . . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/18734 . . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/18741 . . . . . Use of virus, viral particle or viral elements as a vector
- 2760/18742 . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/18743 . . . . . viral genome or elements thereof as genetic vector
- 2760/18744 . . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/18745 . . . . . Special targeting system for viral vectors
- 2760/18751 . . . . . Methods of production or purification of viral material
- 2760/18752 . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/18761 . . . . . Methods of inactivation or attenuation
- 2760/18762 . . . . . by genetic engineering
- 2760/18763 . . . . . by chemical treatment
- 2760/18764 . . . . . by serial passage
- 2760/18771 . . . . . Demonstrated in vivo effect
- 2760/18788 . . . . . for redistribution
- 2760/18811 . . . . Sendai virus
- 2760/18821 . . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/18822 . . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/18823 . . . . . Virus like particles [VLP]
- 2760/18831 . . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/18832 . . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/18833 . . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/18834 . . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/18841 . . . . . Use of virus, viral particle or viral elements as a vector
- 2760/18842 . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/18843 . . . . . viral genome or elements thereof as genetic vector
- 2760/18845 . . . . . Special targeting system for viral vectors
- 2760/18851 . . . . . Methods of production or purification of viral material
- 2760/18852 . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/18861 . . . . . Methods of inactivation or attenuation
- 2760/18862 . . . . . by genetic engineering
- 2760/18863 . . . . . by chemical treatment
- 2760/18864 . . . . . by serial passage
- 2760/18871 . . . . . Demonstrated in vivo effect
- 2760/18888 . . . . . for redistribution
- 2760/20011 . . . . Rhabdoviridae
- 2760/20021 . . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/20022 . . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/20023 . . . . . Virus like particles [VLP]
- 2760/20031 . . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/20032 . . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/20033 . . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory



- 2760/20034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/20041 . . . Use of virus, viral particle or viral elements as a vector
- 2760/20042 . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/20043 . . . . viral genome or elements thereof as genetic vector
- 2760/20044 . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/20045 . . . . Special targeting system for viral vectors
- 2760/20051 . . . Methods of production or purification of viral material
- 2760/20052 . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/20061 . . . Methods of inactivation or attenuation
- 2760/20062 . . . . by genetic engineering
- 2760/20063 . . . . by chemical treatment
- 2760/20064 . . . . by serial passage
- 2760/20071 . . . Demonstrated in vivo effect
- 2760/20088 . . . for redistribution
- 2760/20111 . . . Lyssavirus, e.g. rabies virus
- 2760/20121 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/20122 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/20123 . . . . Virus like particles [VLP]
- 2760/20131 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/20132 . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/20133 . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/20134 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/20141 . . . . Use of virus, viral particle or viral elements as a vector
- 2760/20142 . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/20143 . . . . . viral genome or elements thereof as genetic vector
- 2760/20144 . . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/20145 . . . . . Special targeting system for viral vectors
- 2760/20151 . . . . Methods of production or purification of viral material
- 2760/20152 . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/20161 . . . . Methods of inactivation or attenuation
- 2760/20162 . . . . . by genetic engineering
- 2760/20163 . . . . . by chemical treatment
- 2760/20164 . . . . . by serial passage
- 2760/20171 . . . . Demonstrated in vivo effect
- 2760/20188 . . . . for redistribution
- 2760/20211 . . . Vesiculovirus, e.g. vesicular stomatitis Indiana virus
- 2760/20221 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/20222 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/20223 . . . . Virus like particles [VLP]
- 2760/20231 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/20232 . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/20233 . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/20234 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/20241 . . . . Use of virus, viral particle or viral elements as a vector
- 2760/20242 . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/20243 . . . . . viral genome or elements thereof as genetic vector
- 2760/20244 . . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/20245 . . . . . Special targeting system for viral vectors
- 2760/20251 . . . . Methods of production or purification of viral material
- 2760/20252 . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/20261 . . . . Methods of inactivation or attenuation
- 2760/20262 . . . . . by genetic engineering
- 2760/20263 . . . . . by chemical treatment
- 2760/20264 . . . . . by serial passage
- 2760/20271 . . . . Demonstrated in vivo effect
- 2760/20288 . . . . for redistribution
- 2770/00 ssRNA viruses positive-sense**
- 2770/00011 . Details
- 2770/00021 . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/00022 . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/00023 . . Virus like particles [VLP]
- 2770/00031 . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/00032 . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/00033 . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/00034 . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/00041 . . Use of virus, viral particle or viral elements as a vector
- 2770/00042 . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/00043 . . . viral genome or elements thereof as genetic vector

- 2770/00044 . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/00045 . . . Special targeting system for viral vectors
- 2770/00051 . . . Methods of production or purification of viral material
- 2770/00052 . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/00061 . . . Methods of inactivation or attenuation
- 2770/00062 . . . by genetic engineering
- 2770/00063 . . . by chemical treatment
- 2770/00064 . . . by serial passage
- 2770/00071 . . . Demonstrated in vivo effect
- 2770/00088 . . . for redistribution
- 2770/10011 . . . Arteriviridae
- 2770/10021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/10022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/10023 . . . Virus like particles [VLP]
- 2770/10031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/10032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/10033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/10034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/10041 . . . Use of virus, viral particle or viral elements as a vector
- 2770/10042 . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/10043 . . . . viral genome or elements thereof as genetic vector
- 2770/10044 . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/10045 . . . . Special targeting system for viral vectors
- 2770/10051 . . . . Methods of production or purification of viral material
- 2770/10052 . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/10061 . . . . Methods of inactivation or attenuation
- 2770/10062 . . . . by genetic engineering
- 2770/10063 . . . . by chemical treatment
- 2770/10064 . . . . by serial passage
- 2770/10071 . . . . Demonstrated in vivo effect
- 2770/10088 . . . . for redistribution
- 2770/12011 . . . . Astroviridae
- 2770/12021 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/12022 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/12023 . . . . Virus like particles [VLP]
- 2770/12031 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/12032 . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/12033 . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/12034 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/12041 . . . . Use of virus, viral particle or viral elements as a vector
- 2770/12042 . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/12043 . . . . . viral genome or elements thereof as genetic vector
- 2770/12044 . . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/12045 . . . . . Special targeting system for viral vectors
- 2770/12051 . . . . . Methods of production or purification of viral material
- 2770/12052 . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/12061 . . . . . Methods of inactivation or attenuation
- 2770/12062 . . . . . by genetic engineering
- 2770/12063 . . . . . by chemical treatment
- 2770/12064 . . . . . by serial passage
- 2770/12071 . . . . . Demonstrated in vivo effect
- 2770/12088 . . . . . for redistribution
- 2770/14011 . . . . . Bromoviridae
- 2770/14021 . . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/14022 . . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/14023 . . . . . Virus like particles [VLP]
- 2770/14031 . . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/14032 . . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/14033 . . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/14034 . . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/14041 . . . . . Use of virus, viral particle or viral elements as a vector
- 2770/14042 . . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/14043 . . . . . . viral genome or elements thereof as genetic vector
- 2770/14044 . . . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/14045 . . . . . . Special targeting system for viral vectors
- 2770/14051 . . . . . . Methods of production or purification of viral material
- 2770/14052 . . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/14061 . . . . . . Methods of inactivation or attenuation
- 2770/14062 . . . . . . by genetic engineering
- 2770/14063 . . . . . . by chemical treatment
- 2770/14064 . . . . . . by serial passage
- 2770/14071 . . . . . . Demonstrated in vivo effect

- 2770/14088 . . . for redistribution
- 2770/16011 . . . Caliciviridae
- 2770/16021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/16022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/16023 . . . Virus like particles [VLP]
- 2770/16031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/16032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/16033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/16034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/16041 . . . Use of virus, viral particle or viral elements as a vector
- 2770/16042 . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/16043 . . . . viral genome or elements thereof as genetic vector
- 2770/16044 . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/16045 . . . . Special targeting system for viral vectors
- 2770/16051 . . . . Methods of production or purification of viral material
- 2770/16052 . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/16061 . . . . Methods of inactivation or attenuation
- 2770/16062 . . . . by genetic engineering
- 2770/16063 . . . . by chemical treatment
- 2770/16064 . . . . by serial passage
- 2770/16071 . . . . Demonstrated in vivo effect
- 2770/16088 . . . . for redistribution
- 2770/18011 . . . Comoviridae
- 2770/18021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/18022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/18023 . . . Virus like particles [VLP]
- 2770/18031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/18032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/18033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/18034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/18041 . . . Use of virus, viral particle or viral elements as a vector
- 2770/18042 . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/18043 . . . . viral genome or elements thereof as genetic vector
- 2770/18044 . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/18045 . . . . Special targeting system for viral vectors
- 2770/18051 . . . . Methods of production or purification of viral material
- 2770/18052 . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/18061 . . . . Methods of inactivation or attenuation
- 2770/18062 . . . . by genetic engineering
- 2770/18063 . . . . by chemical treatment
- 2770/18064 . . . . by serial passage
- 2770/18071 . . . . Demonstrated in vivo effect
- 2770/18088 . . . . for redistribution
- 2770/20011 . . . Coronaviridae
- 2770/20021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/20022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/20023 . . . Virus like particles [VLP]
- 2770/20031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/20032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/20033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/20034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/20041 . . . Use of virus, viral particle or viral elements as a vector
- 2770/20042 . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/20043 . . . . viral genome or elements thereof as genetic vector
- 2770/20044 . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/20045 . . . . Special targeting system for viral vectors
- 2770/20051 . . . . Methods of production or purification of viral material
- 2770/20052 . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/20061 . . . . Methods of inactivation or attenuation
- 2770/20062 . . . . by genetic engineering
- 2770/20063 . . . . by chemical treatment
- 2770/20064 . . . . by serial passage
- 2770/20071 . . . . Demonstrated in vivo effect
- 2770/20088 . . . . for redistribution
- 2770/22011 . . . Dicistroviridae
- 2770/22021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/22022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/22023 . . . Virus like particles [VLP]
- 2770/22031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/22032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

- 2770/22033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/22034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/22041 . . . Use of virus, viral particle or viral elements as a vector
- 2770/22042 . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/22043 . . . . viral genome or elements thereof as genetic vector
- 2770/22044 . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/22045 . . . . Special targeting system for viral vectors
- 2770/22051 . . . Methods of production or purification of viral material
- 2770/22052 . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/22061 . . . Methods of inactivation or attenuation
- 2770/22062 . . . . by genetic engineering
- 2770/22063 . . . . by chemical treatment
- 2770/22064 . . . . by serial passage
- 2770/22071 . . . Demonstrated in vivo effect
- 2770/22088 . . . for redistribution
- 2770/24011 . . Flaviviridae
- 2770/24021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/24022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/24023 . . . Virus like particles [VLP]
- 2770/24031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/24032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/24033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/24034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/24041 . . . Use of virus, viral particle or viral elements as a vector
- 2770/24042 . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/24043 . . . . viral genome or elements thereof as genetic vector
- 2770/24044 . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/24045 . . . . Special targeting system for viral vectors
- 2770/24051 . . . Methods of production or purification of viral material
- 2770/24052 . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/24061 . . . Methods of inactivation or attenuation
- 2770/24062 . . . . by genetic engineering
- 2770/24063 . . . . by chemical treatment
- 2770/24064 . . . . by serial passage
- 2770/24071 . . . Demonstrated in vivo effect
- 2770/24088 . . . for redistribution
- 2770/24111 . . . Flavivirus, e.g. yellow fever virus, dengue, JEV
- 2770/24121 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/24122 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/24123 . . . . Virus like particles [VLP]
- 2770/24131 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/24132 . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/24133 . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/24134 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/24141 . . . . Use of virus, viral particle or viral elements as a vector
- 2770/24142 . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/24143 . . . . . viral genome or elements thereof as genetic vector
- 2770/24144 . . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/24145 . . . . . Special targeting system for viral vectors
- 2770/24151 . . . . . Methods of production or purification of viral material
- 2770/24152 . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/24161 . . . . . Methods of inactivation or attenuation
- 2770/24162 . . . . . by genetic engineering
- 2770/24163 . . . . . by chemical treatment
- 2770/24164 . . . . . by serial passage
- 2770/24171 . . . . . Demonstrated in vivo effect
- 2770/24188 . . . . . for redistribution
- 2770/24211 . . . Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- 2770/24221 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/24222 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/24223 . . . . Virus like particles [VLP]
- 2770/24231 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/24232 . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/24233 . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/24234 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/24241 . . . . Use of virus, viral particle or viral elements as a vector
- 2770/24242 . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/24243 . . . . . viral genome or elements thereof as genetic vector

- 2770/24244 . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/24245 . . . . Special targeting system for viral vectors
- 2770/24251 . . . . Methods of production or purification of viral material
- 2770/24252 . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/24261 . . . . Methods of inactivation or attenuation
- 2770/24262 . . . . by genetic engineering
- 2770/24263 . . . . by chemical treatment
- 2770/24264 . . . . by serial passage
- 2770/24271 . . . . Demonstrated in vivo effect
- 2770/24288 . . . . for redistribution
- 2770/24311 . . . . Pestivirus, e.g. bovine viral diarrhea virus
- 2770/24321 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/24322 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/24323 . . . . Virus like particles [VLP]
- 2770/24331 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/24332 . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/24333 . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/24334 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/24341 . . . . Use of virus, viral particle or viral elements as a vector
- 2770/24342 . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/24343 . . . . viral genome or elements thereof as genetic vector
- 2770/24344 . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/24345 . . . . Special targeting system for viral vectors
- 2770/24351 . . . . Methods of production or purification of viral material
- 2770/24352 . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/24361 . . . . Methods of inactivation or attenuation
- 2770/24362 . . . . by genetic engineering
- 2770/24363 . . . . by chemical treatment
- 2770/24364 . . . . by serial passage
- 2770/24371 . . . . Demonstrated in vivo effect
- 2770/24388 . . . . for redistribution
- 2770/26011 . . . Flexiviridae
- 2770/26021 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/26022 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/26023 . . . . Virus like particles [VLP]
- 2770/26031 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/26032 . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/26033 . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/26034 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/26041 . . . . Use of virus, viral particle or viral elements as a vector
- 2770/26042 . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/26043 . . . . viral genome or elements thereof as genetic vector
- 2770/26044 . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/26045 . . . . Special targeting system for viral vectors
- 2770/26051 . . . . Methods of production or purification of viral material
- 2770/26052 . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/26061 . . . . Methods of inactivation or attenuation
- 2770/26062 . . . . by genetic engineering
- 2770/26063 . . . . by chemical treatment
- 2770/26064 . . . . by serial passage
- 2770/26071 . . . . Demonstrated in vivo effect
- 2770/26088 . . . . for redistribution
- 2770/28011 . . . Hepeviridae
- 2770/28021 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/28022 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/28023 . . . . Virus like particles [VLP]
- 2770/28031 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/28032 . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/28033 . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/28034 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/28041 . . . . Use of virus, viral particle or viral elements as a vector
- 2770/28042 . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/28043 . . . . viral genome or elements thereof as genetic vector
- 2770/28044 . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/28045 . . . . Special targeting system for viral vectors
- 2770/28051 . . . . Methods of production or purification of viral material
- 2770/28052 . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/28061 . . . . Methods of inactivation or attenuation
- 2770/28062 . . . . by genetic engineering
- 2770/28063 . . . . by chemical treatment
- 2770/28064 . . . . by serial passage
- 2770/28071 . . . . Demonstrated in vivo effect

- 2770/28088 . . . for redistribution
- 2770/28111 . . . Hepatitis E virus
- 2770/28121 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/28122 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/28123 . . . . Virus like particles [VLP]
- 2770/28131 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/28132 . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/28133 . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/28134 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/28141 . . . . Use of virus, viral particle or viral elements as a vector
- 2770/28142 . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/28143 . . . . . viral genome or elements thereof as genetic vector
- 2770/28144 . . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/28145 . . . . . Special targeting system for viral vectors
- 2770/28151 . . . . . Methods of production or purification of viral material
- 2770/28152 . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/28161 . . . . . Methods of inactivation or attenuation
- 2770/28162 . . . . . by genetic engineering
- 2770/28163 . . . . . by chemical treatment
- 2770/28164 . . . . . by serial passage
- 2770/28171 . . . . . Demonstrated *in vivo* effect
- 2770/28188 . . . . . for redistribution
- 2770/30011 . . . Nodaviridae
- 2770/30021 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/30022 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/30023 . . . . Virus like particles [VLP]
- 2770/30031 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/30032 . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/30033 . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/30034 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/30041 . . . . Use of virus, viral particle or viral elements as a vector
- 2770/30042 . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/30043 . . . . . viral genome or elements thereof as genetic vector
- 2770/30044 . . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/30045 . . . . . Special targeting system for viral vectors
- 2770/30051 . . . . . Methods of production or purification of viral material
- 2770/30052 . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/30061 . . . . . Methods of inactivation or attenuation
- 2770/30062 . . . . . by genetic engineering
- 2770/30063 . . . . . by chemical treatment
- 2770/30064 . . . . . by serial passage
- 2770/30071 . . . . . Demonstrated *in vivo* effect
- 2770/30088 . . . . . for redistribution
- 2770/32011 . . . Picornaviridae
- 2770/32021 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/32022 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/32023 . . . . Virus like particles [VLP]
- 2770/32031 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/32032 . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/32033 . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/32034 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/32041 . . . . Use of virus, viral particle or viral elements as a vector
- 2770/32042 . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/32043 . . . . . viral genome or elements thereof as genetic vector
- 2770/32044 . . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/32045 . . . . . Special targeting system for viral vectors
- 2770/32051 . . . . . Methods of production or purification of viral material
- 2770/32052 . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/32061 . . . . . Methods of inactivation or attenuation
- 2770/32062 . . . . . by genetic engineering
- 2770/32063 . . . . . by chemical treatment
- 2770/32064 . . . . . by serial passage
- 2770/32071 . . . . . Demonstrated *in vivo* effect
- 2770/32088 . . . . . for redistribution
- 2770/32111 . . . . Aphthovirus, e.g. foot-and-mouth disease virus
- 2770/32121 . . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/32122 . . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/32123 . . . . . Virus like particles [VLP]
- 2770/32131 . . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/32132 . . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent



- 2770/32133 . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/32134 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/32141 . . . . Use of virus, viral particle or viral elements as a vector
- 2770/32142 . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/32143 . . . . . viral genome or elements thereof as genetic vector
- 2770/32144 . . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/32145 . . . . . Special targeting system for viral vectors
- 2770/32151 . . . . Methods of production or purification of viral material
- 2770/32152 . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/32161 . . . . Methods of inactivation or attenuation
- 2770/32162 . . . . . by genetic engineering
- 2770/32163 . . . . . by chemical treatment
- 2770/32164 . . . . . by serial passage
- 2770/32171 . . . . Demonstrated *in vivo* effect
- 2770/32188 . . . . for redistribution
- 2770/32211 . . . . Cardiovirus, e.g. encephalomyocarditis virus
- 2770/32221 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/32222 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/32223 . . . . Virus like particles [VLP]
- 2770/32231 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/32232 . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/32233 . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/32234 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/32241 . . . . Use of virus, viral particle or viral elements as a vector
- 2770/32242 . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/32243 . . . . . viral genome or elements thereof as genetic vector
- 2770/32244 . . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/32245 . . . . . Special targeting system for viral vectors
- 2770/32251 . . . . Methods of production or purification of viral material
- 2770/32252 . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/32261 . . . . Methods of inactivation or attenuation
- 2770/32262 . . . . . by genetic engineering
- 2770/32263 . . . . . by chemical treatment
- 2770/32264 . . . . . by serial passage
- 2770/32271 . . . . Demonstrated *in vivo* effect
- 2770/32288 . . . . for redistribution
- 2770/32311 . . . . Enterovirus
- 2770/32321 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/32322 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/32323 . . . . Virus like particles [VLP]
- 2770/32331 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/32332 . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/32333 . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/32334 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/32341 . . . . Use of virus, viral particle or viral elements as a vector
- 2770/32342 . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/32343 . . . . . viral genome or elements thereof as genetic vector
- 2770/32344 . . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/32345 . . . . . Special targeting system for viral vectors
- 2770/32351 . . . . Methods of production or purification of viral material
- 2770/32352 . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/32361 . . . . Methods of inactivation or attenuation
- 2770/32362 . . . . . by genetic engineering
- 2770/32363 . . . . . by chemical treatment
- 2770/32364 . . . . . by serial passage
- 2770/32371 . . . . Demonstrated *in vivo* effect
- 2770/32388 . . . . for redistribution
- 2770/32411 . . . . Hepatovirus, i.e. hepatitis A virus
- 2770/32421 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/32422 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/32423 . . . . Virus like particles [VLP]
- 2770/32431 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/32432 . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/32433 . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/32434 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/32441 . . . . Use of virus, viral particle or viral elements as a vector
- 2770/32442 . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/32443 . . . . . viral genome or elements thereof as genetic vector

2770/32444	. . . .	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	2770/32633	. . . .	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2770/32445	. . . .	Special targeting system for viral vectors	2770/32634	. . . .	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2770/32451	. . . .	Methods of production or purification of viral material	2770/32641	. . . .	Use of virus, viral particle or viral elements as a vector
2770/32452	. . . .	relating to complementing cells and packaging systems for producing virus or viral particles	2770/32642	. . . .	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2770/32461	. . . .	Methods of inactivation or attenuation	2770/32643	. . . .	viral genome or elements thereof as genetic vector
2770/32462	. . . .	by genetic engineering	2770/32644	. . . .	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2770/32463	. . . .	by chemical treatment	2770/32645	. . . .	Special targeting system for viral vectors
2770/32464	. . . .	by serial passage	2770/32651	. . . .	Methods of production or purification of viral material
2770/32471	. . . .	Demonstrated <u>in vivo</u> effect	2770/32652	. . . .	relating to complementing cells and packaging systems for producing virus or viral particles
2770/32488	. . . .	for redistribution	2770/32661	. . . .	Methods of inactivation or attenuation
2770/32511	. . . .	Parechovirus, e.g. human parechovirus	2770/32662	. . . .	by genetic engineering
2770/32521	. . . .	Viruses as such, e.g. new isolates, mutants or their genomic sequences	2770/32663	. . . .	by chemical treatment
2770/32522	. . . .	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	2770/32664	. . . .	by serial passage
2770/32523	. . . .	Virus like particles [VLP]	2770/32671	. . . .	Demonstrated <u>in vivo</u> effect
2770/32531	. . . .	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	2770/32688	. . . .	for redistribution
2770/32532	. . . .	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	2770/32711	. . . .	Rhinovirus
2770/32533	. . . .	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	2770/32721	. . . .	Viruses as such, e.g. new isolates, mutants or their genomic sequences
2770/32534	. . . .	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	2770/32722	. . . .	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2770/32541	. . . .	Use of virus, viral particle or viral elements as a vector	2770/32723	. . . .	Virus like particles [VLP]
2770/32542	. . . .	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	2770/32731	. . . .	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2770/32543	. . . .	viral genome or elements thereof as genetic vector	2770/32732	. . . .	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2770/32544	. . . .	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	2770/32733	. . . .	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2770/32545	. . . .	Special targeting system for viral vectors	2770/32734	. . . .	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2770/32551	. . . .	Methods of production or purification of viral material	2770/32741	. . . .	Use of virus, viral particle or viral elements as a vector
2770/32552	. . . .	relating to complementing cells and packaging systems for producing virus or viral particles	2770/32742	. . . .	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2770/32561	. . . .	Methods of inactivation or attenuation	2770/32743	. . . .	viral genome or elements thereof as genetic vector
2770/32562	. . . .	by genetic engineering	2770/32744	. . . .	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2770/32563	. . . .	by chemical treatment	2770/32745	. . . .	Special targeting system for viral vectors
2770/32564	. . . .	by serial passage	2770/32751	. . . .	Methods of production or purification of viral material
2770/32571	. . . .	Demonstrated <u>in vivo</u> effect	2770/32752	. . . .	relating to complementing cells and packaging systems for producing virus or viral particles
2770/32588	. . . .	for redistribution	2770/32761	. . . .	Methods of inactivation or attenuation
2770/32611	. . . .	Poliovirus	2770/32762	. . . .	by genetic engineering
2770/32621	. . . .	Viruses as such, e.g. new isolates, mutants or their genomic sequences	2770/32763	. . . .	by chemical treatment
2770/32622	. . . .	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	2770/32764	. . . .	by serial passage
2770/32623	. . . .	Virus like particles [VLP]	2770/32771	. . . .	Demonstrated <u>in vivo</u> effect
2770/32631	. . . .	Uses of virus other than therapeutic or vaccine, e.g. disinfectant			
2770/32632	. . . .	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent			

- 2770/32788 . . . . for redistribution
- 2770/34011 . . Potyviridae
- 2770/34021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/34022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/34023 . . . Virus like particles [VLP]
- 2770/34031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/34032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/34033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/34034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/34041 . . . Use of virus, viral particle or viral elements as a vector
- 2770/34042 . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/34043 . . . . viral genome or elements thereof as genetic vector
- 2770/34044 . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/34045 . . . . Special targeting system for viral vectors
- 2770/34051 . . . Methods of production or purification of viral material
- 2770/34052 . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/34061 . . . Methods of inactivation or attenuation
- 2770/34062 . . . . by genetic engineering
- 2770/34063 . . . . by chemical treatment
- 2770/34064 . . . . by serial passage
- 2770/34071 . . . Demonstrated in vivo effect
- 2770/34088 . . . for redistribution
- 2770/36011 . . Togaviridae
- 2770/36021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/36022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/36023 . . . Virus like particles [VLP]
- 2770/36031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/36032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/36033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/36034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/36041 . . . Use of virus, viral particle or viral elements as a vector
- 2770/36042 . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/36043 . . . . viral genome or elements thereof as genetic vector
- 2770/36044 . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/36045 . . . . Special targeting system for viral vectors
- 2770/36051 . . . Methods of production or purification of viral material
- 2770/36052 . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/36061 . . . Methods of inactivation or attenuation
- 2770/36062 . . . . by genetic engineering
- 2770/36063 . . . . by chemical treatment
- 2770/36064 . . . . by serial passage
- 2770/36071 . . . Demonstrated in vivo effect
- 2770/36088 . . . for redistribution
- 2770/36111 . . . Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- 2770/36121 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/36122 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/36123 . . . . Virus like particles [VLP]
- 2770/36131 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/36132 . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/36133 . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/36134 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/36141 . . . . Use of virus, viral particle or viral elements as a vector
- 2770/36142 . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/36143 . . . . . viral genome or elements thereof as genetic vector
- 2770/36144 . . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/36145 . . . . . Special targeting system for viral vectors
- 2770/36151 . . . . Methods of production or purification of viral material
- 2770/36152 . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/36161 . . . . Methods of inactivation or attenuation
- 2770/36162 . . . . . by genetic engineering
- 2770/36163 . . . . . by chemical treatment
- 2770/36164 . . . . . by serial passage
- 2770/36171 . . . . Demonstrated in vivo effect
- 2770/36188 . . . . for redistribution
- 2770/36211 . . . Rubivirus, e.g. rubella virus
- 2770/36221 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/36222 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/36223 . . . . Virus like particles [VLP]
- 2770/36231 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant

- 2770/36232 . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/36233 . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/36234 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/36241 . . . . Use of virus, viral particle or viral elements as a vector
- 2770/36242 . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/36243 . . . . . viral genome or elements thereof as genetic vector
- 2770/36244 . . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/36245 . . . . . Special targeting system for viral vectors
- 2770/36251 . . . . Methods of production or purification of viral material
- 2770/36252 . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/36261 . . . . Methods of inactivation or attenuation
- 2770/36262 . . . . . by genetic engineering
- 2770/36263 . . . . . by chemical treatment
- 2770/36264 . . . . . by serial passage
- 2770/36271 . . . . Demonstrated in vivo effect
- 2770/36288 . . . . for redistribution
- 2770/38011 . . . . Tombusviridae
- 2770/38021 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/38022 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/38023 . . . . Virus like particles [VLP]
- 2770/38031 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/38032 . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/38033 . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/38034 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/38041 . . . . Use of virus, viral particle or viral elements as a vector
- 2770/38042 . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/38043 . . . . . viral genome or elements thereof as genetic vector
- 2770/38044 . . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/38045 . . . . . Special targeting system for viral vectors
- 2770/38051 . . . . Methods of production or purification of viral material
- 2770/38052 . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/38061 . . . . Methods of inactivation or attenuation
- 2770/38062 . . . . . by genetic engineering
- 2770/38063 . . . . . by chemical treatment
- 2770/38064 . . . . . by serial passage
- 2770/38071 . . . . Demonstrated in vivo effect
- 2770/38088 . . . . for redistribution
- 2770/40011 . . . . Tymoviridae
- 2770/40021 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/40022 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/40023 . . . . Virus like particles [VLP]
- 2770/40031 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/40032 . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/40033 . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/40034 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/40041 . . . . Use of virus, viral particle or viral elements as a vector
- 2770/40042 . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/40043 . . . . . viral genome or elements thereof as genetic vector
- 2770/40044 . . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/40045 . . . . . Special targeting system for viral vectors
- 2770/40051 . . . . Methods of production or purification of viral material
- 2770/40052 . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/40061 . . . . Methods of inactivation or attenuation
- 2770/40062 . . . . . by genetic engineering
- 2770/40063 . . . . . by chemical treatment
- 2770/40064 . . . . . by serial passage
- 2770/40071 . . . . Demonstrated in vivo effect
- 2770/40088 . . . . for redistribution
- 2780/00** **Naked RNA viruses**
- 2780/00011 . . . . Details
- 2780/00021 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2780/00022 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2780/00023 . . . . Virus like particles [VLP]
- 2780/00031 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2780/00032 . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2780/00033 . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2780/00034 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2780/00041 . . . . Use of virus, viral particle or viral elements as a vector
- 2780/00042 . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule

- 2780/00043 . . . viral genome or elements thereof as genetic vector
- 2780/00044 . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2780/00045 . . . Special targeting system for viral vectors
- 2780/00051 . . Methods of production or purification of viral material
- 2780/00052 . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2780/00061 . . Methods of inactivation or attenuation
- 2780/00062 . . . by genetic engineering
- 2780/00063 . . . by chemical treatment
- 2780/00064 . . . by serial passage
- 2780/00071 . . Demonstrated in vivo effect
- 2780/00088 . . for redistribution
- 2780/10011 . . Narnaviridae
- 2780/10021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2780/10022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2780/10023 . . . Virus like particles [VLP]
- 2780/10031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2780/10032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2780/10033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2780/10034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2780/10041 . . . Use of virus, viral particle or viral elements as a vector
- 2780/10042 . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2780/10043 . . . . viral genome or elements thereof as genetic vector
- 2780/10044 . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2780/10045 . . . . Special targeting system for viral vectors
- 2780/10051 . . . Methods of production or purification of viral material
- 2780/10052 . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2780/10061 . . . Methods of inactivation or attenuation
- 2780/10062 . . . . by genetic engineering
- 2780/10063 . . . . by chemical treatment
- 2780/10064 . . . . by serial passage
- 2780/10071 . . . Demonstrated in vivo effect
- 2780/10088 . . . for redistribution
- 2790/00** **Viroids or subviral agents**
- 2790/00011 . Details
- 2790/00021 . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2790/00022 . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2790/00023 . . Virus like particles [VLP]
- 2790/00031 . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2790/00032 . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2790/00033 . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2790/00034 . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2790/00041 . . Use of virus, viral particle or viral elements as a vector
- 2790/00042 . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2790/00043 . . . . viral genome or elements thereof as genetic vector
- 2790/00044 . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2790/00045 . . . . Special targeting system for viral vectors
- 2790/00051 . . . Methods of production or purification of viral material
- 2790/00052 . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2790/00061 . . . Methods of inactivation or attenuation
- 2790/00062 . . . . by genetic engineering
- 2790/00063 . . . . by chemical treatment
- 2790/00064 . . . . by serial passage
- 2790/00071 . . Demonstrated in vivo effect
- 2790/00088 . . for redistribution
- 2790/10011 . . Prions
- 2790/10021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2790/10022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2790/10023 . . . Virus like particles [VLP]
- 2790/10031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2790/10032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2790/10033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2790/10034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2790/10041 . . . Use of virus, viral particle or viral elements as a vector
- 2790/10042 . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2790/10043 . . . . viral genome or elements thereof as genetic vector
- 2790/10044 . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2790/10045 . . . . Special targeting system for viral vectors
- 2790/10051 . . . Methods of production or purification of viral material
- 2790/10052 . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2790/10061 . . . Methods of inactivation or attenuation
- 2790/10062 . . . . by genetic engineering

- 2790/10063 . . . . by chemical treatment
- 2790/10064 . . . . by serial passage
- 2790/10071 . . . Demonstrated in vivo effect
- 2790/10088 . . . for redistribution
- 2790/12011 . . Satellite viruses
- 2790/12021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2790/12022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2790/12023 . . . Virus like particles [VLP]
- 2790/12031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2790/12032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2790/12033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2790/12034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2790/12041 . . . Use of virus, viral particle or viral elements as a vector
- 2790/12042 . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2790/12043 . . . . viral genome or elements thereof as genetic vector
- 2790/12044 . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2790/12045 . . . . Special targeting system for viral vectors
- 2790/12051 . . . Methods of production or purification of viral material
- 2790/12052 . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2790/12061 . . . Methods of inactivation or attenuation
- 2790/12062 . . . . by genetic engineering
- 2790/12063 . . . . by chemical treatment
- 2790/12064 . . . . by serial passage
- 2790/12071 . . . Demonstrated in vivo effect
- 2790/12088 . . . for redistribution
- 2790/14011 . . Viroids
- 2790/14021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2790/14022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2790/14023 . . . Virus like particles [VLP]
- 2790/14031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2790/14032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2790/14033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2790/14034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2790/14041 . . . Use of virus, viral particle or viral elements as a vector
- 2790/14042 . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2790/14043 . . . . viral genome or elements thereof as genetic vector
- 2790/14044 . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2790/14045 . . . . Special targeting system for viral vectors
- 2790/14051 . . . Methods of production or purification of viral material
- 2790/14052 . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2790/14061 . . . Methods of inactivation or attenuation
- 2790/14062 . . . . by genetic engineering
- 2790/14063 . . . . by chemical treatment
- 2790/14064 . . . . by serial passage
- 2790/14071 . . . Demonstrated in vivo effect
- 2790/14088 . . . for redistribution
- 2792/00 Archaeobacteria viruses**
- 2792/00011 . Details
- 2792/00021 . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2792/00022 . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2792/00023 . . Virus like particles [VLP]
- 2792/00031 . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2792/00032 . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2792/00033 . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2792/00034 . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2792/00041 . . Use of virus, viral particle or viral elements as a vector
- 2792/00042 . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2792/00043 . . . viral genome or elements thereof as genetic vector
- 2792/00044 . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2792/00045 . . . Special targeting system for viral vectors
- 2792/00051 . . Methods of production or purification of viral material
- 2792/00052 . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2792/00061 . . Methods of inactivation or attenuation
- 2792/00062 . . . by genetic engineering
- 2792/00063 . . . by chemical treatment
- 2792/00064 . . . by serial passage
- 2792/00071 . . Demonstrated in vivo effect
- 2792/00088 . . for redistribution
- 2792/10011 . . Fuselloviridae
- 2792/10021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2792/10022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2792/10023 . . . Virus like particles [VLP]

- 2792/10031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2792/10032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2792/10033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2792/10034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2792/10041 . . . Use of virus, viral particle or viral elements as a vector
- 2792/10042 . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2792/10043 . . . . viral genome or elements thereof as genetic vector
- 2792/10044 . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2792/10045 . . . . Special targeting system for viral vectors
- 2792/10051 . . . Methods of production or purification of viral material
- 2792/10052 . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2792/10061 . . . Methods of inactivation or attenuation
- 2792/10062 . . . . by genetic engineering
- 2792/10063 . . . . by chemical treatment
- 2792/10064 . . . . by serial passage
- 2792/10071 . . . Demonstrated in vivo effect
- 2792/10088 . . . for redistribution
- 2792/12011 . . Guttaviridae
- 2792/12021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2792/12022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2792/12023 . . . Virus like particles [VLP]
- 2792/12031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2792/12032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2792/12033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2792/12034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2792/12041 . . . Use of virus, viral particle or viral elements as a vector
- 2792/12042 . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2792/12043 . . . . viral genome or elements thereof as genetic vector
- 2792/12044 . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2792/12045 . . . . Special targeting system for viral vectors
- 2792/12051 . . . Methods of production or purification of viral material
- 2792/12052 . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2792/12061 . . . Methods of inactivation or attenuation
- 2792/12062 . . . . by genetic engineering
- 2792/12063 . . . . by chemical treatment
- 2792/12064 . . . . by serial passage
- 2792/12071 . . . Demonstrated in vivo effect
- 2792/12088 . . . for redistribution
- 2795/00** **Bacteriophages**
- 2795/00011 . Details
- 2795/00021 . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2795/00022 . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2795/00023 . . Virus like particles [VLP]
- 2795/00031 . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2795/00032 . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2795/00033 . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2795/00034 . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2795/00041 . . Use of virus, viral particle or viral elements as a vector
- 2795/00042 . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2795/00043 . . . viral genome or elements thereof as genetic vector
- 2795/00044 . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2795/00045 . . . Special targeting system for viral vectors
- 2795/00051 . . Methods of production or purification of viral material
- 2795/00052 . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2795/00061 . . Methods of inactivation or attenuation
- 2795/00062 . . . by genetic engineering
- 2795/00063 . . . by chemical treatment
- 2795/00064 . . . by serial passage
- 2795/00071 . . Demonstrated in vivo effect
- 2795/00088 . . for redistribution
- 2795/10011 . . dsDNA Bacteriophages
- 2795/10021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2795/10022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2795/10023 . . . Virus like particles [VLP]
- 2795/10031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2795/10032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2795/10033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2795/10034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2795/10041 . . . Use of virus, viral particle or viral elements as a vector



- 2795/10042 . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2795/10043 . . . . viral genome or elements thereof as genetic vector
- 2795/10044 . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2795/10045 . . . . Special targeting system for viral vectors
- 2795/10051 . . . . Methods of production or purification of viral material
- 2795/10052 . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2795/10061 . . . . Methods of inactivation or attenuation
- 2795/10062 . . . . by genetic engineering
- 2795/10063 . . . . by chemical treatment
- 2795/10064 . . . . by serial passage
- 2795/10071 . . . . Demonstrated in vivo effect
- 2795/10088 . . . . for redistribution
- 2795/10111 . . . . Myoviridae
- 2795/10121 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2795/10122 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2795/10123 . . . . Virus like particles [VLP]
- 2795/10131 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2795/10132 . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2795/10133 . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2795/10134 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2795/10141 . . . . Use of virus, viral particle or viral elements as a vector
- 2795/10142 . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2795/10143 . . . . . viral genome or elements thereof as genetic vector
- 2795/10144 . . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2795/10145 . . . . . Special targeting system for viral vectors
- 2795/10151 . . . . . Methods of production or purification of viral material
- 2795/10152 . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2795/10161 . . . . . Methods of inactivation or attenuation
- 2795/10162 . . . . . by genetic engineering
- 2795/10163 . . . . . by chemical treatment
- 2795/10164 . . . . . by serial passage
- 2795/10171 . . . . . Demonstrated in vivo effect
- 2795/10188 . . . . . for redistribution
- 2795/10211 . . . . Podoviridae
- 2795/10221 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2795/10222 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2795/10223 . . . . Virus like particles [VLP]
- 2795/10231 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2795/10232 . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2795/10233 . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2795/10234 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2795/10241 . . . . Use of virus, viral particle or viral elements as a vector
- 2795/10242 . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2795/10243 . . . . . viral genome or elements thereof as genetic vector
- 2795/10244 . . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2795/10245 . . . . . Special targeting system for viral vectors
- 2795/10251 . . . . . Methods of production or purification of viral material
- 2795/10252 . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2795/10261 . . . . . Methods of inactivation or attenuation
- 2795/10262 . . . . . by genetic engineering
- 2795/10263 . . . . . by chemical treatment
- 2795/10264 . . . . . by serial passage
- 2795/10271 . . . . . Demonstrated in vivo effect
- 2795/10288 . . . . . for redistribution
- 2795/10311 . . . . Siphoviridae
- 2795/10321 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2795/10322 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2795/10323 . . . . Virus like particles [VLP]
- 2795/10331 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2795/10332 . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2795/10333 . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2795/10334 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2795/10341 . . . . Use of virus, viral particle or viral elements as a vector
- 2795/10342 . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2795/10343 . . . . . viral genome or elements thereof as genetic vector
- 2795/10344 . . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2795/10345 . . . . . Special targeting system for viral vectors
- 2795/10351 . . . . . Methods of production or purification of viral material
- 2795/10352 . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2795/10361 . . . . . Methods of inactivation or attenuation

- 2795/10362 . . . . by genetic engineering
- 2795/10363 . . . . by chemical treatment
- 2795/10364 . . . . by serial passage
- 2795/10371 . . . . Demonstrated in vivo effect
- 2795/10388 . . . . for redistribution
- 2795/12011 . . dsRNA Bacteriophages
- 2795/12021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2795/12022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2795/12023 . . . Virus like particles [VLP]
- 2795/12031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2795/12032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2795/12033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2795/12034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2795/12041 . . . Use of virus, viral particle or viral elements as a vector
- 2795/12042 . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2795/12043 . . . . viral genome or elements thereof as genetic vector
- 2795/12044 . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2795/12045 . . . . Special targeting system for viral vectors
- 2795/12051 . . . Methods of production or purification of viral material
- 2795/12052 . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2795/12061 . . . Methods of inactivation or attenuation
- 2795/12062 . . . . by genetic engineering
- 2795/12063 . . . . by chemical treatment
- 2795/12064 . . . . by serial passage
- 2795/12071 . . . Demonstrated in vivo effect
- 2795/12088 . . . for redistribution
- 2795/14011 . . ssDNA Bacteriophages
- 2795/14021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2795/14022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2795/14023 . . . Virus like particles [VLP]
- 2795/14031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2795/14032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2795/14033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2795/14034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2795/14041 . . . Use of virus, viral particle or viral elements as a vector
- 2795/14042 . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2795/14043 . . . . viral genome or elements thereof as genetic vector
- 2795/14044 . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2795/14045 . . . . Special targeting system for viral vectors
- 2795/14051 . . . Methods of production or purification of viral material
- 2795/14052 . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2795/14061 . . . Methods of inactivation or attenuation
- 2795/14062 . . . . by genetic engineering
- 2795/14063 . . . . by chemical treatment
- 2795/14064 . . . . by serial passage
- 2795/14071 . . . Demonstrated in vivo effect
- 2795/14088 . . . for redistribution
- 2795/14111 . . . Inoviridae
- 2795/14121 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2795/14122 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2795/14123 . . . . Virus like particles [VLP]
- 2795/14131 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2795/14132 . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2795/14133 . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2795/14134 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2795/14141 . . . . Use of virus, viral particle or viral elements as a vector
- 2795/14142 . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2795/14143 . . . . . viral genome or elements thereof as genetic vector
- 2795/14144 . . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2795/14145 . . . . . Special targeting system for viral vectors
- 2795/14151 . . . . Methods of production or purification of viral material
- 2795/14152 . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2795/14161 . . . . Methods of inactivation or attenuation
- 2795/14162 . . . . . by genetic engineering
- 2795/14163 . . . . . by chemical treatment
- 2795/14164 . . . . . by serial passage
- 2795/14171 . . . . Demonstrated in vivo effect
- 2795/14188 . . . . for redistribution
- 2795/14211 . . . Microviridae
- 2795/14221 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2795/14222 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2795/14223 . . . . Virus like particles [VLP]
- 2795/14231 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant

- 2795/14232 . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2795/14233 . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2795/14234 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2795/14241 . . . . Use of virus, viral particle or viral elements as a vector
- 2795/14242 . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2795/14243 . . . . . viral genome or elements thereof as genetic vector
- 2795/14244 . . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2795/14245 . . . . . Special targeting system for viral vectors
- 2795/14251 . . . . Methods of production or purification of viral material
- 2795/14252 . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2795/14261 . . . . Methods of inactivation or attenuation
- 2795/14262 . . . . . by genetic engineering
- 2795/14263 . . . . . by chemical treatment
- 2795/14264 . . . . . by serial passage
- 2795/14271 . . . . Demonstrated *in vivo* effect
- 2795/14288 . . . . for redistribution
- 2795/16011 . . ssRNA Bacteriophages negative-sense
- 2795/16021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2795/16022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2795/16023 . . . Virus like particles [VLP]
- 2795/16031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2795/16032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2795/16033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2795/16034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2795/16041 . . . Use of virus, viral particle or viral elements as a vector
- 2795/16042 . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2795/16043 . . . . viral genome or elements thereof as genetic vector
- 2795/16044 . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2795/16045 . . . . Special targeting system for viral vectors
- 2795/16051 . . . Methods of production or purification of viral material
- 2795/16052 . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2795/16061 . . . Methods of inactivation or attenuation
- 2795/16062 . . . . by genetic engineering
- 2795/16063 . . . . by chemical treatment
- 2795/16064 . . . . by serial passage
- 2795/16071 . . . Demonstrated *in vivo* effect
- 2795/16088 . . . for redistribution
- 2795/18011 . . ssRNA Bacteriophages positive-sense
- 2795/18021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2795/18022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2795/18023 . . . Virus like particles [VLP]
- 2795/18031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2795/18032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2795/18033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2795/18034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2795/18041 . . . Use of virus, viral particle or viral elements as a vector
- 2795/18042 . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2795/18043 . . . . viral genome or elements thereof as genetic vector
- 2795/18044 . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2795/18045 . . . . Special targeting system for viral vectors
- 2795/18051 . . . Methods of production or purification of viral material
- 2795/18052 . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2795/18061 . . . Methods of inactivation or attenuation
- 2795/18062 . . . . by genetic engineering
- 2795/18063 . . . . by chemical treatment
- 2795/18064 . . . . by serial passage
- 2795/18071 . . . Demonstrated *in vivo* effect
- 2795/18088 . . . for redistribution
- 2795/18111 . . . Leviviridae
- 2795/18121 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2795/18122 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2795/18123 . . . . Virus like particles [VLP]
- 2795/18131 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2795/18132 . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2795/18133 . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2795/18134 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2795/18141 . . . . Use of virus, viral particle or viral elements as a vector
- 2795/18142 . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2795/18143 . . . . . viral genome or elements thereof as genetic vector

2795/18144	. . . . .	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2795/18145	. . . . .	Special targeting system for viral vectors
2795/18151	. . . . .	Methods of production or purification of viral material
2795/18152	. . . . .	relating to complementing cells and packaging systems for producing virus or viral particles
2795/18161	. . . . .	Methods of inactivation or attenuation
2795/18162	. . . . .	by genetic engineering
2795/18163	. . . . .	by chemical treatment
2795/18164	. . . . .	by serial passage
2795/18171	. . . . .	Demonstrated <i>in vivo</i> effect
2795/18188	. . . . .	for redistribution
<b>2796/00</b>		<b>Viruses not covered by groups</b>
		<a href="#">C12N 2710/00</a> - <a href="#">C12N 2795/00</a>
<b>2799/00</b>		<b>Uses of viruses</b>
		<b><u>WARNING</u></b>
		From March 15, 2012 codes in the range <a href="#">C12N 2799/00</a> - <a href="#">C12N 2799/06</a> are no longer used for the classification of new documents. The documents in this range are being reclassified to the corresponding codes in <a href="#">C12N 2710/00-C12N 2795/00</a>
2799/02	. . . . .	as vector
2799/021	. . . . .	for the expression of a heterologous nucleic acid
2799/022	. . . . .	where the vector is derived from an adenovirus
2799/023	. . . . .	where the vector is derived from a poxvirus
2799/025	. . . . .	where the vector is derived from a parvovirus
2799/026	. . . . .	where the vector is derived from a baculovirus
2799/027	. . . . .	where the vector is derived from a retrovirus
2799/028	. . . . .	where the vector is derived from a herpesvirus
2799/04	. . . . .	<i>in vivo</i>
2799/06	. . . . .	<i>in vitro</i>
<b>2800/00</b>		<b>Nucleic acids vectors</b>
2800/10	. . . . .	Plasmid DNA
2800/101	. . . . .	for bacteria
2800/102	. . . . .	for yeast
2800/103	. . . . .	for invertebrates
2800/105	. . . . .	for insects
2800/106	. . . . .	for vertebrates
2800/107	. . . . .	for mammalian
2800/108	. . . . .	episomal vectors
2800/20	. . . . .	Pseudochromosomes, minichromosomes
2800/202	. . . . .	of bacteriophage origin
2800/204	. . . . .	of bacterial origin, e.g. BAC
2800/206	. . . . .	of yeast origin, e.g. YAC, 2u
2800/208	. . . . .	of mammalian origin, e.g. minichromosome
2800/22	. . . . .	Vectors comprising a coding region that has been codon optimised for expression in a respective host
2800/24	. . . . .	Vectors characterised by the absence of particular element, e.g. selectable marker, viral origin of replication
2800/30	. . . . .	Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
2800/40	. . . . .	Systems of functionally co-operating vectors
2800/50	. . . . .	Vectors for producing vectors
2800/60	. . . . .	Vectors containing traps for, e.g. exons, promoters
2800/70	. . . . .	Vectors containing special elements for cloning, e.g. topoisomerase, adaptor sites
2800/80	. . . . .	Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites
2800/90	. . . . .	Vectors containing a transposable element
2800/95	. . . . .	Protection of vectors from inactivation by agents such as antibodies or enzymes, e.g. using polymers
<b>2810/00</b>		<b>Vectors comprising a targeting moiety</b>
2810/10	. . . . .	Vectors comprising a non-peptidic targeting moiety
2810/40	. . . . .	Vectors comprising a peptide as targeting moiety, e.g. a synthetic peptide, from undefined source
2810/405	. . . . .	Vectors comprising RGD peptide
2810/50	. . . . .	Vectors comprising as targeting moiety peptide derived from defined protein
2810/55	. . . . .	from bacteria
2810/60	. . . . .	from viruses
2810/6009	. . . . .	dsDNA viruses
2810/6018	. . . . .	Adenoviridae
2810/6027	. . . . .	ssDNA viruses
2810/6036	. . . . .	DNA rev transcr viruses
2810/6045	. . . . .	RNA rev transcr viruses
2810/6054	. . . . .	Retroviridae
2810/6063	. . . . .	ds RNA viruses
2810/6072	. . . . .	negative strand RNA viruses
2810/6081	. . . . .	rhabdoviridae, e.g. VSV
2810/609	. . . . .	positive strand RNA viruses
2810/65	. . . . .	from plants
2810/70	. . . . .	from fungi
2810/75	. . . . .	from invertebrates
2810/80	. . . . .	from vertebrates
2810/85	. . . . .	mammalian
2810/851	. . . . .	from growth factors; from growth regulators
2810/852	. . . . .	from cytokines; from lymphokines; from interferons
2810/853	. . . . .	from tumor necrosis factor, TNF
2810/854	. . . . .	from hormones
2810/855	. . . . .	from receptors; from cell surface antigens; from cell surface determinants
2810/856	. . . . .	from integrins
2810/857	. . . . .	from blood coagulation or fibrinolysis factors
2810/858	. . . . .	from apolipoproteins
2810/859	. . . . .	from immunoglobulins
2810/90	. . . . .	avian
<b>2820/00</b>		<b>Vectors comprising a special origin of replication system</b>
2820/002	. . . . .	inducible or controllable
2820/005	. . . . .	cell-cycle regulated
2820/007	. . . . .	tissue or cell-specific
2820/10	. . . . .	multiple origins of replication
2820/55	. . . . .	from bacteria
2820/60	. . . . .	from viruses
2820/65	. . . . .	from plants
2820/70	. . . . .	from fungi
2820/702	. . . . .	yeast
2820/704	. . . . .	<i>S. cerevisiae</i>
2820/706	. . . . .	<i>S. pombe</i>
2820/708	. . . . .	<i>C. albicans</i>
2820/75	. . . . .	from invertebrates
2820/80	. . . . .	from vertebrates
2820/85	. . . . .	mammalian

2820/90	. . avian
<b>2830/00</b>	<b>Vector systems having a special element relevant for transcription</b>
2830/001	. controllable enhancer/promoter combination
2830/002	. . inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
2830/003	. . . tet inducible
2830/005	. . repressible enhancer/promoter combination, e.g. KRAB
2830/006	. . . tet repressible
2830/007	. cell cycle specific enhancer/promoter combination
2830/008	. cell type or tissue specific enhancer/promoter combination
2830/15	. chimeric enhancer/promoter combination
2830/20	. transcription of more than one cistron
2830/205	. . bidirectional
2830/30	. being an enhancer not forming part of the promoter region
2830/32	. being an silencer not forming part of the promoter region
2830/34	. being a transcription initiation element
2830/36	. being a transcription termination element
2830/38	. being a stuffer
2830/40	. being an insulator
2830/42	. being an intron or intervening sequence for splicing and/or stability of RNA
2830/46	. elements influencing chromatin structure, e.g. scaffold/matrix attachment region, methylation free island
2830/48	. regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE
2830/50	. regulating RNA stability, not being an intron, e.g. poly A signal
2830/52	. encoding ribozyme for self-inactivation
2830/55	. from bacteria
2830/60	. from viruses
2830/65	. from plants
2830/70	. from fungi
2830/702	. . yeast
2830/704	. . . S. cerevisiae
2830/706	. . . S. pombe
2830/708	. . . C. albicans
2830/75	. from invertebrates
2830/80	. from vertebrates
2830/85	. . mammalian
2830/90	. . avian
<b>2840/00</b>	<b>Vectors comprising a special translation-regulating system</b>
2840/002	. controllable or inducible
2840/005	. cell cycle specific
2840/007	. cell or tissue specific
2840/10	. regulates levels of translation
2840/102	. . inhibiting translation
2840/105	. . enhancing translation
2840/107	. . inhibiting translational read-through
2840/20	. translation of more than one cistron
2840/203	. . having an IRES
2840/206	. . . having multiple IRES
2840/44	. being a specific part of the splice mechanism, e.g. donor, acceptor

2840/445	. . for trans-splicing, e.g. polypyrimidine tract, branch point splicing
2840/50	. utilisation of non-ATG initiation codon

**NOTE**

This groups covers artificial modification only, i.e. naturally occurring use of non-ATG start codon is not classified here

2840/55	. from bacteria
2840/60	. from viruses
2840/65	. from plants
2840/70	. from fungi
2840/702	. . yeast
2840/704	. . . S. cerevisiae
2840/706	. . . S. pombe
2840/708	. . . C. albicans
2840/75	. from invertebrates
2840/80	. from vertebrates
2840/85	. . mammalian
2840/90	. . avian

**2999/00 Further aspects of viruses or vectors not covered by groups [C12N 2710/00](#) - [C12N 2796/00](#) or [C12N 2800/00](#)**

**NOTES**

1. This group is for classification of patent and non-patent literature documents.
2. When classifying non-patent literature in this group, classification must also be given for the relevant CPC groups, to define the technical area to which they relate.

2999/002	. Adverse teaching
2999/005	. Biological teaching, e.g. a link between protein and disease, new virus causing pandemic
2999/007	. Technological advancements, e.g. new system for producing known virus, cre-lox system for production of transgenic animals